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There is a duality in recognising what an incredible disease it is 
– in terms of its origin, that it emerges out of a normal cell. 
It’s a reminder of what a wonderful thing a normal cell is. 
In a very cold, scientific sense, 





































Die vorliegende Arbeit wurde unter der Anleitung von Dr. Julian Heuberger und Prof. Dr. Walter 




  Table of Contents 
 
Zusammenfassung ................................................................................................................ 1 
Abstract ................................................................................................................................. 2 
1 Introduction ................................................................................................................. 3 
1.1 The intestinal epithelium. ......................................................................................... 4 
1.1.1 Lgr5+ intestinal stem cells maintain the epithelium. .................................................. 5 
1.1.2 Canonical Wnt signalling sustains adult intestinal stem cells. .................................. 6 
1.1.3 Signalling circuits specify the structure and function of the intestinal epithelium. ..... 8 
1.1.4 Cell type plasticity in the intestinal epithelium. ....................................................... 11 
1.1.5 Intestinal organoids - a tool to study epithelial stem cell biology. ........................... 11 
1.2 Wnt signalling and adult intestinal stem cells in colon cancer. ............................... 12 
1.2.1 Deregulation of Wnt signalling in intestinal stem cells initiates colon cancer. ......... 12 
1.2.2 Wnt-dependent cancer stem cells maintain intestinal tumors. ............................... 12 
1.2.3 Targeting cancer stem cells to prevent colon cancer relapse. ............................... 13 
1.3 The epigenetic regulation of gene expression. ...................................................... 15 
1.3.1 Chromatin and epigenetics. ................................................................................... 15 
1.3.2 Epigenetic regulation translates cell signalling into gene expression. .................... 16 
1.3.3 Epigenetic regulation by histone modifications. ..................................................... 17 
1.3.4 Histone lysine methylation. .................................................................................... 17 
1.3.5 H3K4 tri-methylation marks active genes. ............................................................. 18 
1.3.6 H3K4 methyltransferases of the Set1/Mll family. ................................................... 19 
1.3.7 H3K4 methylation by Set1/Mll antagonizes H3K27 methylation and gene silencing 
by Polycomb group proteins. ................................................................................. 20 
1.3.8 Histone methyltransferases in cancer. ................................................................... 20 
1.3.9 The histone methyltransferase Mll1. ...................................................................... 21 
1.3.10 Mll1 in development, tissue homeostasis and disease. ......................................... 22 
2 Aim of the study ........................................................................................................ 25 
3 Results ..................................................................................................................... 26 
3.1 Mll1 expression is upregulated in Wnt-high human colon carcinomas. .................. 26 
3.2 Lgr5+ intestinal stem cells highly express Mll1 in a Wnt-dependent manner. ......... 27 
3.3 The β-cateninGOF-induced intestinal tumorigenesis depends on Mll1. .................... 31 
3.4 Mll1 promotes the β-cateninGOF-driven tumorigenic expansion of intestinal stem 
cells. ...................................................................................................................... 33 
3.4.1 The ablation of Mll1 prevents β-cateninGOF-induced stem cell expansion but does 
not decrease global Wnt activity. ........................................................................... 35 
3.5 Mll1 prevents differentiation of β-cateninGOF intestinal stem cells. .......................... 39 
3.5.1 Mll1 regulates Foxa1 and Gata4 transcription factors in β-cateninGOF stem cells. .. 40 
  Table of Contents 
 
3.6 Inducible shMLL1 colon cancer cell lines - a tool to study MLL1 function. ............. 41 
3.7 MLL1 is required for initiation and growth of human Ls174T colon cancer 
xenografts. ............................................................................................................ 43 
3.8 MLL1 sustains the stemness of human colon cancer cells. ................................... 46 
3.8.1 MLL1 controls the expression of Lgr5+ stem cell genes in human colon cancer cells. 
  .............................................................................................................................. 46 
3.8.2 MLL1 regulates the stemness and self-renewal of human colon cancer cells. ....... 47 
3.8.3 MLL1 epigenetically sustains the expression of specific stem cell genes. .............. 51 
3.8.4 MLL1 antagonizes PcG-mediated silencing of stem cell genes. ............................ 53 
3.8.5 MLL1 is essential for the β-catenin/TCF4-induced expression of LGR5. ............... 56 
3.9 MLL1 prevents differentiation of human colon cancer cells. ................................... 57 
3.10 Exploring the molecular mechanism of differentiation reveals a Mll1-Gata4/6-Bmp4 
axis. ...................................................................................................................... 58 
3.10.1 The ablation of MLL1 induces senescence of Ls174T cells. .................................. 62 
3.11 Mll1 controls Wnt and Mapk signalling to specify secretory differentiation. ............ 65 
3.11.1 Mll1 suppresses Mapk signalling and prevents goblet cell differentiation of Wnt-
activated cells. ....................................................................................................... 65 
3.11.2 Mll1 controls the Wnt/Mapk-driven differentiation of secretory cells. ...................... 66 
3.11.3 Mll1 promotes the crypt proliferation and restricts the goblet cell differentiation 
driven by Mapk signalling. ..................................................................................... 68 
3.12 Translational approaches: Targeting MLL1 in colon cancer. .................................. 70 
4 Discussion ................................................................................................................ 72 
4.1 Mll1 is essential for the β-cateninGOF-induced intestinal stem cell expansion and 
tumorigenesis. ....................................................................................................... 72 
4.2 Mll1 sustains oncogenic Wnt-induced stem cell gene expression and colon cancer 
stemness. .............................................................................................................. 74 
4.3 Mll1 antagonizes Polycomb-dependent silencing to sustain the expression of stem 
cell genes. ............................................................................................................. 75 
4.4 Mll1-deficient cancer cells lose their stemness and differentiate. ........................... 76 
4.5 Mll1 is a gene-specific co-regulator of β-catenin/Tcf4. ........................................... 79 
4.6 Mll1 controls adult epithelial stem cells and cell fate choice in the intestine. .......... 80 
4.7 Mll1 as a rational target for colon cancer therapy. ................................................. 82 
5 Materials and Methods .............................................................................................. 84 
5.1 Mice. ..................................................................................................................... 84 
5.2 Organoid culture. ................................................................................................... 86 
5.3 Cell culture. ........................................................................................................... 86 
5.4 Generation and cloning of shMLL1. ....................................................................... 87 
  Table of Contents 
 
5.5 Generation of lentiviral particles and lentiviral transduction. .................................. 88 
5.6 Serial re-plating and colony formation assay. ........................................................ 88 
5.7 TCF/LEF luciferase reporter assay. ....................................................................... 88 
5.8 Xenografts. ............................................................................................................ 89 
5.9 Histology, immunofluorescence staining and analysis. .......................................... 90 
5.9.1 LacZ whole-mount staining. ................................................................................... 91 
5.9.2 Senescence-associated β-galactosidase (SA-β-Gal) staining................................ 91 
5.9.3 Light microscopy and data analysis. ...................................................................... 91 
5.10 Chromatin immunoprecipitation. ............................................................................ 91 
5.11 SDS-PAGE and Western blotting. ......................................................................... 92 
5.12 RNA preparation for RT-PCR analysis and RNA sequencing. ............................... 93 
5.13 Antibodies. ............................................................................................................ 95 
5.14 Quantification and Statistical analysis.................................................................... 97 
6 List of Figures ........................................................................................................... 98 
7 List of Tables ...........................................................................................................100 
8 Abbreviations ...........................................................................................................101 
9 References ..............................................................................................................103 





  Zusammenfassung 
1 
Zusammenfassung 
Genetisch bedingte Veränderungen im Wnt-Signalweg sind in der Tumorigenese des Darms 
von zentraler Bedeutung. Mutationen des Wnt-Effektormoleküls β-Catenin in den adulten 
Stammzellen des Darmepithels führen zu unkontrollierter Proliferation und Expansion der 
Darmstammzellen und initiieren die Tumorentstehung. Auch in fortgeschrittenen Darmtumoren 
unterstützt die Wnt-Signalgebung maßgeblich das Tumorwachstum und den Erhalt von 
Tumorstammzellen. Nach erfolgreicher chemotherapeutischer Behandlung treten oftmals 
Tumorrezidive auf, für deren Entstehung therapieresistente Tumorstammzellen verantwortlich 
gemacht werden. Trotz intensiver Forschung und Entwicklung fehlen in der Darmkrebstherapie 
nach wie vor Behandlungsansätze zur gezielten Therapie der Tumorstammzellen. Ziel dieser 
Dissertation ist es, unser Verständnis der molekularen Regulationsmechanismen in 
Kolonkarzinomen zu erweitern und dadurch die zukünftige Entwicklung rationaler 
Behandlungsstrategien für Darmkrebspatienten zu fördern. Mittels humaner 
Kolonkarzinomzellen, 3D-Organoidkulturen und genetischem Maus-Tumormodell wurde in der 
vorliegenden Arbeit die Bedeutung der Histonmethyltransferase Mll1 in der epigenetischen 
Regulation humaner und muriner Darmkrebsstammzellen und -tumore identifiziert. Ich konnte 
zeigen, dass humane Kolonkarzinome eine erhöhte Mll1-Expression aufweisen, die mit dem 
Level an nukleärem β-Catenin korreliert. Im adulten Darmepithel ist Mll1 insbesondere in den 
Lgr5-positiven intestinalen Stammzellen exprimiert und maßgeblich an der Wnt/β-Catenin-
induzierten Stammzellexpansion sowie der Tumorentstehung beteiligt. Der konditionelle 
Verlust von Mll1 im murinen Darmkrebsmodell verhindert die β-Catenin-induzierte 
Tumorigenese. Mll1 unterstützt die Selbsterneuerungsfähigkeit und Proliferation der 
Tumorstammzellen, indem es die Expression von essentiellen Stammzellgenen wie dem Wnt-
abhängigen Stammzellmarker Lgr5 aufrechterhält und ihre Repression durch Polycomb-
vermittelte H3K27 Tri-methylierung verhindert. Mll1 fördert zudem die Expression der 
Transkriptionsfaktoren Gata4/6, die zum Erhalt der Stammzellfunktion beitragen. Der Verlust 
von Mll1 verringert progressiv die Selbsterneuerungsfähigkeit der Tumorstammzellen und 
induziert eine Mapk-vermittelte Differenzierung. Meine Ergebnisse zeigen, dass Mll1 als 
epigenetischer Regulator der Tumorstammzellen maßgeblich an der Wnt/β-Catenin-
induzierten Tumorigenese des Darmepithels beteiligt ist. Eine Inhibition der Mll1-Funktion in 
der Darmkrebstherapie kann eine gezielte Eliminierung der Tumorstammzellen ermöglichen, 
wodurch sowohl das fortschreitende Tumorwachstum unterbunden als auch die Bildung von 
Rezidiven verhindert werden kann. 
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Abstract 
Genetic mutations inducing aberrant activity of Wnt signalling are causative for intestinal 
tumorigenesis. Mutations of the Wnt effector molecule β-catenin in adult stem cells of the 
intestinal epithelium drive uncontrolled proliferation, expand the stem cell pool and initiate 
tumor formation. In advanced tumors, aberrant Wnt signalling promotes tumor growth and 
maintains cancer stem cells. The cancer stem cells are highly resistant to conventional 
chemotherapy and frequently initiate tumor relapse after completion of treatment. Despite 
extensive research, we are still lacking efficient therapies for colon cancer that specifically 
eliminate the cancer stem cells. This dissertation aims to expand our knowledge on molecular 
gene regulatory mechanisms in colon cancer cells to promote the identification and future 
development of rational therapies for colon cancer patients. Studying human colon carcinoma 
cells, intestinal organoid cultures and the in vivo tumorigenesis in a mouse tumor model, 
I identified the histone methyltransferase Mll1 as an epigenetic regulator in human and mouse 
intestinal cancer stem cells and tumors. I demonstrate that human colon carcinomas with 
nuclear β-catenin exhibit high levels of Mll1. In the adult intestinal epithelium of mice, Mll1 is 
highly expressed in the Lgr5+ stem cells and is a prerequisite for the oncogenic Wnt/β-catenin-
mediated stem cell expansion and tumorigenesis. Conditional knockout of Mll1 in an intestinal 
mouse tumor model prevents the β-catenin-driven intestinal tumorigenesis. Knockdown of Mll1 
impairs the self-renewal and proliferation of colon cancer sphere cultures and halts tumor 
growth in xenografts. Mechanistically, Mll1 sustains the expression of specific intestinal stem 
cell genes including the Wnt/β-catenin target gene Lgr5 by antagonizing gene silencing 
through polycomb repressive complex 2 (PRC2)-mediated H3K27 tri-methylation. Mll1 further 
promotes the expression of Gata4/6 transcription factors to maintain stem cell identity. 
Mll1-deficient colon cancer cells progressively lose their stemness and differentiate in a 
Mapk-dependent manner. Taken together, my data demonstrate that Mll1 is essential for the 
Wnt/β-catenin-induced intestinal tumorigenesis and cancer stemness. Interfering with Mll1 
function can efficiently eliminate colon cancer stem cells, and has potential as a rational 
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1 Introduction 
Cancer is a genetic disease causing uncontrolled growth of mammalian cells. It is a major 
cause of morbidity and mortality in humans. Colon cancer ranks the third most common cause 
of cancer-related deaths in the western world1. Recent years have seen great progress in the 
early detection and surgical removal of benign intestinal polyps, which has strongly improved 
colon cancer prevention. The overall 5-year survival rate of patients with late-stage colon 
cancer is only 10%, however, due to high rates of post-intervention recurrence and the lack of 
targeted therapies1. Colon cancer arises from intestinal epithelial cells as a consequence of 
cumulative genetic mutations. Loss-of-function mutations in the tumor suppressor gene APC 
(adenomatous polyposis coli) and gain-of-function mutations in the proto-oncogene β-catenin 
(CTNNB1) deregulate Wnt signalling and initiate the adenoma-carcinoma sequence of 
intestinal tumorigenesis2 (Figure 1.1). The aberrant Wnt activity expands mutant intestinal 
epithelial cells, giving rise to dysplastic crypts. Subsequent mutations in KRAS, SMAD4 and 
p53 sequentially drive tumor progression from benign polyps and adenomas to aggressive 
carcinomas, eventually followed by metastasis2. 
 
Figure 1.1: The adenoma-carcinoma sequence in colon cancer. 
The Vogelstein model describes intestinal tumorigenesis as a stepwise accumulation of genetic 
mutations, which sequentially transforms the intestinal epithelium (mucosa) into adenomas and 
carcinomas. Malignant carcinomas invade the submucosa and subjacent muscle layer (muscularis) of 
the intestinal wall, eventually spreading to distant organs and forming metastases. 
The malignancy of colon carcinomas is assessed using the American Joint Cancer Committee 
tumor/node/metastasis (TNM) staging system which classifies cancer based on the size and 
invasiveness of the primary tumor (T0/Tis-T4), the extent of spread to nearby lymph nodes 
(N0-N2) and the presence or absence of distant metastasis (M0-M1). Stage T0/Tis describes 
carcinomas in situ, meaning the tumor is confined to the intestinal mucosa. Stage T1 tumors 
invade the submucosa, stage T2 tumors the underlying muscle layer. Stage T3 tumors extend 
to the serosa and tumors classified as stage T4 have spread to adjacent organs. 
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Single-cell sequencing and cancer genome studies have revealed a mutational heterogeneity 
in advanced tumors that cannot be reached by sequential acquisition of several driver 
mutations3. The mutational heterogeneity causes a high variability in the growth and 
progression of benign adenomatous intestinal polyps4. Only 5% of polyps progress to 
malignant carcinomas, thus questioning the strict linear adenoma-carcinoma sequence 
proposed by the Vogelstein model. Genetic mutations in APC, KRAS, SMAD4 and p53 are 
recurrently found in colon cancers, though, and are critical for intestinal tumor growth and 
progression5, 6. The malignant growth destroys tissue architecture and impairs organ function. 
Colon carcinomas frequently metastasize to the liver and lung. These distant metastases are 
a major cause of mortality from colon cancer7. 
Therapies for advanced-stage colon cancer patients (T3-T4) mostly rely on non-specific 
radiation and chemotherapy. Chemotherapeutic agents are cytostatics that kill proliferating 
cells by blocking DNA synthesis or inhibiting nucleic acid metabolism. As tumor cells show a 
high proliferation rate8, they are hit by chemotherapy. Due to their non-targeted mechanism of 
action, however, radiation and chemotherapy do not only destroy tumor cells but also severely 
harm healthy proliferative tissue. Targeted therapeutic approaches exploit the addiction of 
cancer cells to oncogenic signalling and metabolic processes9. A targeted therapy aims to 
specifically eliminate tumor cells, while minimizing collateral damage. To date, only few 
targeted therapies for colon cancer are approved for use in the clinic. As cancer cells hijack 
the same signalling circuits that control the growth of normal epithelial cells, it is difficult to 
safely eliminate colon cancer cells without damaging healthy epithelium. Our ability to 
specifically target cancer cells will critically rely on understanding the differences between 
normal and cancer cells. The knowledge of the intestinal epithelium, its cell types, signalling 
and gene regulatory networks is key to understand how oncogenic mutations change the 
identity of intestinal epithelial cells and transform them into tumor-initiating cancer cells. 
1.1 The intestinal epithelium. 
The inner surface of the mammalian gastrointestinal tract is covered by a mono-layered 
epithelium that is specialized on nutrient uptake and digestion. In the small intestine, the 
epithelium is organized in crypt and villi structures (Figure 1.2a). Protruding long into the 
intestinal lumen, the villi magnify the absorptive surface area for efficient nutrient uptake. 
Multiple epithelial invaginations located at the base of each villus, the crypts of Lieberkühn, 
form the niches for the adult intestinal stem cells that constantly renew the epithelium10. In the 
colon, the epithelium does not possess villi but has a flat surface interspersed by crypts (Figure 
1.2b). Along the longitudinal length of the gastrointestinal tract, i.e. from the duodenal, jejunal 
and ileal parts of the small intestine to the colon, the epithelium shows a gradual decrease in 
the activity of Wnt signalling and the abundance of stem cells. Distinct levels of Wnt 
over-activation are required in the individual segments to reach a tumor-initiating threshold, 
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the ‘just-right’ level of Wnt activity11, 12. The stabilization of β-catenin in the intestinal epithelium 
of mice efficiently transforms epithelial cells in the small intestine, while colonic lesions are rare 
or absent11. In contrast, human gastrointestinal tumors mostly occur in the colon and rectum; 
a discrepancy that is attributed to variations in the physiological Wnt levels and stem cell 
numbers between humans and mice11. 
           
Figure 1.2: Structure of the small intestinal and colon epithelium. 
Scanning electron micrographs of the small intestinal epithelium (a). Multiple crypts are located at the 
base of each villus. The epithelium in the colon (b) has a flat surface interspersed with crypts, modified 
from Barker (2014)13. 
 
1.1.1 Lgr5+ intestinal stem cells maintain the epithelium. 
The intestinal epithelium is a highly proliferative tissue with a fast turnover time of 4-5 days13. 
Actively proliferating stem cells maintain the epithelium. Located at the base of the crypts, the 
stem cells are well protected from damage by harmful toxins and pathogens in the gut. Due to 
their column-shaped appearance the stem cells were initially described as crypt base columnar 
(CBC) cells14. CBC cells express the leucine-rich repeat-containing G-protein coupled 
receptor 5 (Lgr5/Gpr49), a 7-transmembrane receptor for R-spondins, which has emerged as 
a powerful marker for adult intestinal stem cells15. Each crypt contains about six stem cells that 
divide approximately once every 24h and give rise to all cell types of the epithelium15. The 
maintenance and self-renewal of the intestinal stem cells critically depend on active Wnt 
signalling16. Interfering with canonical Wnt signalling severely impairs intestinal crypt 
homeostasis. Genetic deletion of the Wnt effectors Tcf4 or β-catenin in the intestinal epithelium 
inhibits cell proliferation and causes loss of stem cells16, 17. 
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1.1.2 Canonical Wnt signalling sustains adult intestinal stem cells. 
The Wnt signalling pathway plays crucial roles in embryogenesis and adult tissue homeostasis 
and is highly conserved in multicellular organisms18. In canonical Wnt signalling, secreted Wnt 
ligands bind to LRP/Frizzled receptor complexes at the cell surface and trigger a signalling 
cascade that stabilizes β-catenin (Figure 1.3). 
In the absence of a Wnt stimulus (Wnt OFF), β-catenin is retained in a destruction complex 
composed of adenomatous polyposis coli (APC), the Ser/Thr kinases glycogen synthase 
kinase 3β (GSK3β) and casein kinase Iα (CKI), and Axin/conductin19-22. CKI and GSK3β 
sequentially phosphorylate serine and threonine residues in the N-terminus of β-catenin, 
marking β-catenin for ubiquitination and degradation by the ubiquitin-proteasome system21, 23. 
 
Figure 1.3: Canonical Wnt signalling in intestinal stem cells. 
Left: In the absence of Wnt ligands, β-catenin is degraded by the destruction complex and the Wnt target 
genes are silenced in a Groucho-dependent manner. Right: Wnt ligand binding to LRP/Frizzled 
receptors inactivates the destruction complex. β-catenin accumulates and translocates to the nucleus, 
activating the expression of Wnt target genes. In intestinal stem cells, R-spondin binding to Lgr5 
receptors potentiates Wnt signalling. 
LRP/Frizzled receptor activation by Wnt ligands (Wnt ON) sequesters and inactivates the 
destruction complex in a Dishevelled (Dvl)-dependent manner, and suppresses β-catenin 
ubiquitination24, 25. Free cytosolic and de novo synthesized β-catenin cannot be marked for 
degradation, accumulates and translocates to the nucleus. Once in the nucleus, β-catenin 
interacts with T-cell factor/lymphoid enhancer factor-1 (Tcf/Lef1) transcription factors to drive 
target gene expression26. In the intestinal epithelium, the major nuclear effector of Wnt 
signalling is the Tcf isoform 4 (Tcf4)27. Tcf transcription factors occupy their DNA target sites 
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also in the absence of a Wnt signal, but by then form a complex with co-repressor proteins of 
the Groucho/Tle (transducin-like enhancer of split) family, which keep the target genes 
silenced28. Upon Tcf interaction with β-catenin, co-repressors are inactivated and co-activators 
like the CREB-binding protein (CBP)/p300, Pygo2 and Bcl9/Bcl9-like activate the expression 
of β-catenin/Tcf target genes such as Axin2 29-33. 
Wnt signalling in intestinal stem cells activates the expression of the stem cell gene Lgr5 which 
encodes a receptor for R-spondins34 (Figure 1.3). R-spondin binding to Lgr5 potentiates the 
cellular Wnt signalling response by stimulating an association of Lgr5 with the Frizzled/LRP 
receptor complex35. R-spondin binding further induces an interaction of Lgr5 with the stem cell-
specific transmembrane E3 ubiquitin ligases RNF43 (ring finger protein 43) and ZNRF3 (zinc 
and ring finger 3), which ubiquitinate Frizzled receptors and target them for endocytosis and 
degradation36, 37. The interaction with Lgr5 stimulates RNF43/ZNRF3 internalization and 
membrane clearance, and thus enhances Wnt signalling by increasing the membrane level of 
Frizzled receptors37. The potentiation of Wnt activity by R-spondins is critical for stem cell self-
renewal38. Wnt ligands by themselves are insufficient to sustain the self-renewal of Lgr5+ 
intestinal stem cells, but are essential to the intestinal stem cells in that they stimulate the 
expression of Lgr5 and hence render the cells responsive to R-spondins38. In the absence of 
Wnt ligands, R-spondins fail to induce canonical Wnt signalling, the stem cells lose their self-
renewal capacity and differentiate38. 
A tight control of Wnt signalling by Bmp and Notch is critical for stem cell maintenance. 
Deregulation of Wnt signalling perturbs intestinal homeostasis, promotes stem cell 
differentiation and initiates intestinal tumorigenesis39. A tightly controlled level of Wnt signalling 
is therefore critical for stem cell maintenance. Bmp and Notch signals crosstalk with Wnt 
signalling to adequately balance the Wnt activity in the intestinal crypts40, 41. Bmp signalling 
restricts stemness and proliferation by repressing the expression of stem cell genes and Wnt 
signalling40, 42. Mesenchymal cells surrounding the crypts produce Bmp antagonists such as 
Noggin and Gremlin to ensure proper balancing of Wnt and Bmp signalling for stem cell 
maintenance but prevent Bmp-mediated terminal differentiation40, 43. Stem cell maintenance 
further depends on active Notch signalling44. Inhibition of Notch signalling increases the Wnt 
activity at the crypt base and enforces secretory cell differentiation of intestinal stem cells41. 
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1.1.3 Signalling circuits specify the structure and function of the intestinal epithelium. 
Lgr5+ intestinal stem cells give rise to highly proliferative transit-amplifying (TA) progenitor 
cells, which are located above the stem cells in the crypt. TA cells undergo 4-5 cell divisions 
within a remarkably short time frame of 12h45. Moving upwards towards the crypt-villus 
junction, the TA cells differentiate into absorptive enterocytes and secretory cells, including 
Paneth cells, mucus-secreting goblet cells, hormone-producing enteroendocrine cells and tuft 
cells10 (Figure 1.4a). Except for the Paneth cells, the differentiated cells constantly migrate up 
the villi. Once they reach the villus tip, the epithelial cells are shed into the intestinal lumen and 
undergo anoikis, a form of apoptosis induced by the loss of attachment to the extracellular 
matrix. Paneth cells escape the crypt-villus movement and migrate down into the crypt, where 
they intersperse the Lgr5+ stem cells and persist for 6-8 weeks46, 47 (Figure 1.4a). The Paneth 
cells secrete antimicrobial peptides such as defensins and lysozyme and provide Wnt ligands 
and other growth factors for stem cell maintenance48. The downward migratory path of the 
Paneth cells is guided by a counter-gradient of ephrin receptor B3 (EphB3) and its ligand 
ephrin-B46. Paneth cells express high levels of the receptor EphB3 and are repulsed by the 
differentiated cells of the villus that highly express ephrin-B ligands46. The Paneth cells are a 
major source of the Wnt ligand Wnt3a and the Notch ligands Dll1 and Dll4 in the crypt stem 
cell niche48. Mesenchymal cells surrounding the crypts also secrete Wnt ligands and 
R-spondins, which are sufficient to maintain the stem cells in the absence of Paneth cells49-51. 
 
Figure 1.4: The crypt-villus axis and signalling circuits in intestinal epithelial differentiation. 
a) The intestinal crypt-villus axis, adapted from Barker (2014)13. Lgr5+ intestinal stem cells give rise to 
transit-amplifying (TA) progenitor cells that proliferate and differentiate into all cell types of the 
epithelium. b) Opposing gradients of Wnt and Bmp signalling organize the epithelium in proliferative 
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crypt and differentiated villus compartments. c) Cell type specification in the intestinal epithelium is 
guided by a network of signalling systems, modified from Barker (2014)13. Wnt and Notch signalling 
maintain Lgr5+ intestinal stem cells at the crypt base. The stem cells self-renew and give rise to TA cells 
which are specified towards the secretory or absorptive lineage depending on the activity of Notch 
signalling. Absorptive progenitor cells differentiate into enterocytes. Secretory progenitors express 
Atoh1 and differentiate into Paneth, goblet, enteroendocrine or tuft cells. 
Inverse gradients of Wnt and Bmp signalling shape the crypt-villus axis. 
Opposing gradients of Wnt and Bmp signalling organize the intestinal epithelium in proliferative 
crypt and differentiated villus compartments (Figure 1.4b). High concentrations of Wnt ligands 
at the base of the intestinal crypt ensure high Wnt activity in the stem cell niche52. The 
abundance of Wnt receptors presented on the cell surface and progressive dilution of receptor-
bound Wnt ligands through cell division establish a Wnt gradient from the crypt base to the 
villus53. Wnt signalling is low in the villus, where high concentrations of Bmp ligands secreted 
by intra-villus mesenchymal cells stimulate Bmp signalling and promote cell differentiation54. 
Absorptive versus secretory lineage specification by Notch and Atoh1. 
A tightly regulated network of signalling pathways guides cellular differentiation in the intestinal 
epithelium (Figure 1.4c). The first lineage decision takes place in the proliferative TA zone. TA 
cells are specified towards absorptive or secretory progenitor cells depending on the activity 
of Notch signalling and the expression of Atoh1. TA cells with high Notch activity express the 
transcription factor Hes1 and are prone to differentiate into absorptive enterocytes55. Hes1 
prohibits secretory differentiation by repressing Atoh1 (also known as Math1 in mouse, Hath1 
in humans), a transcription factor critical for secretory lineage specification55, 56. Low Notch 
activity in TA cells and the consequent absence of Hes1 allow for Atoh1 production, specifying 
the cells towards the secretory lineage56 (Figure 1.5). Genetic ablation of the Notch 
transcription factor Rbp-j disables Hes1 expression and converts intestinal epithelial crypt cells 
in secretory goblet cells57. Vice versa, the ablation of Atoh1 converts secretory cells into 
absorptive enterocytes58. 
       
Figure 1.5: Notch/Hes1 and Atoh1 control the absorptive versus secretory fate in TA cells. 
Absorptive specification depends on Notch-induced expression of the transcription factor Hes1. TA cells 
with low Notch activity express the transcription factor Atoh1 and differentiate towards the secretory 
lineage, modified from Barker (2014)13. 
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Hes transcription factors suppress the expression of Cdk inhibitors and boost the proliferation 
of absorptive lineage progenitors59. In contrast, secretory progenitor cells exit the cell cycle 
and stop proliferating, which lets absorptive enterocytes outnumber secretory cells by far60. 
Wnt and Mapk signalling specify Paneth and goblet cell differentiation of secretory 
progenitor cells. 
Atoh1+ secretory progenitor cells differentiate into the diverse cell types of the secretory 
lineage. The transcription factor Gfi1 acts downstream of Atoh1 to select Paneth/goblet cell 
fates versus the enteroendocrine fate61 (Figure 1.6a). Downstream of Atoh1 and Gfi1, the ETS 
transcription factor Spdef further directs secretory progenitor maturation in goblet and Paneth 
cells62, 63. Deletion of Spdef in the mouse intestine leads to an accumulation of immature 
secretory progenitor cells62. 
       
Figure 1.6: Specification of Paneth and goblet cells by Wnt and Mapk signalling. 
a) Secretory progenitor maturation towards Paneth and goblet cells is specified by Wnt and Mapk 
signalling, modified from Barker (2014)13, Heuberger et al. (2014)64. b) Scheme of the Mapk signalling 
cascade. Growth factor signalling via epidermal growth factor receptor (Egfr) or transforming growth 
factor beta receptor (Tgfbr) induces phosphorylation (P) and activation of the protein kinase Mek1/2. 
Mek1/2 activates Erk1/2 kinases which phosphorylate transcription factors (TFs) to activate gene 
expression. 
High Wnt activity in secretory progenitor cells promotes the differentiation of Paneth cells65 
(Figure 1.6a). Paneth cells are absent in Tcf4-deficient mice65. High Wnt activity blocks goblet 
cell differentiation, as goblet cells are absent in Apc-mutant intestine66. Mitogen-activated 
protein kinase (Mapk) signalling impedes the Wnt-induced maturation of Paneth cells and 
shifts the differentiation of common Paneth-goblet progenitors towards a goblet cell fate64 
(Figure 1.6a, b). 
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1.1.4 Cell type plasticity in the intestinal epithelium. 
The intestinal epithelium possesses a remarkable plasticity and a high regenerative capacity67. 
Upon injury to the stem cell niche or experimental ablation of Lgr5+ intestinal stem cells, these 
stem cells are rapidly replaced by committed progenitor cells that de-differentiate and adopt a 
stem-like identity. Non-cycling secretory progenitors located at the “+4” position directly above 
the Paneth cells re-enter the cell cycle and convert into actively cycling Lgr5+ cells upon crypt 
damage; these progenitor cells are also known as label-retaining Bmi1+ quiescent stem 
cells68, 69. Atoh1+ secretory progenitor cells revert to functional Lgr5+ stem cells both upon injury 
and at homeostasis70, 71. Highly proliferative alkaline phosphatase (Alpi+) enterocyte precursors 
in the upper crypt can also generate proliferating stem cells and Paneth-like cells after targeted 
ablation of Lgr5+ stem cells72. A “point-of-no-return” defining the loss of de-differentiation 
capability of terminally differentiated intestinal epithelial cells has not been clearly determined. 
Even fully differentiated Paneth cells can gain multipotency and stem-like features to 
regenerate the epithelium upon Lgr5+ stem cell loss73. In contrast, Alpi+ enterocytes which have 
exited the crypt for longer than three days stop proliferating and lose the de-differentiation 
capacity of the Alpi+ cells in the upper crypt72. The plasticity of intestinal epithelial cells thus 
appears to depend on a certain proximity to the crypt and its growth factor-rich environment, 
which imposes stemness on intestinal progenitor cells. Moreover, a cell-intrinsic permissive 
state is a prerequisite for cellular plasticity and de-differentiation, as Notch1+ absorptive 
progenitor cells lack regenerative capacity despite their proximity to the crypt stem cell niche70. 
1.1.5 Intestinal organoids - a tool to study epithelial stem cell biology. 
Single Lgr5+ intestinal stem cells cultured in vitro in a basal lamina-like gelatinous matrix can 
self-organize into three-dimensional organoids, also called “mini-guts” 74. Intestinal organoid 
formation and growth critically depend on a specialized serum-free growth medium 
supplemented with the Wnt amplifier R-spondin1, the Bmp antagonist Noggin and epidermal 
growth factor (EGF) that mimic the in vivo stem cell niche. Intestinal organoids preserve the 
cellular complexity of the intestinal epithelium: crypt-like domains comprising stem cells and a 
TA compartment project outward and bud from a hollow roundish structure of differentiated 
epithelial cells organized in villus domains. Goblet and Paneth cells secrete towards the lumen 
of the organoid, whereto also dead cells are shed. The lack of innervation, blood vessels, 
immune cells and a proper in vivo microenvironment are limitations to the organoid technology. 
Closely recapitulating the in vivo epithelium and selecting for a purely epithelial culture, though, 
intestinal organoids have emerged as a valuable system to study epithelial stem cell biology, 
dissect signalling pathways in organ development and disease, and to investigate the impact 
of genetic mutations on epithelial homeostasis75. Patient-derived tumor organoids are of great 
value to predict drug response in vitro76.   
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1.2 Wnt signalling and adult intestinal stem cells in colon cancer. 
1.2.1 Deregulation of Wnt signalling in intestinal stem cells initiates colon cancer. 
Deregulated Wnt signalling is a hallmark of colon cancer. 85% of all sporadic and hereditary 
colon cancers show mutations in APC that disrupt its ability to induce the degradation of 
β-catenin2. The remaining 15% of colon cancers with wild-type APC frequently show point 
mutations in CTNNB1 that alter the serine/threonine residues in the N-terminal domain of 
β-catenin and render it insensitive to GSK3β-mediated phosphorylation, ubiquitination and 
proteasomal degradation77. Loss of APC and expression of a stabilized form of β-catenin both 
lead to deregulated nuclear accumulation of β-catenin and aberrant activation of Wnt target 
genes, inducing crypt hyperplasia and adenoma formation in mice66, 78. Over-activation of Wnt 
signalling in Lgr5+ intestinal stem cells induces adenoma formation, whereas deregulation of 
Wnt signalling in differentiated intestinal epithelial cells is insufficient to initiate tumorigenesis79. 
This led to the ‘bottom-up’ model of intestinal tumorigenesis in which stem cells at the crypt 
base are hit by an oncogenic mutation and initiate tumorigenesis80. Contrary to the ‘bottom-up’ 
hypothesis, very early adenomatous polyps are frequently observed at the top of colon crypts 
without any contact to the stem cell niche. A ‘top-down model of adenoma morphogenesis’ 
therefore challenges the bottom-up hypothesis81. In accordance with a top-down model, 
inflammation-activated NF-κB signalling promotes Wnt-driven tumor formation from 
differentiated Lgr5-negative epithelial cells82. The NF-κB activity potently enhances Wnt 
signalling to induce a crypt-progenitor phenotype. The de novo crypt-like structures evert from 
the villus epithelium and form a niche, enforcing a stem-like state on epithelial villus cells and 
restoring the expression of Lgr5+ stem cell genes82. Accordingly, the deregulation of Wnt 
signalling can initiate tumorigenesis also in a non-stem cell population but requires additional 
stimuli such as inflammation-induced NF-κB signalling. Both the bottom-up and the top-down 
intestinal tumorigenesis depend on the emergence of stem-like cells that initiate intestinal 
transformation in a Wnt-driven manner. 
1.2.2 Wnt-dependent cancer stem cells maintain intestinal tumors. 
Deregulation of Wnt signalling does not only initiate intestinal tumorigenesis, but high Wnt 
activity is continuously required for the proliferation and growth of intestinal tumors83. Restoring 
Apc function in advanced-stage Apc-deficient intestinal tumors induces differentiation of the 
tumor cells and re-establishes intestinal homeostasis in spite of additional oncogenic mutations 
in Kras and p53 84. Even though mutations in APC or β-catenin are expected to uniformly 
activate Wnt signalling, intestinal tumors exhibit strikingly heterogeneous levels of Wnt 
activity85. Lineage tracing in Apc-mutant tumors revealed that intestinal tumors consist of a 
heterogeneous population of cells in various differentiation states and retain a cell type 
hierarchy which is reminiscent of the intestinal epithelium86. A small fraction of tumor cells has 
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a particularly high tumorigenic potential and fuels tumor growth. These cancer cells resemble 
adult tissue stem cells in that they self-renew and give rise to differentiated non-stem tumor 
cells, and are therefore called ‘cancer stem cells’ 87. Tumor cells with high Wnt signalling have 
turned out to be functional cancer stem cells, whereas tumor cells with low Wnt activity are 
rather differentiated88. High Wnt activity is thus crucial for the formation and maintenance of 
colon cancer stem cells. 
The gene expression programme of intestinal cancer stem cells is highly reminiscent of the 
transcriptional profile in Lgr5+ intestinal stem cells, while non-stem cancer cells resemble TA 
and differentiated epithelial cells86, 89. Human colon adenomas show a strong expansion of 
Lgr5-expressing stem-like cells90. Genetic ablation of Lgr5+ cancer stem cells through 
diphtheria toxin halts colon cancer growth, highlighting the relevance of these stem cells for 
tumorigenesis91. High Wnt signalling promotes colon cancer stemness by directly inducing the 
expression of stem cell genes like Lgr5 15, Ascl2 (Achaete-scute complex-like 2)92 and 
Cd44 93. In addition, colon cancer stem cells express Wnt-independent stem cell genes such 
as Igfbp4 (insulin-like growth factor-binding protein 4), Smoc2 (secreted modular calcium-
binding matricellular protein-2) and Olfm4 (Olfactomedin-4)89, implying that an interplay of Wnt 
signalling and Wnt-independent regulatory mechanisms defines colon cancer stemness. 
Smoc2 expression is activated by the L1CAM-ezrin-NF-κB signalling pathway94, Olfm4 
expression is regulated by Notch signalling95. A recent study has proposed a Wnt-dependent 
activation of Olfm4 96. However, Olfm4 is absent in Wnt-driven adenomas, in which high Wnt 
activity represses Notch signalling92. The expression of stem cell genes has been shown to 
predict disease relapse in colon cancer patients: high expression of Lgr5+ stem cell genes 
characterizes aggressive and metastasized colon cancer and associates with a high risk of 
tumor recurrence89. 
1.2.3 Targeting cancer stem cells to prevent colon cancer relapse. 
Therapeutic interventions in cancer are often ineffective due to cancer stem cells that escape 
chemotherapy, initiate relapse and metastatic dissemination97. Chemotherapy might initially 
cause tumor shrinkage because the bulk of proliferating tumor cells is effectively killed. It often 
fails, however, to induce complete tumor regression as highly tumorigenic cancer stem cells 
survive chemotherapy and re-establish the tumor (Figure 1.7). Relapsing tumors are often 
more aggressive than the initial tumors, as they are highly enriched for cancer stem cells98. It 
is believed that targeted therapeutic elimination of cancer stem cells will greatly enhance 
treatment efficacy. Cancer stem cell-targeting therapies are not yet available in the clinic, 
though, and we are still in search of adequate molecular targets and potent therapeutic agents. 
Recent studies have revealed a so far unacknowledged plasticity of intestinal tumors. 
Differentiated colon cancer cells can revert into fully active Lgr5+ colon cancer stem cells and 
re-grow the tumor after Lgr5+ cell-eliminating therapy91, 99. In preclinical models, the 
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reprogramming of differentiated cancer cells and subsequent tumor regrowth were 
successfully prevented by combining the depletion of Lgr5+ cancer stem cells with conventional 
chemotherapy99. An efficient tumor therapy hence needs to succeed in both the elimination of 
cancer stem cells and the depletion of the differentiated but plastic tumor bulk. 
 
Figure 1.7: The concept of targeting cancer stem cells. 
Conventional chemotherapy depletes the tumor bulk, but cancer stem cells (CSCs) remain and initiate 
relapse. CSC-targeting therapies eliminate CSCs, but fail to prevent de-differentiation of non-stem tumor 
cells that replenish CSCs and fuel tumor regrowth. A combination therapy of conventional chemotherapy 
and targeting of CSCs promises to efficiently halt tumor growth. 
Given the strong Wnt-dependency of intestinal cancer stem cells and tumors, therapeutic 
targeting of the Wnt pathway has emerged as a rational treatment for colon cancer. The 
restoration of Apc function in Apc-deficient colon cancer in mice promotes tumor cell 
differentiation and re-establishes homeostatic tissue function84, highlighting the therapeutic 
potential of targeting aberrant Wnt signalling. In recent years, small molecules which target the 
Wnt pathway have been developed. The small-molecule inhibitor LF3 disrupts the interaction 
of Tcf4 with β-catenin and blocks β-catenin/Tcf4-driven Wnt target gene activation100. ICG-001 
interferes with the interaction of β-catenin and CBP, inhibiting the transactivation activity of the 
β-catenin/Tcf4 complex101. Therapeutic interference with β-catenin activity in colon cancer cells 
shows strong anti-tumorigenic effects in preclinical studies100, 101. Clinical trials for the ICG-001-
derivative PRI-724 are underway, but thus far we are lacking a clinically approved drug to 
target oncogenic Wnt signalling in colon cancer with mutations in APC or β-catenin. A major 
concern in direct targeting of the Wnt pathway is the critical requirement of Wnt activity for the 
maintenance and self-renewal of adult intestinal stem cells102. A targeted therapy for colon 
cancer requires the identification of therapeutic targets that discriminate cancer cells from 
normal epithelial cells. 
Epigenetic regulators have emerged as crucial players in tumorigenesis. Their abnormal 
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activities in cancer cells alter cell-specific gene expression and contribute to tumor 
progression103. Due to their dynamic and reversible nature, epigenetic modifications represent 
promising targets for cancer therapy. In recent years, several small-molecule inhibitors 
targeting chromatin-modifying enzymes have been developed that show efficacy in resetting 
the cancer epigenome in various tumor entities in preclinical studies103. 
1.3 The epigenetic regulation of gene expression. 
1.3.1 Chromatin and epigenetics. 
All cells of a given organism carry identical genetic information, but are capable of adopting 
various phenotypes to build different tissues with distinct functions. In the early 1940s, Conrad 
Waddington introduced the term ‘epigenetics’, meaning ‘in addition to changes in genetic 
sequence’, to describe the phenomenon of heritable phenotypic divergence without changes 
to the DNA sequence104. In eukaryotic cells, the genetic material is organized in complex 
structures of DNA-protein interactions, the so-called chromatin (Figure 1.8). 147bp of DNA 
wrap around histone octamers of the core histone proteins H2A, H2B, H3 and H4 to form a 
nucleosome. The linker histone H1 ensures stability of nucleosomal histone-DNA particles105. 
   
 Figure 1.8: Chromatin structure. 
 Modified from Shilatifard (2012)105. 
Thinking of the DNA in its unfolded state, the nucleosomes appear like ‘beads on a string’, 
threaded in a regular distance from each other. Histone-histone as well as histone-DNA 
interactions alter the packing density of the nucleosomes. Eukaryotic nuclei compart into 
euchromatic “open” regions with loose chromatin packaging and areas with densely packed 
nucleosomes and a “closed” chromatin structure, the heterochromatin. Heterochromatic areas 
remain condensed throughout the cell-cycle interphase and contain mostly silenced genes. 
The open chromatin structure of euchromatic regions confers DNA accessibility and allows for 
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active gene expression. Hence, epigenetic regulation determines which genes are active and 
which ones are silenced, and thereby establishes cell identity. 
1.3.2 Epigenetic regulation translates cell signalling into gene expression. 
Cellular signalling pathways converge in epigenetic regulation to translate intrinsic and 
extrinsic signals into appropriate lineage-specific gene expression profiles. The number of 
signalling pathways and signal transducers is limited. To achieve the cellular and phenotypic 
diversity required to build a functional organism, signalling pathways induce different sets of 
target genes in distinct cells, rather than instructing a universal gene expression programme106. 
In the intestinal epithelium, Wnt/β-catenin signalling maintains stem cells and drives the 
proliferation of progenitor cells but also promotes the differentiation of Paneth cells. Distinct 
sets of activated Wnt/β-catenin target genes underlie these diverse functions: the 
β-catenin/Tcf4-regulated genes c-Myc, Cd44 and cyclin D1 are expressed in the proliferative 
cells of the transit-amplifying compartment, while Mmp7 and EphB3 define terminally 
differentiated Paneth cells107. In intestinal stem cells, Wnt signalling induces the expression of 
stem cell genes such as Lgr5, Ascl2 and Znrf3 15, 107. The regulatory mechanisms underlying 
these differential lineage-specific target gene responses to Wnt signalling are largely unknown. 
Cell type-specific β-catenin/Tcf occupancy at target sites would be an obvious explanation for 
differential Wnt responses, but this concept turned out to be oversimplified: upon activation of 
Wnt signalling, Tcf/Lef and β-catenin occupy all Wnt target sites regardless of whether the 
corresponding genes will become expressed in the particular cell or not108. The recruitment of 
β-catenin to target genes does not imply transcriptional activation, β-catenin binding has 
proven necessary but not sufficient for gene activation106. Consequently, regulatory 
mechanisms apart from β-catenin/Tcf occupancy must determine the lineage-specific 
activation of Wnt target genes. The histone acetyltransferases CBP and p300 associate with 
β-catenin in a mutually exclusive manner to activate transcription, inducing fundamentally 
different transcriptional responses29. While CBP/β-catenin complexes activate the expression 
of genes promoting cell proliferation, p300/β-catenin complexes induce cell differentiation109. 
Epigenetic regulation thus emerges as a determinant of the differential tissue- and cell type-
specific expression of Wnt target genes. Various kinds of epigenetic modifications can 
modulate chromatin structure and gene expression in a cell type-specific manner, among these 
DNA methylation, chromatin remodelling, long non-coding RNAs and histone modifications. 
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1.3.3 Epigenetic regulation by histone modifications. 
The N-terminal tails of the histone proteins protrude from the nucleosomes and are extensively 
decorated with posttranslational modifications110. These histone modifications directly 
influence gene activity by altering nucleosome density and chromatin condensation at 
promoter and enhancer regions. They also offer docking sites for proteins implicated in diverse 
biological processes. Histone modifications are highly dynamic and reversible, constantly 
translating developmental and environmental cues into changes in gene activity. Epigenetic 
modifications and the chromatin structure determine which genes are active and which ones 
are silenced, thus defining the cellular transcriptome and enabling the emergence of different 
cell types from an identical genetic code. Various types of histone modifications have been 
identified, among others histone methylation, acetylation, phosphorylation and ubiquitination 
that act in concert with transcription factors and co-regulatory proteins to regulate gene 
expression110. Certain types of histone modifications are associated with active gene 
expression, e.g. the tri-methylation of histone H3 at lysine K4 (H3K4me3) and the acetylation 
of histone H3 lysine residues, while others repress gene activity, e.g. the tri-methylation of 
histone H3 at lysine K27 (H3K27me3)111. There is evidence for a crosstalk of distinct histone 
marks, with some modifications acting sequentially or in combination and others being mutually 
exclusive. This yields a ‘histone code’ that is ‘written’, ‘read’ and ‘erased’ by histone-modifying 
proteins and dictates chromatin structure and gene regulation112. The ‘readers’ of histone 
modifications are equipped with specialized domains: PHD fingers, WD40-repeat domains, 
chromodomains and Tudor domains recognize methyl marks, bromodomains read 
acetylations110. Once bound to a particular histone mark, the ‘readers’ recruit transcriptional 
co-activators or co-repressors, chromatin-remodelling enzymes, transcription factors and 
components of the RNA polymerase II (RNA pol II) basal transcription machinery to translate 
histone modifications in gene activity. The language of histone modifications has turned out to 
be highly complex and we have only started learning how to understand this complexity. 
1.3.4 Histone lysine methylation. 
Histone methylation occurs on lysine and arginine residues of histone N-terminal tails, mainly 
of histones H3 and H4. Histone lysine methyltransferases catalyse the transfer of a methyl 
group (-CH3) from the methyl group donor S-adenosyl-methionine (SAM) to the ε-amino group 
of lysine residues (Figure 1.9). Several lysine residues in the histone H3 and H4 tails have 
been identified, which can all be mono-, di- and tri-methylated: histone H3 is methylated at the 
lysine residues K4, K9, K27, K36 and K79, histone H4 methylation takes place at lysine K20110. 
Depending on the position of the methylated residue on the histone tail, histone lysine 
methylation induces either gene activation or repression. 
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Figure 1.9: Catalysis of histone lysine methylation. 
Histone lysine methyltransferases (KMTs) catalyse the transfer of a methyl group (-CH3) from 
S-adenosyl-methionine (SAM) to the ε-amino group of lysine residues. SAM thereby converts to 
S-adenosyl homocysteine (SAH). Modified from Zhang and Reinberg (2001)113. 
The methylation of histone lysine residues is catalysed by histone lysine methyltransferases 
(KMTs). All but one of these methyltransferases contain a 130-amino acid catalytic SET 
domain. This enzymatic domain has first been described as a conserved sequence in the three 
Drosophila methyltransferases suppressor of variegation 3-9 (Su(var)3-9), enhancer of zeste 
(E(z)) and trithorax (Trx)114. The non-SET domain lysine methyltransferase Dot1l (disruptor of 
telomeric silencing-1-like) is the only known lysine methyltransferase that does not possess a 
SET domain; it methylates lysine K79 within the globular domain of histone H3115. Specialized 
histone lysine demethylases (KDMs) erase lysine methylation marks and render histone lysine 
methylation a reversible and dynamic histone mark116. 
1.3.5 H3K4 tri-methylation marks active genes. 
Methylation of histone H3 at lysine 4 (H3K4) is found in euchromatic regions of active gene 
expression. Di-methylated H3K4 (H3K4me2) appears broadly associated with transcribed 
regions117, and mono-methylated H3K4 (H3K4me1) is mostly found at active enhancer regions 
of the genome118. The tri-methylation of H3K4 (H3K4me3) is commonly associated with an 
open chromatin structure and gene activation. A PHD finger of the NURF chromatin-
remodelling complex binds H3K4me3 marks, coupling H3K4 tri-methylation to the opening of 
the chromatin structure119. The basal transcription factor TFIID recognizes H3K4me3 via a 
PHD finger in its TAF3 subunit, which facilitates RNA pol II recruitment to transcription start 
sites and transcription initiation120. H3K4me3 marks are closely linked to actively transcribed 
genes and tend to occur as defined sharp peaks at the transcription start site, suggesting a 
direct and essential role in activating transcription121. However, experimental evidence for a 
global instructive role of H3K4me3 in the activation of transcription is lacking. Genome-wide 
loss of H3K4me3 has only minimal effect on global transcription rates and gene activation122. 
That is why the H3K4me3 mark has been proposed to rather associate than instruct 
transcription123. Recent studies indeed reported a functional role of H3K4 methylation in 
maintaining lineage-specific gene expression and stabilizing transcription124, 125. In any case, 
the strong positive correlation of H3K4me3, transcription rates and RNA pol II occupancy 
renders H3K4me3 a marker for active genes. 
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1.3.6 H3K4 methyltransferases of the Set1/Mll family. 
H3K4 methyltransferases were originally identified in the yeast Saccharomyces cerevisiae. 
The yeast Set1 enzyme associates in a large multi-protein complex, the ‘complex of proteins 
associated with Set1’ (COMPASS), to catalyse the mono-, di- and tri-methylation of H3K4126. 
While Set1 is the only H3K4 methyltransferase in yeast, the fruit fly Drosophila melanogaster 
possesses three related enzymes (dSet1, trithorax (Trx) and trithorax-related (Trr))127. 
Mammals express six Set1-related H3K4 methyltransferases, the members of the Mll (mixed 
lineage leukemia)/Kmt2 (histone lysine N-methyltransferase 2) family105 (Figure 1.10). Mll1 
(Kmt2a) and Mll2 (Kmt2b) are the mammalian orthologues of Drosophila trithorax (Trx) which 
preferentially di- and tri-methylate H3K4 at promoter regions105. They account for about 50% 
of all Mll complexes and are the most abundant Mll methyltransferases in mammalian cells128. 
Mll1 and Mll2 proteins are present in roughly equal amounts128. Mll3 (Kmt2c) and Mll4 (Kmt2d) 
are the mammalian orthologues of Drosophila trithorax-related (Trr) which mono-methylate 
H3K4 at enhancer regions129. Setd1a (Kmt2f) and Setd1b (Kmt2g) are responsible for the bulk 
of H3K4 tri-methylation at gene promoters130, 131. Setd1a is more abundant than Setd1b, 
accounting for ~25% and ~7% of all Mll proteins, respectively128. The paralogues Mll1/Mll2, 
Ml3/Mll4 and Setd1a/Setd1b have each arisen from chromosomal duplication in mammalian 
evolution132. 
           
Figure 1.10: The Set1/Mll family of H3K4 methyltransferases. 
Yeast Set1 mono-, di- and tri-methylates H3K4. Drosophila possesses three enzymes with distinct 
methylation activities. Mammals comprise six Set1-related H3K4 methyltransferases with distinct H3K4 
methylation preferences. 
The six methyltransferases of the mammalian Mll family exert non-redundant functions. 
Despite similar domain structures and interaction partners, even the two paralogues in each 
subgroup are non-redundant and exhibit largely non-overlapping subnuclear distributions132. 
Similar to yeast Set1, the mammalian Mll family members reside in multi-protein complexes105. 
A common core complex composed of the WD40-repeat containing protein 5 (Wdr5), 
retinoblastoma-binding protein 5 (Rbbp5), Ash2-like (Ash2l) and Dpy30, termed WRAD, 
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assembles around the SET domains and strongly enhances the otherwise weak H3K4 
methylation activities of the Mll enzymes133. 
1.3.7 H3K4 methylation by Set1/Mll antagonizes H3K27 methylation and gene silencing 
by Polycomb group proteins. 
H3K4 methylation established by Set1/Mll methyltransferases of the Trithorax Group (TrxG) 
counteract the repressive tri-methylation of histone H3 at lysine K27 (H3K27me3) catalysed 
by Polycomb Group (PcG) proteins134. PcG proteins exist in two major complexes with distinct 
enzymatic properties, the polycomb repressive complexes 1 and 2 (PRC1 and PRC2)135. 
PRC2 complexes comprise the H3K27 methyltransferases Ezh1 and Ezh2, PRC1 complexes 
contain the E3 ubiquitin ligases Ring1a and Ring1b which ubiquitinate H2A at lysine K119 
(H2AK119ub). H3K27me3 marks established by PRC2 are recognized by PRC1 complexes 
that can subsequently catalyse H2A ubiquitination and instruct chromatin compaction to 
silence gene transcription136. The antagonism of TrxG and PcG proteins defines H3K4 and 
H3K27 methylation at lineage-specific genes to establish and maintain cell type-specific gene 
expression patterns and cell identity134. By bookmarking lineage-specific genes, TrxG and PcG 
proteins constitute a ‘cellular memory’ which allows cells to keep their identity and remember 
it through cell divisions137. The biological functions of the TrxG-PcG antagonism in adult 
mammalian tissues are diverse and depend on the cellular context: in adult stem cells, the 
counteracting activities of TrxG and PcG proteins define stem cell identity by sustaining the 
expression of stem cell genes and repressing differentiation-associated genes138. Upon 
differentiation, the TrxG-PcG antagonism is crucial to fine-tune cell type specification by 
ensuring lineage-specific gene expression and supressing alternate cell fates138. 
1.3.8 Histone methyltransferases in cancer. 
The dynamic nature of the epigenome poses a risk for misregulation. Aberrations in histone 
modifications and mutations in chromatin-modifying enzymes are recurrently found in 
cancer103. In colon cancer, high levels of H3K4me3 are associated with a poor prognosis139. 
Methyltransferases of the Trithorax and Polycomb groups regulate cell identity. Their 
deregulated activities alter cellular gene expression profiles and drive tumorigenesis134. 
Polycomb PRC1 complexes have been implicated in Wnt-driven intestinal tumorigenesis140. 
The H3K4 methyltransferase Setd1a has been linked to the regulation of distinct Wnt/β-catenin 
target genes in colon cancer cells141. Tumor-promoting functions have also been reported for 
the histone methyltransferase Mll2142, 143. The family member Mll1 has not yet been studied in 
colon cancer. Genomic translocations of the Mll1 gene at 11q23 fuse ~1400 amino acids of 
the Mll1 N-terminus in frame to a variety of different translocation partners and drive aggressive 
human leukemia144. To date, over 70 different oncogenic MLL fusion proteins have been 
identified, among these fusions to ENL, AF9, AF4, ELL and AF10144. The enzymatic SET 
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domain is invariably deleted in MLL fusion proteins and is replaced by the activity and function 
of the particular fusion partner. MLL fusion proteins aberrantly activate transcription, often by 
recruiting the H3K79 methyltransferase Dot1l and the transcription elongation factors Cdk9 
and cyclinT1, also known as pTEFb144. MLL-rearranged leukemia commonly preserves at least 
one wild-type Mll1 allele with an intact SET domain. Recent data suggest that leukemogenesis 
in fact requires the wild-type allele of Mll1 145, although there is controversy on the need of wild-
type Mll1 and instead Mll2 has been attributed a major role in sustaining MLL-rearranged 
leukemia146. Given the central role of Mll1 in leukemogenesis, there is great interest in 
designing small-molecule inhibitors which target Mll1 function. The Menin inhibitor 2 (MI-2) 
inhibits the interaction of Mll1/Mll2 with Menin (Men1, multiple endocrine neoplasia-1), an 
essential oncogenic co-factor of MLL fusion proteins in leukemia147. Targeting the Menin-MLL 
interaction inhibits proliferation and induces differentiation of MLL leukemia cells in preclinical 
models147. The WRAD complex subunit Wdr5 is part of all Mll complexes, but only the integrity 
and methyltransferase activity of the Mll1 complex strongly depend on the interaction with 
Wdr5. Targeting the Mll1-Wdr5 interaction with the small molecules MM-401 and OICR-9429 
specifically interferes with the methyltransferase function of wild-type Mll1 and succeeds in 
inhibiting MLL leukemia cell growth148, 149. 
1.3.9 The histone methyltransferase Mll1. 
The histone methyltransferase Mll1 is a large 3969-amino acid protein with multiple domains. 
At its N-terminus, Mll1 comprises three DNA-binding AT hooks and a cysteine-rich CxxC zinc-
finger domain through which Mll1 binds to non-methylated CpG islands and protects these 
sites from DNA methylation150 (Figure 1.11). PHD finger motifs, a PHD-flanking acetyl-lysine 
binding bromodomain and a transactivation domain (TAD) are followed by a WDR5 interaction 
(Win) motif and the C-terminal catalytic SET domain151. The mature Mll1 protein is 
proteolytically cleaved by taspase-1 (threonine aspartase-1)152. The cleaved N-terminal (N320) 
and C-terminal (C180) fragments re-associate via their FYRN/C domains and form a stable 
Mll1N320/C180 heterodimer153. Post-cleavage association ensures Mll1 protein stability and 
correct nuclear localization153. 
Multiple interaction partners strongly enhance the methyltransferase activity of Mll1. The 
WRAD complex composed of Wdr5, Rbbp5, Ash2l and Dpy30 directly associates with the 
C-terminal SET domain and is essential for enzymatic activity154. The Mll1 N-terminus forms a 
tri-molecular complex with the scaffold protein Menin and the lens epithelium-derived growth 
factor Ledgf, which assists in recruitment to chromatin target sites155, 156. Menin co-regulates a 
subset of Mll1-controlled genes, especially homeobox (Hox) targets and the cyclin-dependent 
kinase inhibitors p27Kip1 and p18Ink4c 157, 158. However, not all Mll1 target genes depend on the 
co-regulation by Menin157. Mll1 also interacts with the histone acetyltransferase MOF (Kat8) 
which acetylates H4 at K16 (H4K16ac) and coordinates with Mll1 activity to induce 
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transcription159. The Mll1 transactivation domain (TAD) associates with the CREB-binding 
protein (CBP)160. Through CBP, Mll1 interacts with the β-catenin/TCF4 complex161, 162. 
  
Figure 1.11: Mll1 protein structure and interaction partners. 
Full-length Mll1 (upper part) is cleaved by taspase-1. The N- and C-terminal cleavage fragments 
assemble in a multi-protein complex (lower part). CxxC cysteine-rich zinc finger domain, PHD plant 
homeodomain, BD bromodomain, TAD transactivation domain, Win WDR5 interaction motif, FYRN/C 
FY-rich domain N-terminal/C-terminal. 
Mll1-induced H3K4me3 proceeds transcription initiation and is required for the binding of the 
RNA pol II basal transcription machinery163. The intrinsic DNA- and CpG island-binding motifs 
of Mll1 and its interaction partners direct Mll1 binding to specific target sites. The long non-
coding RNA HOTTIP also recruits the Mll1 complex to distinct chromatin sites164. Loss of Mll1 
does not affect global H3K4 tri-methylation levels and leads to strikingly few changes in gene 
expression163. Less than 5% of promoter H3K4me3 marks are actually dependent on Mll1163. 
At these specific sites, however, Mll1 strongly affects H3K4 methylation and gene expression. 
Mll1 thus acts in a highly specific way to control the expression of distinct target genes that are 
crucial for development and tissue homeostasis. 
1.3.10 Mll1 in development, tissue homeostasis and disease. 
The deficiency for Mll1 is lethal between embryonic day E10.5 and E13.5165, 166. Mice with 
heterozygous deletion of Mll1 are viable but show developmental defects in the patterning of 
the axial skeleton and in hematopoiesis165. Mll1 maintains the expression of Hox genes, which 
specify body segmentation in development, particularly Hoxa7 and Hoxa9 167. The 
misregulation of these Hox genes is causative for the skeletal transformations and 
hematopoietic abnormalities of Mll1-deficient mice167, 168. In humans, deleterious de novo 
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mutations in one MLL1 allele cause a rare genetic disorder known as the Wiedemann-Steiner 
syndrome (WSS)169. WSS patients exhibit a MLL1 haploinsufficiency that causes multiple 
congenital anomalies, e.g. a short stature due to delayed skeletal maturation, intellectual 
disability and distinctive facial appearance169. 
Mll1 is crucial for fetal and adult hematopoiesis170, 171. Definitive hematopoiesis at E10.5 
critically depends on Mll1172. In the adult, Mll1 maintains hematopoietic stem and progenitor 
cells171. Hematopoietic stem cells (HSCs) lacking Mll1 fail to self-renew170, 171. Quiescent HSCs 
deficient for Mll1 show ectopic cell cycle entry, which rapidly causes HSC exhaustion and 
depletes the entire stem cell pool, resulting in fatal bone marrow failure170, 171. To sustain 
hematopoiesis, Mll1 regulates Hox genes and self-renewal factors in a manner both dependent 
and independent of its co-factor Menin157. The methyltransferase activity of Mll1 is dispensable 
for hematopoiesis, but Mll1-dependent recruitment of the histone acetyltransferase MOF is 
essential for the maintenance of HSC target gene expression173. Hematopoietic progenitor 
cells show a reduced proliferation upon ablation of Mll1, while committed lymphoid and myeloid 
cells no longer require Mll1 and are unaffected by Mll1 ablation171. Apart from its prominent 
role in the hematopoietic system, Mll1 has been implicated in the regulation of stem cell self-
renewal and cell fate specification in other adult tissues. It is essential for neurogenesis from 
postnatal neural stem cells in the subventricular zone174. Mll1-deficient neural stem cells 
efficiently generate glial progenitors but fail to induce neuronal differentiation174. Mll1 
contributes to the de novo transcriptional activation of the myogenic regulatory factor Myf5 
after asymmetric division of muscle satellite cells by controlling the expression of the 
transcription factor Pax7175, 176. The Mll1-induced expression of Pax7 is essential for 
proliferation and self-renewal of activated muscle satellite stem cells and for skeletal muscle 
regeneration176. Satellite stem cells deficient for Mll1 fail to self-renew and differentiate, 
causing a progressive depletion of the satellite stem cell pool176. 
Somatic mutations of Mll1 are found in various tumor entities177. 78% of somatic Mll1 mutations 
have been reported to be missense mutations that cause gain-of-function phenotypes177. The 
missense mutations R3864C and R3841W are located in the Mll1 SET domain and increase 
the catalytic activity of Mll1 independent of the regulatory WRAD complex177. Even if not 
mutated, Mll1 and its methyltransferase activity might be exploited by oncogenic signalling to 
promote tumorigenesis, as has been demonstrated for Wnt-driven salivary gland and head and 
neck cancers162, 178. Interaction with oncogenic β-catenin also implicates Mll1 in cervical 
carcinoma progression179. Wild-type Mll1 has further been linked to glioblastoma stem cell 
maintenance180, cervical cancer181 and melanoma cell growth182. Gain-of-function mutants of 
p53 upregulate the expression of Mll1, Mll4 and the histone acetyltransferase Moz to promote 
tumorigenesis183. Mll1 further acts as a co-activator of the androgen receptor signalling 
complex in prostate cancer184. 
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As exemplified for Mll1, oncogenic signalling in cancer cells can exploit epigenetic regulators 
to fuel tumor growth132. Similar to the concept of ‘oncogene addiction’ 9, which describes the 
addiction of cancer cells to the presence of a certain oncogene, the viability of cancer cells can 
strictly depend on the hijacked epigenetic mechanism103. Such cancer cells will be highly 
sensitive to appropriate epigenetic inhibitors103. By playing on the addiction to certain 
oncogenes and epigenetic modifiers in cancer therapy we might be able to specifically 
eliminate cancer cells, while minimizing detrimental effects on normal tissue function. 
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2 Aim of the study 
Colon cancer is a major cause of cancer death worldwide. Treatment successes are moderate 
and rational therapies are desperately needed. Current therapies are often ineffective due to 
cancer stem cells, which can resist conventional chemotherapy and initiate tumor relapse and 
metastasis. Oncogenic signalling in cancer cells frequently exploits epigenetic mechanisms to 
fuel tumor growth. The tumorigenicity of the cancer cells then critically relies on cancer-specific 
epigenetic changes. A comprehensive understanding of the epigenetic changes in cancer is 
expected to have high therapeutic potential. Epigenetic therapies hold great promise to inhibit 
tumor growth and cancer cell plasticity by resetting the cancer epigenome. The reversible 
nature of histone modifications makes chromatin modifiers attractive targets for therapeutic 
manipulation. The present study aims to understand the role of epigenetic regulation by the 
histone methyltransferase Mll1 in Wnt-driven colon cancer to promote the identification of 
potential therapeutic targets and the future development of rational treatment. Previous work 
in our lab has implicated non-mutant Mll1 in Wnt-driven salivary gland and head and neck 
tumorigenesis. So far, a role for Mll1 in intestinal tumorigenesis and colon cancer stemness 
has not been determined. Given the high Wnt activity in colon cancer cells and in particular in 
colon cancer stem cells, we postulated a crucial role of Mll1 in Wnt-driven colon cancer. The 
understanding of Mll1 function in Wnt-activated colon cancer cells will establish novel 
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3 Results 
3.1 Mll1 expression is upregulated in Wnt-high human colon carcinomas. 
To assess the expression of the histone methyltransferase MLL1 in colon carcinomas, biopsies 
from colon cancer patients were analysed by immunohistochemistry. Human colon carcinomas 
showed substantial MLL1 expression: weak to moderate and strong MLL1 staining intensities 
were observed at all tumor stages (T0-T4) (Figure 3.1a, upper left panel, stainings of tumor 
stages T1-T4 in Supplementary Figure 1a, left panel, page 114). The majority of tumors 
exhibited moderate to strong MLL1 expression (Figure 3.1b), which was associated with high 
levels of nuclear β-catenin, indicating high activity of Wnt signalling (Figure 3.1a, c, 
Supplementary Figure 1, page 114): at all tumor stages, carcinomas with strong expression of 
MLL1 exhibited high levels of nuclear β-catenin. Vice versa, carcinomas with weak MLL1 
expression had predominantly low levels of nuclear β-catenin. Accordingly, MLL1 expression 
is upregulated in Wnt-high human colon carcinomas. 
           
Figure 3.1: High Mll1 expression correlates with high nuclear β-catenin in human colon 
carcinomas. 
a) Immunohistochemistry for MLL1 (upper panels) and β-catenin (lower panels) on naïve colon cancer 
patient biopsies, tumor stage T0, with high expression (left) and low expression (right) of MLL1 and 
β-catenin, magnifications in insets i and ii. Biopsy sections were kindly provided by Michael Vieth, 
Pathology Klinikum Bayreuth. Immunohistochemistry staining was performed by Julian Heuberger, 
MDC. Staining specificity was verified as described in section 5.9, page 90 and Supplementary Figure 
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2, page 115. b) Quantification of MLL1 stainings scored as weak, moderate and strong in human colon 
carcinomas: tumor stages T0-T4, n=8 each. c) Quantification of nuclear β-catenin staining scored as 
low and high in tumors with weak, moderate and strong expression of MLL1 across all stages, n=39. 
3.2 Lgr5+ intestinal stem cells highly express Mll1 in a Wnt-dependent manner. 
Lgr5+ intestinal stem cells have been identified as the cells-of-origin in colon cancer79. High 
Wnt activity in the intestinal crypts sustains Lgr5+ stem cells that constantly produce secretory 
and absorptive progenitors. These progenitor cells migrate out of the Wnt-high niche and 
differentiate once they reach the villus compartment enriched for differentiation-inducing 
factors such as Bmp410, 185 (scheme in Figure 3.2a). We used immunofluorescence to examine 
the expression of Mll1 along the intestinal crypt-villus axis of mice. Mll1 expression is high at 
the base of the crypt and in the proliferating cells of the transit-amplifying (TA) zone, and is 
gradually lost towards the differentiated villus compartment (Figure 3.2b). We observed 
highest expression of Mll1 in the stem cells which were identified by the Lgr5-EGFP-IRES-
CreERT2 reporter15 (Figure 3.2c, white arrows). The differentiated Paneth cells in the crypt, 
which were distinguished from adjacent stem cells by immunofluorescence for Mmp7186, 
exhibited low levels of Mll1 expression (Figure 3.2c, lower panel, white asterisks). Quantitative 
immunofluorescence confirmed strongest expression of Mll1 in Lgr5+ stem cells, which 
gradually decreased in the TA cells, Paneth cells and enterocytes (Figure 3.2d). 
The high expression of Mll1 in the Wnt-high crypt compartment and particularly in Lgr5+ stem 
cells suggested that Mll1 is crucial for stemness and is lost upon differentiation. We addressed 
the role of the inverse Wnt/Bmp gradients, which define the crypt stem cell niches and the 
differentiated villus compartments of the intestinal epithelium, in regulating the expression of 
Mll1. We used intestinal organoids which depend on a defined culture medium containing the 
essential growth factors EGF, Noggin and R-spondin1 that mimic the crypt stem cell niche74 
(compare 1.1.5, page 11). Modulating stem cell niche properties in organoid culture through 
removal of the Bmp antagonist Noggin and administration of Bmp4 led to a reduction of the 
expression of Mll1, accompanied by a repression of the stem cell gene Lgr5 in a concentration-
dependent manner (Figure 3.2e). The activation of Bmp signalling and the triggering of 
differentiation were confirmed by increased expression of Id2 187 (Figure 3.2e). Stimulating Wnt 
activity by adding the Wnt ligand Wnt3a increased the expression of Mll1 (Figure 3.2e). Wnt3a 
treatment also increased the expression of the Wnt-regulated stem cell gene Lgr5 15 and the 
classical Wnt target Axin2 33 (Figure 3.2e). Our data reveal that the opposing Wnt/Bmp 
gradients restrict Mll1 expression to the Wnt-activated crypt cells. 
Crypt-villus fractionations of mouse small intestinal epithelia confirmed the strong expression 
of Mll1 in the crypts (Figure 3.2f). The crypt enrichment was proven by high expression of Lgr5. 
Like Mll1, the Mll family members Mll2-4, Setd1a and Setd1b also exhibited a higher 
expression in the crypts compared to villi (Figure 3.2f). In accordance, we observed a crypt-
villus gradient for H3K4 tri-methylation (H3K4me3), the active chromatin mark established by 
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enzymes of the Mll family (Figure 3.2g). A similar distribution of Mll1 and H3K4me3 was 
observed in the epithelium of the mouse colon (Figure 3.2h). 
 
Figure 3.2: High Mll1 expression in Lgr5+ stem cells and Wnt-activated crypt cells of the mouse 
intestinal epithelium. 
a) Scheme of the murine small intestinal crypt-villus axis. In the lower crypt, Lgr5+ stem cells (green) 
intersperse between Paneth cells (yellow). Stem cells produce progeny that proliferate and differentiate 
in the transit-amplifying (TA) zone (grey). Terminally differentiated cells (e.g. enterocytes and goblet 
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cells, light blue) move into the villus. Opposing gradients of Wnt and Bmp signalling specify proliferation 
and differentiation along the crypt-villus axis. b) Immunofluorescence staining for Mll1 (red) on the small 
intestine of Lgr5-GFP mice reveals a gradual decrease in Mll1 expression from crypt to villus. Stem cells 
marked by Lgr5-GFP (green), nuclei in blue (DAPI). c) Magnification of the crypt region; upper panel, 
white arrows mark stem cells with high Mll1 expression (red); lower panel, asterisks mark Paneth cells 
stained by Mmp7 (yellow) with low Mll1 expression. E-cadherin (white) stains cell borders. Nuclei in blue 
(DAPI), scale bars 10µm. d) Quantification of the Mll1 staining intensity in nuclei of crypt and villus cells, 
normalized to the mean Mll1 expression in TA cells located just above the stem cell niche (up to relative 
+8 position), quantified from independent stainings of 5 mice, Mann-Whitney test for significance relative 
to stem cells. e) Mll1, Lgr5, Id2 and Axin2 mRNA expression in intestinal organoids treated with 10ng/ml 
and 100ng/ml Bmp4 and 0.66µg/ml recombinant Wnt3a for 24h, n=5, unpaired t test. f) mRNA 
expression of Lgr5, Mll1 and Mll family members in intestinal crypts relative to villi fractions, n=4, 
unpaired t test. g) H3K4me3 (red) and Lgr5-GFP (green) staining on the small intestine, nuclei in blue 
(DAPI), scale bar 20µm. h) Immunofluorescence for Mll1 or H3K4me3 (red) and Lgr5-GFP (green) in 
colon crypts of Lgr5-GFP mice, nuclei in blue (DAPI), scale bars 20µm. 
Given the particularly strong expression of Mll1 in the stem cells of the mouse intestine (see 
Figure 3.2, page 28), we investigated the effect of Mll1 ablation on the viability and self-renewal 
of the Lgr5+ intestinal stem cells. To ablate Mll1 specifically in the Lgr5+ stem cells, we crossed 
Lgr5-EGFP-IRES-CreERT2 mice with Mll1flox mice188. Mutagenesis was induced by 
intraperitoneal injections of tamoxifen in Lgr5-EGFP-IRES-CreERT2; Mll1flox/+ and Lgr5-EGFP-
IRES-CreERT2; Mll1flox/flox mice (referred to as Mll1+/- and Mll1-/-, respectively). Lgr5+ cells, in 
which the Lgr5 promoter is active, express eGFP and a tamoxifen-inducible Cre recombinase 
that allows for conditional mutagenesis15. The Cre activity deletes the floxed exon 2 of the Mll1 
locus, introducing a premature stop codon and causing loss of Mll1 protein expression188 
(compare Materials and Methods, Figure 5.1a, page 84). A crossed-in LacZ reporter allele189 
allowed us to trace recombined cells and their progeny. Conditional mutagenesis using the 
Lgr5-CreERT2 caused a mosaic of recombined LacZ+ and non-recombined (wild-type) crypts 
(Figure 3.3a, upper panel). The insertion of the EGFP-IRES-CreERT2 cassette into the first exon 
of the Lgr5 locus abolishes Lgr5 protein production. As the homozygous ablation of Lgr5 is 
neonatally lethal, only mice which are heterozygous for the Lgr5-GFP-IRES-CreERT2 allele are 
viable15, 190. Selective silencing of the Lgr5-GFP-IRES-CreERT2 knock-in allele has been 
reported, producing a mosaic of Lgr5-EGFP-IRES-CreERT2 expression191. Consequently, a 
substantial portion of Lgr5+ intestinal stem cells produces neither GFP nor the Lgr5-CreERT2 
and escapes mutagenesis. 
LacZ lineage tracing revealed that mutant Mll1-/- stem cells produced LacZ+ progeny up to 
20 days after the induction of mutagenesis. From 20 days onwards, LacZ+ Mll1-/- crypts were 
progressively lost and replaced by non-recombined crypts (Figure 3.3a lower panels, 
quantification on the right), but a substantial number of Mll1-/- crypts persisted beyond 50 days 
after the induction of mutagenesis, as assessed by immunohistochemistry staining for Mll1 
(Figure 3.3b). The number of Mll1-/- crypts decreased from initial 30-40% mutant crypts at 
10-20 days down to 25-30% at 50 days after induction (Figure 3.3b, quantification on the right). 
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The Mll1-/- mice did not show any abnormalities. Until 50 days after induction the intestinal 
epithelium remained intact and overall organ function was not visibly impeded, as 
non-recombined stem cells functionally replaced Mll1-/- crypts and preserved the intestinal 
homeostasis. The functional replacement of mutant crypts by fission of non-recombined crypts 
had previously been described in the intestine of mice with conditional knockout of the stem 
cell gene Ascl2 92. Our data indicate that, under normal homeostatic conditions, the loss of Mll1 
causes a mild phenotype, with a slow reduction of mutant stem cells over time. 
 
Figure 3.3: A functional role of Mll1 in intestinal stem cells. 
a) Lineage tracing: sections of LacZ (blue) whole-mount stainings of intestines of Lgr5-EGFP-IRES-
CreERT2; Rosa-LacZ; Mll1flox/+ and Lgr5-EGFP-IRES-CreERT2; Rosa-LacZ; Mll1flox/flox mice (referred to as 
Mll1+/- and Mll1-/-, respectively) at days 10 (n=2 Mll1+/-, n=4 Mll1-/-), 20 (n=3 Mll1+/-, n=5 Mll1-/-) and 
30 (n=2 Mll1+/-, n=3 Mll1-/-) after Cre induction. Nuclear fast red counter-staining, scale bars 50µm. 
Quantification of LacZ+ crypts per total crypts on the right, dot plot with mean and standard deviation, 
unpaired t test. b) Immunohistochemistry for Mll1 on sections of Mll1-/- intestines at days 10 (n=2), 
20 (n=3), 30 (n=4) and 50 (n=3) after induction, nuclei counter-stained with hematoxylin, scale bars 
100µm. Orange asterisks mark Mll1-/- crypts. Quantification of Mll1-/- crypts per total crypts on the right, 
dot plot with mean and standard deviation. 
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3.3 The β-cateninGOF-induced intestinal tumorigenesis depends on Mll1. 
The tight correlation of Mll1 and nuclear β-catenin in human colon cancer specimens (see 
Figure 3.1, page 26) and the high expression of Mll1 in the Lgr5+ intestinal stem cells, the cells-
of-origin in colon cancer79, suggested a role of Mll1 in Wnt-driven intestinal tumorigenesis. We 
made use of a Wnt/β-catenin-dependent genetic mouse model of intestinal cancer78: 
Cre-mediated recombination deletes the exon 3 of the β-catenin locus (compare Materials and 
Methods, Figure 5.1b, page 84), which removes the N-terminal phosphorylation sites of 
β-catenin and impedes its ubiquitin-proteasomal degradation, resulting in a stabilized 
oncogenic form, β-catGOF. By intraperitoneal injections of tamoxifen we induced the activation 
of β-catenin and loss of Mll1 in the Lgr5+ stem cells of Lgr5-EGFP-IRES-CreERT2; β-catGOF; 
Mll1flox/+ and Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mll1flox/flox mice (hereafter called β-catGOF; 
Mll1+/- and β-catGOF; Mll1-/- mice). Mice were analysed at different time points up to 100 days 
after induction. 
The intestines of the β-catGOF; Mll1+/- mice became severely dysplastic within 30 days and 
developed adenomas which were highly proliferative, as indicated by Ki67 staining, and 
contained islets with high Mll1 expression (Figure 3.4a, upper panel). Other tissues with Lgr5+ 
stem cells like skin, liver, kidney, and stomach192-194 appeared normal. The β-catGOF; Mll1+/- 
mice were viable up to 40 days after the induction of mutagenesis. In contrast, the homozygous 
ablation of Mll1 led to normal crypt-villus structures in β-catGOF; Mll1-/- mice, with proliferation 
restricted to the crypt regions (Figure 3.4a, lower panel). We observed Mll1-depleted crypts 
among non-recombined Mll1-expressing crypts (Figure 3.4a, inset in bottom right panel). The 
homozygous ablation of Mll1 prevented the β-cateninGOF-induced intestinal tumorigenesis, as 
shown by a Kaplan-Meier plot of tumor incidence (Figure 3.4b). β-catGOF; Mll1-/- mice did not 
show any tumors up to 100 days after the induction of mutagenesis. 
 
Figure 3.4: β-cateninGOF-induced intestinal tumorigenesis depends on Mll1. 
a) Sections of intestines of Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mll1+/- and Lgr5-EGFP-IRES-CreERT2; 
β-catGOF; Mll1-/- mice, called β-catGOF; Mll1+/- and β-catGOF; Mll1-/-, at 30 days after induction with 
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tamoxifen: H&E staining (left), scale bar 50µm; Ki67 staining (middle), nuclei counter-stained with 
hematoxylin, scale bar 100µm; Mll1 immunohistochemistry (right), scale bar 50µm, with magnification 
of Mll1 knockout crypt in inset, scale bar 20µm. b) Kaplan-Meier plot of tumor incidence in β-catGOF; 
Mll1+/- and β-catGOF; Mll1-/- mice. p<0.0001 Log-rank test, β-catGOF; Mll1+/- n=24, β-catGOF; Mll1-/- n=32. 
We crossed in a LacZ reporter allele189 to trace the recombined cells and their progeny. Equal 
recombination was observed at day 5 after the induction of mutagenesis: about 25% of crypts 
overall were LacZ+ in both β-catGOF; Mll1+/- and β-catGOF; Mll1-/- mice (Figure 3.5a, upper panel, 
quantification in b). Subsequently, the mutant cells in β-catGOF; Mll1+/- mice expanded at day 10 
and had formed LacZ+ dysplasias by day 30. In contrast, β-catGOF; Mll1-/- mice showed a 
gradual reduction of LacZ+ cells down to 10% over time (Figure 3.5a, quantification in b). At 
30 days, complete crypts in β-catGOF; Mll1+/- intestines were LacZ+, whereas the intestines of 
the β-catGOF; Mll1-/- mice exhibited crypts with LacZ+ long-lived Paneth cells interspersed with 
non-mutant (LacZ-) stem cells (Figure 3.5c, marked by an arrow). This indicates that Mll1-
deficient stem cells had produced LacZ+ progeny, were subsequently lost and replaced by non-
recombined stem cells. Despite the widespread loss of Mll1-deficient crypts, a substantial 
number of LacZ+ β-catGOF; Mll1-/- crypts persisted up to 100 days after the induction of 
mutagenesis. 
    
Figure 3.5: Progressive loss of β-cateninGOF stem cells upon ablation of Mll1. 
a) Transgenic lineage tracing: a Rosa-LacZ reporter allele was used to trace recombined cells and their 
progeny. Mutant mouse intestinal cells (blue) at days 5, 10, and 30 after the induction of mutagenesis. 
Nuclear fast red counter-staining, scale bars 50µm. b) Quantification of LacZ+ crypts per total crypts in 
β-catGOF; Mll1+/- (blue) and β-catGOF; Mll1-/- mice (green) at days 5 (n=4 β-catGOF; Mll1+/-, n=3 β-catGOF; 
Mll1-/-), 10 (n=4 β-catGOF; Mll1+/-, n=4 β-catGOF; Mll1-/-), 30 (n=2 β-catGOF; Mll1+/-, n=4 β-catGOF; Mll1-/-), 50 
(n=3 β-catGOF; Mll1-/-) and 100 (n=2 β-catGOF; Mll1-/-), dot plot with mean and standard deviation. β-catGOF; 
Mll1+/- mice do not survive past 40 days after induction. c) Magnification of LacZ+ crypts in β-catGOF; 
Mll1+/- (upper panel) and β-catGOF; Mll1-/- mice (lower panel) at day 30 after induction. Arrow marks non-
mutated (LacZ-) stem cell adjacent to long-lived mutant (LacZ+) Paneth cells in crypts of Rosa-LacZ; 
β-catGOF; Mll1-/- mice. Paneth cells were identified by lysosomal vesicles. Nuclei visualized by nuclear 
fast red staining, scale bar 20µm.  
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3.4 Mll1 promotes the β-cateninGOF-driven tumorigenic expansion of intestinal 
stem cells. 
The dysplastic tissue in the β-catGOF; Mll1+/- intestines showed expansions of Lgr5-GFP+ stem 
cells (Figure 3.6a). The β-catGOF tumors exhibited an increased expression of the stem cell 
genes Lgr5, Smoc2 and Cd44 195 (Figure 3.6b). The stem cell expansion in β-catGOF tumorous 
intestines was associated with an increase in Mll1 protein levels (Figure 3.6c). The β-catGOF 
tumorous tissue displayed high levels of nuclear β-catenin (Figure 3.6d). Specifically, tumor 
cells with high levels of β-catenin, among these also Lgr5-GFP+ stem cells, expressed high 
levels of Mll1 (Figure 3.6e; green arrows mark β-cateninhigh cells, white arrowheads indicate 
β-cateninlow cells). 
        
Figure 3.6: β-cateninGOF-induced tumors show expansions of Lgr5+ intestinal stem cells. 
a) Tile scan of immunostaining for Lgr5-GFP (green) and β-catenin (red) on β-catGOF; Mll1+/- tumor 
section, scale bar 100µm. b) mRNA expression of the intestinal stem cell markers Lgr5, Smoc2 and 
Cd44 in mouse control and β-catGOF intestines, n=3, unpaired t test. c) Western blot for Mll1 and 
β-catenin in control (n=1) and β-catGOF intestines (n=2), vinculin as control for equal loading. 
Quantification below, normalized to vinculin and relative to control. Mutant deltaEx3 β-catGOF is marked 
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by an arrow. d) Immunohistochemistry for β-catenin on β-catGOF mouse intestinal tumor section, scale 
bar 50µm. Magnification of inset below, scale bar 25µm. Arrowheads (green) mark cells with nuclear β-
catenin. e) Immunostaining for β-catenin (red, upper panel), Mll1 (red, lower panel) and Lgr5-GFP 
(green) on β-catGOF mouse intestinal tumor section, scale bars 20µm. Nuclei in blue (DAPI). Green 
arrows mark β-cateninhigh cells, white arrowheads mark β-cateninlow cells. Right: quantification of Mll1 
staining intensity in low β-catenin, high β-catenin and Lgr5-GFP+ tumor cells, n=3, Mann-Whitney test. 
The heterozygous loss of Mll1 did not affect the β-cateninGOF-driven stem cell expansion 
(Figure 3.7a, upper panel). The expanding Lgr5-GFP+ stem cells in the β-catGOF; Mll1+/- tumors 
exhibited nuclear β-catenin (Figure 3.7a, insets a in the upper panel). Remarkably, the 
homozygous ablation of Mll1 prevented the β-cateninGOF-induced expansion of stem cells 
(Figure 3.7a, lower panel). Although a large part of mutant crypts was progressively lost from 
β-catGOF; Mll1-/- intestines (see Figure 3.5, page 32), we observed normally shaped crypts 
depleted for Mll1 but with nuclear β-catenin (β-catGOF) and positive for Lgr5-GFP that persisted 
up to 100 days after mutagenesis (Figure 3.7a, insets b in the lower panel). 
  
Figure 3.7: Mll1 is a prerequisite for the β-cateninGOF-induced stem cell expansion. 
a) Immunofluorescence for Lgr5-GFP stem cells (green) and β-catenin (red) on intestinal sections of 
β-catGOF; Mll1+/- and β-catGOF; Mll1-/- mice at day 30 after induction with tamoxifen, scale bars 100µm. 
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Insets (a, b) middle: immunostaining for Lgr5-GFP (green) and Mll1 (red), scale bars 20µm. Insets (a, b) 
right: immunostaining for β-catenin (red) on β-catGOF; Mll1+/- and β-catGOF; Mll1-/- intestine, scale bars 
20µm. Nuclei in blue (DAPI). Magnifications in insets i and ii, scale bars 10µm, nuclear β-catenin marked 
by white arrows. b) Immunofluorescence for BrdU (red) and Lgr5-GFP (green) in crypts of β-catGOF; 
Mll1+/- and β-catGOF; Mll1-/- mice at day 30 after induction, nuclei in blue (DAPI), scale bars 20µm. BrdU 
incorporation for 2h before sacrifice. Quantification of BrdU+ stem cells relative to total Lgr5-GFP+ stem 
cells on the right, n=5 independent mice, unpaired t test. c) Immunostaining for cleaved Caspase-3 (red) 
and Lgr5-GFP (green) on β-catGOF; Mll1-/- intestine, nuclei in blue (DAPI), scale bars 20µm. 
The Lg5-GFP+ cells in persisting β-catGOF; Mll1-/- crypts exhibited a slightly reduced 
proliferation, as seen by a decrease in the incorporation of the thymidine analogue BrdU 
compared to stem cells in β-catGOF; Mll1+/- crypts (Figure 3.7b). Apoptosis (cleaved Caspase-3) 
was not detected in the β-catGOF; Mll1-/- crypts (Figure 3.7c). 
3.4.1 The ablation of Mll1 prevents β-cateninGOF-induced stem cell expansion but does 
not decrease global Wnt activity. 
To explore the role of Mll1 in the β-cateninGOF-driven intestinal stem cell expansion, we made 
use of the organoid system (compare 1.1.5, page 11). Organoids from β-catGOF, β-catGOF; 
Mll1+/- and β-catGOF; Mll1-/- mice were mutated in culture by administration of tamoxifen. The in 
vitro mutagenesis does not recombine all stem cells and leads to a mixed culture containing 
recombined and non-recombined organoids. We selected for recombined β-catGOF organoids 
by withdrawing the Wnt-stimulating growth factor R-spondin1 from the culture medium. All 
β-catGOF organoids grew independently of R-spondin1 (Figure 3.8). Non-recombined control 
organoids did not survive past day 4 of R-spondin1 withdrawal (Figure 3.8, fourth panel). The 
ablation of Mll1 did not impair the R-spondin1-independent growth, demonstrating functional 
β-catGOF activity in the β-catGOF; Mll1-/- organoids. 
 
Figure 3.8: R-spondin1 withdrawal selects for β-cateninGOF-mutant organoids. 
Brightfield images of tamoxifen-induced Lgr5-GFP-IRES-CreERT2; β-catGOF, Lgr5-GFP-IRES-CreERT2; 
β-catGOF; Mll1+/- and Lgr5-GFP-IRES-CreERT2; β-catGOF; Mll1-/- intestinal organoids at day 0 and after 
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4 weeks of R-spondin1-free culture in crypt medium supplemented with EGF and Noggin (EN). Non-
induced control organoids do not survive past day 4 in the absence of R-spondin1, scale bar 200µm. 
 
Non-recombined (control) intestinal organoids from Lgr5-EGFP-IRES-CreERT2 mice 
recapitulated the Mll1 expression pattern observed in the control (wild-type) intestines (see 
Figure 3.2, page 28): highest expression is seen in Wnt-dependent Lgr5-GFP+ stem cells 
(Figure 3.9a, b first panel). β-catGOF induced a strong expansion of Lgr5-GFP+ stem cells 
(Figure 3.9a, b, second panel). This stem cell expansion was maintained in organoids with 
heterozygous deletion of Mll1, β-catGOF; Mll1+/- (Figure 3.9a, b, third panel). In contrast, 
homozygous deletion of Mll1 hampered the β-catGOF-driven expansion of the stem cell 
population in β-catGOF; Mll1-/- organoids (Figure 3.9a, b, fourth panel). Western blotting for 
Lgr5-GFP confirmed the stem cell expansion phenotype (Figure 3.9c, quantification below). 
 
Figure 3.9: Mll1 is essential for the β-cateninGOF-induced stem cell expansion in organoids. 
a) Fluorescence live imaging of non-induced (control) and tamoxifen-induced β-catGOF, β-catGOF; Mll1+/- 
and β-catGOF; Mll1-/- intestinal organoids. Lgr5-GFP (green) marks intestinal stem cells, scale bars 
100µm. b) Immunofluorescence staining for Lgr5-GFP (green) and Mll1 (red) on sections of organoids 
of the four genotypes, nuclei in blue (DAPI), scale bars 30µm. c) Western blot for Lgr5-GFP in control 
and tamoxifen-induced β-catGOF, β-catGOF; Mll1+/- and β-catGOF; Mll1-/- organoids, vinculin as control for 
equal loading. Below: quantification of Lgr5-GFP protein levels in mutant organoids normalized to 
vinculin and relative to control, n=2, unpaired t test. 
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We confirmed the heterozygous and homozygous ablation of Mll1 in β-catGOF; Mll1+/- and 
β-catGOF; Mll1-/- organoids, respectively, by RT-PCR analysis of the mutant lines (Figure 3.10a). 
β-catGOF; Mll1-/- organoids exhibited a decrease in the expression of the intestinal stem cell 
genes Lgr5, Smoc2 and Olfm4 195, compared to β-catGOF and β-catGOF; Mll1+/- organoids 
(Figure 3.10b). The expression of the Wnt-regulated stem cell gene Ascl2 92 and the Wnt target 
gene Axin2 33 was unaffected by the ablation of Mll1 (Figure 3.10b). 
  
Figure 3.10: The ablation of Mll1 decreases the expression of specific stem cell genes in 
β-cateninGOF organoids. 
mRNA expression of a) Mll1 and b) intestinal stem cell genes in β-catGOF; Mll1+/- and β-catGOF; Mll1-/- 
organoids relative to β-catGOF organoids, n=4, unpaired t test. 
The loss of Mll1 slightly reduced the proliferation of Lgr5-GFP+ stem cells in β-catGOF; Mll1-/- 
organoids compared to β-catGOF; Mll1+/- organoids, as seen by a decrease in the incorporation 
of the thymidine analogue EdU (Figure 3.11, white arrows). 
   
Figure 3.11: The loss of Mll1 decreases the proliferation of stem cells in β-cateninGOF organoids. 
Optical section of whole-mount confocal images of EdU incorporation (red) in β-catGOF; Mll1+/- (left panel) 
and β-catGOF; Mll1-/- (right panel) organoid crypt buds. White arrows indicate Lgr5-GFP+ stem cells 
(green), nuclei stained with Hoechst (blue), scale bars 20µm. Quantification of EdU+ relative to total 
Lgr5-GFP+ stem cells per crypt on the right, n=11, unpaired t test. 
  Results 
38 
To further investigate the proliferation and self-renewal of the Mll1-deficient cells, β-catGOF; 
Mll1-/- organoids were dissociated into single cells and organoid formation was traced upon 
serial re-plating in crypt medium supplemented with EGF, Noggin and R-spondin1. Single 
β-catGOF; Mll1-/- cells expanded into spheroid-shaped organoids, owing to the high Wnt activity 
induced by β-catGOF as previously described196. β-catGOF; Mll1-/- cells re-formed organoids over 
many passages with high efficiency (Figure 3.12a), demonstrating proliferative potential and 
self-renewal capacity of Mll1-deficient β-catGOF cells. From the seventh passage on, β-catGOF; 
Mll1-/- cells formed less organoids which were smaller and acquired a thick-walled shape 
(Figure 3.12a, b), indicating differentiation and progressive exhaustion of stemness upon loss 
of Mll1. Apoptosis was not prominent, but late-passage β-catGOF; Mll1-/- organoids exhibited a 
strong expression of the differentiation marker ITF (Figure 3.12c). 
  
Figure 3.12: Progressive exhaustion of Mll1-deficient β-cateninGOF stem cells. 
a) Serial re-plating of β-catGOF; Mll1-/- intestinal organoids by single cell dissociation. Numbers of 
organoids counted as triplicates in n=4 independent assays from two organoid lines. Cells were cultured 
in crypt medium supplemented with EGF, Noggin and R-spondin1. Significance calculated versus 
passage 1, unpaired t test. b) Brightfield images of single cell-derived β-catGOF; Mll1-/- organoids at 
passages 2 and 7, scale bars 100µm. c) Immunostaining for cleaved Caspase-3 (red) and ITF (green) 
on sections of single cell-derived β-catGOF; Mll1-/- organoids at passage 7, scale bars 50µm. Nuclei 
stained with DAPI (blue). 
In summary, these data demonstrate by genetic means that Mll1 is essential for the 
β-cateninGOF-driven stem cell expansion and tumorigenesis. The loss of Mll1 did not interfere 
with β-catGOF function per se, as Mll1 knockout crypts exhibited nuclear β-catenin, β-catGOF; 
Mll1-/- organoids grew independently of R-spondin1, and the expression of classical Wnt target 
genes such as Axin2 was not decreased. Apoptosis was not detected, but the β-catGOF; Mll1-/- 
cells progressively lost their self-renewal capacity and differentiated. Accordingly, Mll1 is 
crucial to maintain the stemness of β-catenin-activated intestinal stem cells.  
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3.5 Mll1 prevents differentiation of β-cateninGOF intestinal stem cells. 
To gain deeper insights into how the ablation of Mll1 prevented the β-cateninGOF-driven 
intestinal stem cell expansion and tumorigenesis, we applied a high-throughput next-
generation sequencing approach and analysed the transcriptome of β-catGOF; Mll1-/- stem cells. 
In collaboration with Neha Goveas, Andrea Kranz and Francis Stewart at the Technical 
University in Dresden (Germany), we isolated the Lgr5-GFP+ intestinal stem cells from 
β-catGOF; Mll1+/- and β-catGOF; Mll1-/- mice at 10 days after the induction of mutagenesis using 
fluorescence-activated cell sorting (FACS) and analysed transcriptomic changes by RNA 
sequencing. The bioinformatic analysis was performed by Ramon Oliveira Vidal and Sascha 
Sauer from the Laboratory of Functional Genomics, Scientific Genomics Platforms of the Max 
Delbrück Center for Molecular Medicine (BIMSB/BIH). The transcriptome analysis revealed 
that β-catGOF; Mll1+/- stem cells exhibited a Paneth-like phenotype, which was caused by high 
Wnt activity due to the β-catGOF mutation39. Immunofluorescence staining of β-catGOF; Mll1+/- 
tumor sections and RT-PCR analysis of β-catGOF-mutant intestines revealed a strong 
expression of the Paneth cell marker Mmp7186 (Figure 3.13a). 
 
Figure 3.13: The ablation of Mll1 enforces differentiation of β-cateninGOF intestinal stem cells. 
a) Left: Immunostaining for Mmp7 (green) and Mll1 (red) on β-catGOF; Mll1+/- tumor section, scale 
bar 50µm. Nuclei stained with DAPI (blue), E-cadherin (yellow) stains cell borders. Right: mRNA 
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expression of Mmp7 in control and β-catGOF intestines, n=3, unpaired t test. b) Volcano plot of 
differentially expressed genes in β-catGOF; Mll1-/- relative to β-catGOF; Mll1+/- Lgr5-GFP+ stem cells 
isolated from 4 independent mice each, represented as blue dots. Cut-off log2 fold change ≥ 0.5. Goblet 
and Paneth cell-specific genes197 marked in red and green, respectively, and indicated by name. 
c) Immunostainings on sections of adjacent non-recombined (left) and recombined (right) small 
intestinal crypts in β-catGOF; Mll1-/- mice, left: for Mmp7 (green) and Mll1 (red), middle: for Mll1 (brown) 
and Alcian blue; nuclear counter-staining with hematoxylin, right: for Lyz (green) and ITF (red), scale 
bars 20µm. Insets on the right: magnifications of mutant double-positive cells, scale bars 10µm. Nuclei 
stained with DAPI (blue), E-cadherin (yellow) stains cell borders. 
A volcano plot of the differentially expressed genes in β-catGOF; Mll1-/- versus β-catGOF; Mll1+/- 
stem cells showed both up- and downregulation of genes upon ablation of Mll1 (Figure 3.13b). 
This included a global increase in the expression of goblet cell-specific genes, among these 
Tff3 (Itf) and Muc2 198. Downregulated genes included specific markers for Paneth cells, e.g. 
Defa5, Defa17, Lyz1 186, indicating that the ablation of Mll1 shifted the Paneth-like identity of 
β-catGOF stem cells towards a goblet cell fate. β-catGOF; Mll1-/- stem cells exhibited a strongly 
increased expression of Atoh1, a transcription factor essential for secretory lineage 
determination56, and its target gene Spdef, which instructs secretory cell differentiation in 
Paneth and goblet cells62, 199 (Figure 3.13b; compare 1.1.3, page 9). The expression of Hes1, 
a Notch-controlled transcription factor that represses Atoh1 expression55, was not 
downregulated in the β-catGOF; Mll1-/- stem cells. There were also no decreases in other Notch 
target genes such as Hes5 and Hey1 (not shown), which meant that the upregulation of Atoh1 
occurred independently of a global decrease in Notch signalling. The Paneth cell gene Mmp7 
was increased in β-catGOF; Mll1-/- stem cells, suggesting a priming towards a mixed Paneth-
goblet state. Mll1-deficient crypts of β-catGOF; Mll1-/- mutant mice exhibited large cells which 
were double-positive for Paneth cell (Mmp7 and Lyz) and goblet cell markers (Alcian blue 
(mucin) and ITF) (right crypt in Figure 3.13c). Such Paneth-goblet intermediate cells were not 
observed in adjacent non-recombined Mll1-expressing crypts on the same section (left crypt 
in Figure 3.13c). Taken together, the stem cell transcriptome revealed that the ablation of Mll1 
primed β-catGOF intestinal stem cells for differentiation and shifted the Wnt-imposed Paneth-
like identity towards a goblet cell fate. Thus, Mll1 maintains stemness by restricting 
differentiation of β-catGOF intestinal stem cells. 
3.5.1 Mll1 regulates Foxa1 and Gata4 transcription factors in β-cateninGOF stem cells. 
Apart from the differentiation phenotype, the RNA sequencing of the sorted Lgr5-GFP+ stem 
cells also revealed that β-catGOF; Mll1-/- stem cells exhibited a decreased expression of several 
transcription factors and intestinal stem cell genes (Figure 3.14). As illustrated in a volcano 
plot, Mll1-deficient β-catGOF stem cells showed a decreased expression of the intestinal stem 
cell gene Olfm4. Lgr5 and Smoc2 expression was not significantly altered (Figure 3.14a). The 
ablation of Mll1 did not affect the expression of the Wnt target gene Axin2 (Figure 3.14a), as 
had also been observed in β-catGOF; Mll1-/- organoids (see Figure 3.10, page 37). In β-catGOF; 
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Mll1-/- stem cells, the expression of the transcription factors Foxa1 and Gata4 was 
downregulated (Figure 3.14a), the latter of which had previously been proposed as a Mll1 
target gene163. Immunostaining confirmed a strong reduction of the GATA binding protein 4 
(Gata4) in Mll1-deficient crypts compared to non-recombined Mll1-expressing crypts on 
sections of β-catGOF; Mll1-/- small intestines (Figure 3.14b). 
   
Figure 3.14: Mll1 regulates Foxa1 and Gata4 expression in β-cateninGOF intestinal stem cells. 
a) Volcano plot showing differentially expressed stem cell genes and transcription factors in β-catGOF; 
Mll1-/- relative to β-catGOF; Mll1+/- Lgr5-GFP+ stem cells isolated from 4 independent mice each, 
represented as dark blue dots. Cut-off log2 fold change ≥ 0.5. b) Immunostaining for Gata4 (yellow, 
upper panel) and Mll1 (red, lower panel) on sections of adjacent non-recombined (left) and recombined 
(right) small intestinal crypts in β-catGOF; Mll1-/- mice, scale bars 20µm. Nuclei stained with DAPI (blue). 
3.6 Inducible shMLL1 colon cancer cell lines - a tool to study MLL1 function. 
We aimed to generate a tool to further clarify the molecular role of MLL1 in Wnt-dependent 
intestinal cancer stem cells. The human colon adenocarcinoma cell lines Ls174T and DLD1 
are frequently used in mechanistic studies connected to Wnt signalling. Ls174T cells harbour 
a β-catGOF mutation, but are diploid and wild-type for p53 and APC, and are classified as Dukes’ 
type B adenocarcinoma of the colon200. DLD1 cells are predominantly diploid, classified as 
Dukes’ type C adenocarcinoma of the colon and harbour APC mutations and a non-functional 
Ser241Phe mutation in p53 that prevents its DNA binding200. Given their high Wnt activity due 
to β-catenin gain-of-function and APC loss-of-function mutations, the Ls174T and DLD1 cells 
emerged as suitable cell lines to study the role of MLL1 in Wnt-driven colon cancer. Both cell 
lines have previously been used to establish the intestinal Wnt signature and exhibit substantial 
  Results 
42 
expression of intestinal stem cell genes107, thus offering the chance to assess the regulatory 
role of MLL1 in colon cancer stemness. 
Using a CRISPR/Cas9-based approach to delete MLL1, we did not obtain viable cell clones, 
indicating a strong MLL1 dependency of the colon cancer cells. By lentiviral transduction, we 
established stable doxycycline-inducible shMLL1 knockdown cell lines, using the pInducer11 
system201. Transduced cells constitutively express GFP and a reverse Tet repressor (rtTA3) 
which binds Tet response elements (TRE) only in the presence of doxycycline (Figure 3.15a). 
Treatment with doxycycline induces the production of dsRed and a miR30-based shRNA 
against MLL1 (shMLL1). By FACS for GFP and dsRed we isolated ‘high responders’ with 
strong shMLL1 induction (Figure 3.15b). 
 
Figure 3.15: Establishment and characterization of inducible shMLL1 human colon cancer cells. 
a) The doxycycline-inducible pInducer11 system. Transduced cells constitutively express GFP and the 
reverse Tet repressor (rtTA3) that binds Tet response elements (TRE) in the presence of doxycycline, 
inducing dsRed and shMLL1 production. b) Representative FACS plots of Ls174T cells transduced with 
pInducer11-shMLL1. Transduced cells constitutively express GFP (green dashed box). Blue dashed 
box contains apoptotic cells and cell debris. Doxycycline treatment induces dsRed expression (right plot, 
red dashed box). Gate P4 (grey box) contains GFP+ dsRed+ double-positive cells that represent ‘high 
responders’. c) Immunofluorescence for MLL1 (red) on control and 3d doxycycline-induced shMLL1 
Ls174T cells. Nuclei in blue (DAPI), scale bars 20µm. Right: quantification of MLL1 staining intensity in 
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control and three shMLL1 Ls174T cell clones, n=7, Mann-Whitney test. d) MLL1 Western blot of three 
shMLL1 Ls174T cell clones #2, #3, #6 both non-induced and 3d doxycycline-induced, and shCtr cells 
with shRNA against Renilla luciferase, vinculin as control for equal loading. e) MLL1 mRNA expression 
in control and shMLL1 Ls174T cell clones, n=4, unpaired t test. f) mRNA expression of MLL family 
members in control and shMLL1 Ls174T cells, n=4. g) Left: MLL1 Western blot of shMLL1 DLD1 cells 
both non-induced and 3d doxycycline-induced, vinculin as control for equal loading. Right: MLL1 mRNA 
expression in control and shMLL1 DLD1 cells, n=3, unpaired t test. 
We identified three shMLL1 Ls174T single cell clones that exhibited an efficient knockdown of 
MLL1 (Figure 3.15c-e). MLL1 knockdown cells were compared to non-induced cells and to 
cells transduced with a non-targeted shRNA against Renilla luciferase (shCtr)202, revealing no 
difference between non-induced and shCtr cells. The ablation of MLL1 did not significantly 
alter the expression of the MLL family members MLL2, MLL3, MLL4, SETD1A and SETD1B 
(Figure 3.15f). DLD1 cells transduced with shMLL1 were used as a pool of ‘high responders’ 
that exhibited a profound knockdown of MLL1 (Figure 3.15g). 
3.7 MLL1 is required for initiation and growth of human Ls174T colon cancer 
xenografts. 
To test the role of MLL1 in tumor initiation and growth of human colon cancer, we studied the 
in vivo growth of the human shMLL1 Ls174T colon cancer cells in xenograft assays. 
Doxycycline-induced shMLL1 and control Ls174T colon cancer cells were subcutaneously 
engrafted in nude mice. Mice inoculated with shMLL1 cells were administered doxycycline 
throughout the experiment. Control cells formed large tumors within 28 days (Figure 3.16a). In 
contrast, the tumor formation by shMLL1 cells was reduced by 75%. The residual shMLL1 
Ls174T xenografts showed a substantial reduction of MLL1 protein (Figure 3.16b). 
     
Figure 3.16: MLL1 is required for initiation and growth of human colon cancer xenografts. 
a) Xenografts of control and shMLL1 human Ls174T cells in NMRInu/nu mice. Mice inoculated with 
shMLL1 cells were administered doxycycline from day -1 throughout the experiment as indicated. Left: 
tumor growth curves of control (black) and shMLL1 Ls174T cells (red) plotted as median with range, 
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n=6, unpaired t test. Right: dissected tumors at day 28, scale bars 2cm. b) Western blot for MLL1 from 
control and shMLL1 Ls174T xenografts at day 28, vinculin as control for equal loading. Quantification 
below, normalized to vinculin and relative to control, n=6 tumors, unpaired t test. 
Residual shMLL1 xenografts exhibited reduced levels of H3K4me3 (Figure 3.17a left) and 
significantly fewer Ki67+ proliferating cells (Figure 3.17a right). The apoptosis marker cleaved 
Caspase-3 did not increase in shMLL1 xenografts (Figure 3.17b, c). The residual shMLL1 
tumors were less densely packed than control tumors, and exhibited an enlarged cell 
morphology (Figure 3.17d). 
        
Figure 3.17: Reduced H3K4me3 and proliferation in shMLL1 xenografts. 
a) H3K4me3 and Ki67 stainings (red) of control and shMLL1 tumor sections, scale bars 25µm. Nuclei in 
blue (DAPI). Quantifications below, n=4, Mann-Whitney test. b) Immunofluorescence for cleaved 
Caspase-3 (red) on control and shMLL1 xenograft sections, nuclei in blue (DAPI), scale bars 20µm. 
c) Cleaved Caspase-3 Western blot of two pairs of control and shMLL1 tumors (right), tubulin as control 
for loading. Puromycin (2µg/ml) treatment for 24h as positive control. d) H&E stainings of control and 
shMLL1 tumor sections, scale bars 50µm. 
To address the role of MLL1 in the growth and maintenance of established colon tumors, we 
performed subcutaneous xenograft assays with the Ls174T cell clones and induced the 
knockdown of MLL1 after the establishment of the primary tumor, i.e. at day 6 after cell 
inoculation (Figure 3.18a). Control cells continuously grew and formed large tumors within 
20 days (Figure 3.18b). In contrast, the growth of MLL1-depleted tumors was markedly slowed 
down, indicating a crucial role of MLL1 also in established intestinal tumors. The level of growth 
reduction strictly depended on the efficiency of MLL1 depletion (Figure 3.18b, c; compare 
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growth curves and MLL1 protein expression in knockdown tumors Mll1med (green) and 
Mll1low-1, low-2 (blue)). Taken together, the xenograft data show that MLL1 is crucial for tumor 
formation and growth of human Ls174T colon cancer cells. 
        
Figure 3.18: MLL1 in tumor maintenance. 
a) Xenografts of control and shMLL1 human Ls174T cells in NMRInu/nu mice. Mice inoculated with 
shMLL1 cells were administered doxycycline starting from day 6 after cell inoculation as indicated. 
b) Tumor growth curves of control (black dots) and shMLL1 Ls174T cells (green and blue dots), plotted 
as mean with SD, n=3, unpaired t test. c) Western blot for MLL1 from control and shMLL1 xenografts, 
vinculin as control for equal loading. Quantification below, normalized to vinculin and relative to control. 
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3.8 MLL1 sustains the stemness of human colon cancer cells. 
3.8.1 MLL1 controls the expression of Lgr5+ stem cell genes in human colon cancer 
cells. 
To identify the gene expression programme regulated by MLL1 in Wnt-driven colon cancer 
cells, we investigated transcriptomic changes upon knockdown of MLL1 by RNA sequencing. 
The knockdown of MLL1 induced a predominant downregulation of gene expression, as 
illustrated in a heatmap of the three Ls174T single cell clones compared to control cells 
(Figure 3.19a), demonstrating that MLL1 acts as a transcriptional activator in Wnt-driven colon 
cancer cells. Comparison of the differentially expressed genes with a signature of Mll1-ablated 
fibroblasts163 revealed a downregulation of MLL1 target genes such as SMOC2 and ENPP1 
(Figure 3.19b), confirming the validity of our knockdown approach. Of note, the human shMLL1 
colon cancer cells also showed decreases in the expression of FOXA1 and GATA6, the colon 
homologue of GATA4 203, which we had identified as Mll1-regulated genes in murine β-catGOF; 
Mll1-/- intestinal stem cells (see Figure 3.14, page 41). Gene set enrichment analysis (GSEA) 
revealed that the knockdown of MLL1 interfered with the expression of Lgr5+ stem cell 
signature genes (Figure 3.19c). 
 
Figure 3.19: MLL1 regulates Lgr5+ intestinal stem cell genes. 
a) Heatmap of differentially expressed genes in three control versus shMLL1 Ls174T cell clones at 
3 days after induction with doxycycline, cut-off log2 fold change ≥ 0.5, adjusted p-value ≤ 0.05. 
Bioinformatics performed by Ramon Oliveira Vidal and Sascha Sauer from the Laboratory of Functional 
Genomics, Scientific Genomics Platforms of the MDC (BIMSB/BIH). b) Volcano plot of differentially 
expressed genes in human shMLL1 Ls174T cells, represented as blue dots. Genes of a mouse 
embryonic fibroblast (MEF) Mll1-/- signature163 marked in red and indicated by name. c) GSEA analysis 
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of differentially expressed genes in shMLL1 Ls174T cells reveals negative correlation with a Lgr5+ 
intestinal stem cell signature89; p-value 0.001, NES -1.65, FDR 0.001. d) Differentially expressed genes 
in shMLL1 Ls174T cells compared to intestinal stem cell signatures reported by the groups of Clevers195, 
Soshnikova204 and Batlle89. The correlation table indicates the number of common genes, green colour 
gradations encode the Jaccard index of similarity between the signatures, the lighter the colour the 
higher the similarity. e) Volcano plot of the differentially expressed genes in shMLL1 Ls174T cells 
overlaid with our MLL1-regulated colon cancer stem cell signature (Supplementary Table 1, page 116), 
genes of the signature are marked as green dots and indicated by name. 
Comparisons of the differentially expressed genes in shMLL1 Ls174T cells with intestinal stem 
cell signatures reported by the groups of Clevers195, Soshnikova204 and Batlle89 revealed a 
significant overlap of genes (Figure 3.19d: Clevers 36, Soshnikova 106 and Batlle 19 genes). 
The correlation table in Figure 3.19d illustrates both the number of overlapping genes and the 
degree of similarity between the compared stem cell signatures (Jaccard index). A high number 
of overlapping genes does not necessarily indicate that two signatures are the most similar 
because of differences in the number of genes comprising each signature: ‘Soshnikova and 
shMLL1’ are less similar to each other than ‘Clevers and shMLL1’, despite the fact that the 
former pair shares a higher number of overlapping genes. The ‘Soshnikova’ signature contains 
many more genes than the ‘Clevers’ signature. 132 deregulated stem cell genes were 
compiled to establish a MLL1-regulated colon cancer stem cell signature (Supplementary 
Table 1, page 116). A volcano plot of the deregulated genes overlaid with this signature 
showed predominant downregulation of intestinal stem cell genes upon knockdown of MLL1; 
these included OLFM4, SMOC2, IGFBP4 and the Wnt-regulated gene LGR5 (Figure 3.19e, 
Supplementary Table 1, page 116). 
3.8.2 MLL1 regulates the stemness and self-renewal of human colon cancer cells. 
The observed deregulation of stem cell genes in shMLL1 cells suggested a role of MLL1 in 
sustaining the stemness and self-renewal of colon cancer cells. We therefore assessed the 
self-renewal capacity of shMLL1 Ls174T and DLD1 cells. MLL1 was essential for the clonal 
expansion of Ls174T cells in a colony formation assay; shMLL1 cells were unable to expand 
into cell colonies (Figure 3.20a). Non-adherent sphere culture growth and high re-plating 
efficiency are characteristic properties of cancer stem cells87, 162. Ls174T cells cultured as 
3D non-adherent colon cancer spheres expressed the stem cell genes LGR5, SMOC2 and 
CD44, and showed an increased expression of the cancer stem cell marker CD166 93 
(Figure 3.20b). MLL1 protein levels were strongly increased in the non-adherent, self-renewing 
sphere cultures of human Ls174T cells compared to adherent cultures (Figure 3.20c). 
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Figure 3.20: MLL1 and the stemness of human colon cancer cells. 
a) Crystal violet staining of cell colonies from control and shMLL1 Ls174T cells, quantification on the 
right, n=6, unpaired t test. b) mRNA expression of the stem cell genes LGR5, SMOC2, CD44 and the 
cancer stem cell marker CD166 in Ls174T cells cultured under adherent and non-adherent conditions. 
c) Western blot for MLL1 and SETD1A in Ls174T cells cultured under adherent and non-adherent 
conditions, vinculin as control for equal loading. Quantification on the right, normalized to vinculin, n=3, 
unpaired t test. 
The expression of the MLL family member SETD1A was not increased in the non-adherent 
sphere cultures of Ls174T cells (Figure 3.20c). SETD1A had previously been reported to 
regulate the expression of several Wnt target genes in colon cancer cells141. Given the strong 
correlation of oncogenic Wnt signalling and MLL1 expression in human colon cancer patient 
samples and β-catGOF mouse intestinal tumors (see Figure 3.1, page 26 and Figure 3.6, 
page 33), we investigated whether MLL1 controlled the expression of reported SETD1A-
regulated Wnt target genes. The knockdown of MLL1 did not affect the expression of the 
SETD1A-regulated Wnt targets TCF1 and TCF4 141 (Figure 3.21), indicating that the two 
histone methyltransferases MLL1 and SETD1A regulate distinct Wnt target genes in colon 
cancer cells. 
    
Figure 3.21: MLL1 and SETD1A regulate distinct Wnt target genes in colon cancer cells. 
mRNA expression of the SETD1A-regulated Wnt target genes TCF1 and TCF4 in control and shMLL1 
Ls174T and DLD1 sphere cells, n=4, unpaired t test.  
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We investigated the effect of MLL1 ablation on the growth of Ls174T and DLD1 colon cancer 
cells in adherent and non-adherent cultures. Serial re-plating assays revealed that the 
knockdown of MLL1 did not immediately affect viability and proliferation of Ls174T and DLD1 
cells in adherent 2D cultures. A significant growth reduction was detected only after four 
passages at 10-14 days after shMLL1 induction (Figure 3.22a, b). In contrast to the 2D culture, 
the knockdown of MLL1 in non-adherent 3D sphere cultures of Ls174T and DLD1 cells had a 
rapid effect on the growth and self-renewal of the cancer cells. Secondary sphere formation of 
shMLL1 cells was reduced by 80% in Ls174T and by 60% in DLD1 cells compared to control 
cells (Figure 3.22c, d). 
  
Figure 3.22: MLL1 is crucial for the self-renewal of human colon cancer cells. 
Serial re-plating assays: quantification of viable (a) shMLL1 Ls174T and (b) shMLL1 DLD1 cells cultured 
under 2D adherent conditions at indicated time points after shMLL1 induction relative to control cells, 
n=4, unpaired t test. c) Brightfield images of control and 6d doxycycline-induced shMLL1 Ls174T 
secondary spheres, scale bars 100µm. Quantification of spheres >50µm in size on the right, n=3, 
unpaired t test. d) Brightfield images of control and 8d doxycycline-induced shMLL1 DLD1 secondary 
spheres, scale bars 100µm. Quantification of spheres >50µm in size on the right, n=3, unpaired t test. 
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Residual spheres exhibited minimal MLL1 expression and reduced proliferation as shown by 
staining for Ki67 (Figure 3.23a). shMLL1 spheres were negative for the apoptosis marker 
cleaved Caspase-3 (Figure 3.23a, b). 
 
Figure 3.23: MLL1 is required for 3D sphere growth of human colon cancer cells. 
a) Brightfield images of control and shMLL1 Ls174T spheres, scale bars 25µm. MLL1 (green), Ki67 (red) 
and cleaved Caspase-3 (red) stainings in control and shMLL1 Ls174T spheres, scale bars 20µm. DAPI 
(blue) stains nuclei. b) Western blot for cleaved Caspase-3, tubulin as control for loading. Puromycin 
(2µg/ml) treatment for 24h as positive control for apoptosis. 
Our studies in the human colon cancer cell lines Ls174T and DLD1 demonstrate a crucial role 
of the histone methyltransferase MLL1 in sustaining the stemness of Wnt-activated colon 
cancer cells. MLL1 was highly expressed in non-adherent sphere cultures and was crucial for 
the self-renewal of the tumor cells. Our findings in the shMLL1 cells correlated well with the 
stem cell expansion phenotype that we had observed in Mll1-deficient β-catGOF mouse 
intestinal tumors and organoids, approving the Ls174T and DLD1 cells as suitable model 
systems to investigate the epigenetic mechanism underlying the role of MLL1 in colon cancer 
stemness. 
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3.8.3 MLL1 epigenetically sustains the expression of specific stem cell genes. 
The ablation of MLL1 in Ls174T cells deregulated the expression of intestinal stem cell genes 
(see Figure 3.19, page 46). RT-PCR analyses of sphere cultures confirmed the decrease in 
the expression of the stem cell genes: the expression of LGR5, IGFBP4, SMOC2 and 
OLFM4 195 was downregulated upon knockdown of MLL1 (Figure 3.24a). CD44 and LRIG1 195 
expression was not significantly decreased. There was no reduction in the expression of the 
Wnt-regulated genes ASCL2 92, SOX9 205 and AXIN2 33 (Figure 3.24a). The selective 
regulation of Wnt target genes was likewise observed in DLD1 colon cancer cells 
(Figure 3.24b): the knockdown of MLL1 decreased the expression of LGR5 but not ASCL2 and 
AXIN2. The ablation of MLL1 did not affect the overall activity of Wnt signalling, as shown by 
a TCF/LEF luciferase reporter assay (TOPflash)206 in comparison to cells either treated with 
the Wnt activator CHIR99021207 or the Wnt inhibitor LF3100 (Figure 3.24c). 
 
Figure 3.24: The ablation of MLL1 downregulates specific stem cell genes but does not decrease 
global Wnt activity in colon cancer cells. 
a) mRNA expression of intestinal stem cell genes and classical Wnt targets in control and 6d 
doxycycline-induced shMLL1 Ls174T sphere cells from 3 independent single cell clones, n=4, unpaired 
t test. b) mRNA expression of Wnt-regulated genes in 8d doxycycline-induced control and shMLL1 
DLD1 sphere cells, n=4, unpaired t test. c) TCF/LEF luciferase reporter assays in control and shMLL1 
Ls174T cells treated with doxycycline for 10 days, n=6 of 3 independent experiments, unpaired t test. 
Wnt-responsive luciferase activity (TOPflash) calculated relative to control (FOPflash). 3µM CHIR99021 
and 50µM LF3 added for 24h to stimulate and repress Wnt signalling, respectively, n=3, unpaired t test. 
To find out whether the regulated stem cell genes are directly controlled by MLL1 and its H3K4 
tri-methyltransferase activity, we performed chromatin immunoprecipitation (ChIP) of the 
activating and repressive chromatin marks H3K4me3 and H3K27me3. This revealed high 
H3K4me3 and low H3K27me3 levels at the transcription start sites (TSS) of the MLL1-
regulated stem cell genes LGR5, SMOC2, IGFBP4 and OLFM4. Ablation of MLL1 shifted the 
epigenetic state of the stem cell genes from transcriptionally permissive (H3K4me3) to 
repressed (H3K27me3) (Figure 3.25a). There were no changes in the levels of H3K4me3 and 
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H3K27me3 at the TSS of ASCL2 and AXIN2 (Figure 3.25b), which was in line with the 
unaffected expression of these Wnt target genes (see Figure 3.24, page 51). ChIP validity was 
confirmed by H3K4me3 enrichment at the GAPDH TSS and its absence at a negative control 
region (Figure 3.25c). Global levels of H3K4 and H3K27 methylation were not changed 
(Figure 3.25d), demonstrating a gene-specific function of the histone methyltransferase MLL1. 
 
Figure 3.25: The ablation of MLL1 switches H3K4me3 marks to repressive H3K27me3 at specific 
stem cell genes. 
ChIP for H3K4me3 and H3K27me3 at the TSS of a) LGR5, SMOC2, IGFBP4 and OLFM4 (n=7) and of 
b) ASCL2 and AXIN2 (n=4) in non-induced control (light grey columns) and 11d doxycycline-induced 
shMLL1 Ls174T cells (black columns), represented as % input. Unpaired t test, significance calculated 
for control versus shMLL1. c) GAPDH TSS and Myoglobin Exon 2 as positive and negative controls, 
n=7. d) Western blots for global H3K4 and H3K27 methylation in non-induced (utr) and 6d doxycycline-
induced shCtr (n=1) and shMLL1 (n=3) cells. Quantification below, normalized to total H3. 
We established ChIP for MLL1 and identified MLL1 binding to the promoters of the intestinal 
stem cell genes LGR5, SMOC2, IGFBP4 and OLFM4 (Figure 3.26a). ChIP specificity was 
confirmed by MLL1 binding to MECOM, a previously reported MLL1 target gene208, and by 
comparison to a negative control region (TAL1+70141). MLL1 binding to the LGR5 promoter 
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was also detected in DLD1 colon cancer cells (Figure 3.26b). Strongly reduced binding of 
MLL1 was observed in shMLL1 cells (Figure 3.26a, b; knockdown control Western blot in 
Figure 3.26c). 
 
Figure 3.26: MLL1 binds to the promoters of stem cell genes. 
a) ChIP for MLL1 in non-induced control (light grey columns) and 6d doxycycline-induced shMLL1 
Ls174T cells (black columns), binding at the LGR5, SMOC2, IGFBP4 and OLFM4 promoters, 
represented as % input, n=6, unpaired t test, significance calculated for control versus shMLL1 and IgG. 
MECOM TSS and +70kb downstream region of the TAL1 promoter positive and negative controls. 
b) ChIP for MLL1 in non-induced control (light grey columns, n=6) and 8d doxycycline-induced shMLL1 
DLD1 cells (black columns, n=3), binding at the LGR5 promoter, negative control region TAL1 +70, 
represented as % input. Unpaired t test, significance calculated for control versus shMLL1 and IgG. 
c) Representative MLL1 knockdown control Western blot from cells used for ChIP analyses. 
3.8.4 MLL1 antagonizes PcG-mediated silencing of stem cell genes. 
The ablation of MLL1 shifted the epigenetic state of the regulated stem cell genes from 
transcriptionally permissive (H3K4me3) to repressed (H3K27me3) (see Figure 3.25, page 52). 
H3K27me3 marks are deposited by the polycomb repressive complex 2 (PRC2)134 
(compare 1.3.7, page 20). To assess an antagonistic control of the stem cell genes by Mll1 
and PRC2, we treated MLL1 knockdown cells with the small molecule Gsk126209, an inhibitor 
of the catalytic PRC2 subunit Ezh2 (scheme in Figure 3.27a). Gsk126 treatment partially 
restored the decreased expression of LGR5, SMOC2, IGFBP4 and OLFM4 even in the 
absence of MLL1 (Figure 3.27b). H3K4me3 marks at the TSS of the stem cell genes were not 
restored upon Gsk126 treatment (Figure 3.27c), indicating that the re-initiation of LGR5, 
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SMOC2, IGFBP4 and OLFM4 expression was independent of MLL1 and its methyltransferase 
activity. The expression of the MLL1-independent Wnt target genes ASCL2 and AXIN2 was 
unaffected by Gsk126 treatment (Figure 3.27d), and H3K4me3 and H3K27me3 TSS marks 
were unchanged (Figure 3.27e). 
 
Figure 3.27: MLL1 antagonizes PRC2 to sustain the expression of specific stem cell genes. 
a) Scheme: The antagonism of Mll1-dependent H3K4me3 and PRC2-mediated H3K27me3 controls 
gene expression. The chemical compound Gsk126 inhibits the H3K27 tri-methyltransferase activity of 
Ezh2 and blocks the PRC2-mediated tri-methylation of H3K27. b) mRNA expression of LGR5, SMOC2, 
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IGFBP4 and OLFM4 in control (dark grey), 6d doxycycline-induced shMLL1 Ls174T cells (dark green) 
and shMLL1 Ls174T cells following 4-day Gsk126 treatment (light green), n=6, unpaired t test. c) ChIP 
for H3K4me3 (dark grey columns) and H3K27me3 (light grey columns) at the TSS of LGR5, SMOC2, 
IGFBP4 and OLFM4 (n=3) in control, 11d doxycycline-induced shMLL1 Ls174T cells and shMLL1 
Ls174T cells following 4-day Gsk126 treatment, represented as % input. d) mRNA expression of ASCL2 
and AXIN2 in control (dark grey), 6d doxycycline-induced shMLL1 Ls174T cells (dark green) and 
shMLL1 Ls174T cells following 4-day Gsk126 treatment (light green), n=6, unpaired t test. e) ChIP for 
H3K4me3 (dark grey columns) and H3K27me3 (light grey columns) at the TSS of ASCL2 and AXIN2 
(n=3) in control, 11d doxycycline-induced shMLL1 Ls174T cells and shMLL1 Ls174T cells following 
4-day Gsk126 treatment, represented as % input. 
These data demonstrate that the intestinal stem cell genes LGR5, SMOC2, IGFBP4 and 
OLFM4 are antagonistically controlled by MLL1 and the polycomb repressive complex 2 
(PRC2). MLL1 counteracts the PcG-mediated silencing of the stem cell genes. 
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3.8.5 MLL1 is essential for the β-catenin/TCF4-induced expression of LGR5. 
The expression of the stem cell gene LGR5 is controlled by Wnt/β-catenin signalling107. We 
asked whether the ablation of MLL1 changed the promoter occupancy of the β-catenin/TCF4 
complex. ChIP for TCF4 and β-catenin revealed binding of the β-catenin/TCF4 complex at the 
LGR5 promoter (Figure 3.28a, b). There was no change in β-catenin/TCF4 occupancy upon 
knockdown of MLL1 (Figure 3.28a, b). 
 
Figure 3.28: β-catenin/TCF4 binding to the LGR5 promoter in control and shMLL1 Ls174T colon 
cancer cells. 
ChIP for TCF4 (a) and β-catenin (b) at the LGR5 promoter in non-induced control (light grey columns) 
and 6d doxycycline-induced shMLL1 Ls174T cells (black columns), negative control region TAL1 +70, 
represented as % input, n=5. Unpaired t test, significance calculated for control versus shMLL1 and IgG. 
Taken together, our results show that the histone methyltransferase MLL1 sustains the 
oncogenic Wnt-driven expression of specific stem cell genes by antagonizing PcG-mediated 
gene silencing. In the absence of MLL1, PRC2 catalyses the tri-methylation of H3K27me3 and 
mediates gene repression. In the case of LGR5, this occurs regardless of the promoter 
occupancy of β-catenin/TCF4 (summarized in the schemes in Figure 3.29). 
      
Figure 3.29: Scheme of the antagonistic control of LGR5 by MLL1 and PRC2. 
Scheme of β-catenin/TCF4-MLL1-dependent regulation of LGR5 in colon cancer cells. MLL1 prevents 
PRC2-mediated gene silencing to sustain LGR5 expression. This is associated with the MLL1-
dependent H3K4 tri-methylation at the LGR5 TSS. Right: Ablation of MLL1 results in PRC2-mediated 
H3K27me3 and silencing of LGR5 expression. 
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3.9 MLL1 prevents differentiation of human colon cancer cells. 
The shMLL1 Ls174T human xenograft tumors and sphere cells showed enhanced 
differentiation with an increase in the expression of the Paneth cell genes DEFA5 and LYZ and 
the goblet cell markers MUC2 and ITF (Figure 3.30a, b), as was also observed in the β-catGOF 
mouse tumor model (see Figure 3.13, page 39). Ls174T spheres also increased the 
expression of the enterocyte differentiation marker cytokeratin KRT20 210 upon knockdown of 
MLL1 (Figure 3.30b on the right). DLD1 sphere cells did not express Paneth cell genes and 
showed unchanged MUC2 expression, but upregulated the expression of ITF and KRT20 upon 
knockdown of MLL1 (Figure 3.30c). Our data suggest that MLL1 maintains human colon 
cancer cells in a non-differentiated stem-like state. The ablation of MLL1 induces differentiation 
of xenograft tumors and sphere cultures. 
 
Figure 3.30: The knockdown of MLL1 induces differentiation of human colon cancer cells. 
a), b) mRNA expression of Paneth cell (green), goblet cell (red) and enterocyte (blue) markers in human 
shMLL1 Ls174T xenograft tumors (n=4) and sphere cells (n=4) relative to non-induced controls, 
unpaired t test. c) mRNA expression of goblet cell (red) and enterocyte (blue) markers in human shMLL1 
DLD1 sphere cells relative to control sphere cells, n=4, unpaired t test. 
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3.10 Exploring the molecular mechanism of differentiation reveals a Mll1-
Gata4/6-Bmp4 axis. 
We sought to determine the molecular mechanism underlying the differentiation of 
Mll1-deficient tumor-propagating cells in β-catGOF; Mll1-/- intestinal stem cells and organoids 
and in human colon cancer xenografts and spheres (see Figure 3.13, page 39 and Figure 3.30, 
page 57). The transcriptome profiling of β-catGOF; Mll1-/- intestinal stem cells had identified the 
transcription factor Gata4 as a Mll1-regulated gene in Wnt-activated tumor-initiating cells (see 
Figure 3.14, page 41). Gata4 expression is restricted to the small intestine211, mouse and 
human colon epithelia express the homologue Gata6203. Ablation of Gata6 in mouse and 
human colon cancer cells has been shown to upregulate the expression of the Bmp receptor 
ligand Bmp4, suppressing self-renewal and inducing differentiation of cancer stem cells203. 
We observed a decreased expression of Gata4 in β-catGOF; Mll1-/- small intestinal organoids, 
compared to β-catGOF and β-catGOF; Mll1+/- organoids (Figure 3.31a, b). The decreased Gata4 
expression was associated with a strong increase in the expression of Bmp4 (Figure 3.31b). 
       
Figure 3.31: The ablation of Mll1 shifts Gata4 and Bmp4 expression in small intestinal organoids. 
a) Immunofluorescence staining for Mll1 (red) and Gata4 (green) on sections of β-catGOF and β-catGOF; 
Mll1-/- organoids. Nuclei in blue (DAPI), scale bars 20µm. b) mRNA expression of Gata4 and Bmp4 in 
β-catGOF; Mll1+/- and β-catGOF; Mll1-/- organoids, n=3, unpaired t test. 
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In Ls174T and DLD1 colon cancer sphere cells, the ablation of MLL1 decreased the expression 
of GATA6, while BMP4 expression increased (Figure 3.32a). GATA4 expression was not 
detectable in the colon cancer cells. ChIP revealed MLL1 binding to the GATA6 promoter 
(Figure 3.32b). The MLL1 binding was strongly reduced in shMLL1 cells and was absent at a 
negative control region 70kb downstream of the TAL1 promoter (Figure 3.32b). Histone 
methylation at the GATA6 TSS switched from activating H3K4me3 to repressive H3K27me3 
upon knockdown of MLL1 (Figure 3.32c). Immunohistochemistry staining confirmed a strong 
decrease in GATA6 levels in shMLL1 Ls174T sphere cells (Figure 3.32d). These data suggest 
that MLL1 acts as an upstream regulator of GATA6 to prevent a BMP4-induced differentiation 
of the colon cancer cells. 
 
Figure 3.32: MLL1 controls the expression of GATA6 in human colon cancer cells. 
a) mRNA expression of GATA6 (beige) and BMP4 (red) in control and shMLL1 Ls174T (upper panel) 
and shMLL1 DLD1 sphere cells (lower panel), n=4, unpaired t test. b) ChIP for MLL1 in control (light 
grey columns) and 6d doxycycline-induced shMLL1 Ls174T cells (black columns; upper panel, n=6) and 
in control (light grey columns) and 8d doxycycline-induced shMLL1 DLD1 cells (black columns; lower 
panel, n=4), binding at the GATA6 promoter, TAL1 +70kb as negative control region, represented as 
% input, unpaired t test, significance calculated for control versus shMLL1 and IgG. c) ChIP for 
H3K4me3 and H3K27me3 at the TSS of GATA6 in control (light grey columns) and 11d doxycycline-
induced shMLL1 Ls174T cells (black columns), represented as % input, n=4. d) Immunohistochemistry 
for GATA6 on sections of control and shMLL1 Ls174T spheres, scale bars 50µm, insets 25µm. 
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Bmp signalling has previously been shown to suppress intestinal stem cell genes and induce 
differentiation of Lgr5+ intestinal stem cells42. This has been associated with the expression of 
the cell cycle inhibitor and differentiation marker p21CIP1/WAF1 (Cdkn1a). The ablation of MLL1 
in Ls174T cells strongly increased p21 expression over time, while LGR5 expression gradually 
decreased (Figure 3.33a). This inverse regulation was observed on both mRNA and protein 
level. The expression of p21 was also markedly upregulated in shMLL1 Ls174T sphere cells 
(Figure 3.33b, c). Along with the increased p21 expression, the MLL1-depleted cells showed 
a slight decrease in c-MYC protein levels (Figure 3.33d). Increased p21 levels and decreased 
c-MYC protein levels were also observed in shMLL1 Ls174T xenograft tumors 
(Figure 3.33e, f). A complementary pattern of c-Myc and p21 has previously been reported in 
the crypts and villi of the intestinal epithelium212. Interference with Wnt/β-catenin signalling by 
introduction of dnTCF4 in Ls174T cells reduced c-MYC protein levels and released its 
interaction with MIZ-1 at the p21 promoter, upregulating p21 expression and causing secretory 
and enterocyte differentiation212. 
 
Figure 3.33: shMLL1 Ls174T cells upregulate the cell cycle inhibitor p21. 
a) mRNA expression of LGR5 (green) and p21 (black) in control and shMLL1 Ls174T cells at indicated 
time points after shMLL1 induction, n=1. Below: Western blot for MLL1, LGR5 and p21, vinculin as 
control for equal loading. b) Immunostaining for p21 (red) in control and shMLL1 Ls174T sphere cells. 
Nuclei in blue (DAPI), scale bars 20µm. Right: p21 mRNA expression in control and shMLL1 Ls174T 
sphere cells, n=4, unpaired t test. c) Western blot for p21 in control and shMLL1 Ls174T sphere cells, 
tubulin as control for equal loading. Quantification on the right, normalized to tubulin, n=3, unpaired 
t test. d) Western blot for c-MYC in control and shMLL1 Ls174T sphere cells, tubulin as control for equal 
loading. Quantification on the right, normalized to tubulin, n=3. e) Immunostaining for p21 (red) on 
control and shMLL1 Ls174T xenograft sections. Nuclei in blue (DAPI), scale bars 20µm. Right: p21 
mRNA expression in control and shMLL1 Ls174T xenografts, n=6, unpaired t test. f) Western Blot for 
c-MYC in two pairs of control and shMLL1 Ls174T xenografts, tubulin as control for equal loading. 
Quantification on the right, normalized to tubulin, n=6, unpaired t test. 
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We considered the increased levels of BMP4 causative for the upregulation of p21 in the 
shMLL1 Ls174T cells. Treatment of Ls174T colon cancer spheres with BMP4 induced the 
expression of p21 (Figure 3.34a). Mouse intestinal organoids treated with increasing 
concentrations of BMP4 under Noggin-free conditions upregulated the expression of the Bmp 
target gene and differentiation marker Id2 and of p21 in a concentration-dependent manner 
(Figure 3.34b). The Bmp inhibitor Noggin blocks Bmp signal transduction by inhibiting Bmp 
receptor activation and thus preventing phosphorylation of SMAD signal transducing proteins, 
the hallmark of active Bmp signalling213. Noggin treatment reduced phospho-SMAD1/5/8 levels 
and effectively decreased the strong p21 induction in shMLL1 Ls174T cells (Figure 3.34c, 
quantifications on the right). 
 
Figure 3.34: BMP4 induces p21 expression and differentiation. 
a) Western blot for p21 in control and 48h BMP4-treated Ls174T sphere cells, tubulin as control for 
equal loading. Quantification on the right, normalized to tubulin, n=2. b) Id2 and p21 mRNA expression 
in mouse intestinal organoids treated with 10ng/ml and 100ng/ml of BMP4 for 24h, n=5, unpaired t test. 
c) Western blot for p21, p-SMAD1/5/8 and SMAD1/5/8 in untreated and 48h Noggin-treated control and 
7d doxycycline-induced shMLL1 Ls174T sphere cells, tubulin as control for equal loading. 
Quantifications of p21 and p-SMAD1/5/8 levels normalized to tubulin and SMAD1/5/8, respectively, in 
control, shMLL1 and Noggin-treated shMLL1 cells on the right, n=4, unpaired t test. d) mRNA 
expression of Lgr5, Smoc2 and Olfm4 in mouse intestinal organoids treated with 10ng/ml and 100ng/ml 
of BMP4 for 24h, n=5, unpaired t test. e) mRNA expression of Gob5, Mmp7 and Lyz in mouse intestinal 
organoids treated with 10ng/ml and 100ng/ml of BMP4 for 24h, n=5, unpaired t test. 
In line with Qi et al. (2017)42, BMP4-treated intestinal organoids strongly reduced the 
expression of the stem cell genes Lgr5, Smoc2 and Olfm4 (Figure 3.34d). BMP4 treatment 
upregulated the expression of the goblet cell-specific gene Gob5 214 but reduced the 
  Results 
62 
expression of the Paneth cell markers Mmp7 and Lyz (Figure 3.34e), promoting differentiation 
towards a goblet cell fate. 
Of note, the knockdown of MLL1 did not increase the levels of phospho-SMAD1/5/8 in the 
Ls174T cells (Figure 3.34c, first two lanes and quantification on the right), indicating that the 
increased levels of BMP4 in shMLL1 Ls174T cells induced the expression of p21 independent 
of an increased activity of the classical Bmp pathway. As p21 is a well-established p53 target 
gene215, we investigated the role of p53 in inducing p21 expression in the shMLL1 cells. The 
p53-mutant DLD1 cells did not show an increased expression of p21 upon knockdown of MLL1 
(Figure 3.35a). In shMLL1 Ls174T sphere cells, total levels of p53 protein did not change 
compared to control cells, indicating that basal levels of p53 are present but do not increase 
upon knockdown of MLL1 in Ls174T cells (Figure 3.35b). Binding of p53 to the p53 binding 
site -2283bp upstream of the p21 promoter216 did not increase in shMLL1 Ls174T cells 
(Figure 3.35c). These data indicate that the induction of p21 expression in shMLL1 Ls174T 
cells was not a consequence of p53 activation. Basal levels of p53 seem to be required for p21 
expression, though, as DLD1 cells failed to induce p21. 
       
Figure 3.35: The p21 induction in shMLL1 human colon cancer cells depends on p53. 
a) p21 mRNA expression in control and shMLL1 DLD1 sphere cells, n=4, unpaired t test. b) Western 
blot for p21 and p53 in control and shMLL1 Ls174T sphere cells, tubulin as control for equal loading. 
Quantification below, normalized to tubulin, n=3, unpaired t test. c) ChIP for p53 in control (light grey 
columns) and 11d doxycycline-induced shMLL1 Ls174T cells (black columns), binding at the p53 binding 
site -2283bp upstream of the p21 promoter216, n=2, represented as % input. 
3.10.1 The ablation of MLL1 induces senescence of Ls174T cells. 
The upregulation of p21 has been implicated in cellular senescence, a state of permanent cell 
cycle arrest that cells might undergo in response to oncogene activation, DNA damage, 
chromatin perturbation and other stressors217. Epigenetic silencing of Lgr5 has recently been 
reported to induce a p21-mediated senescence in aging intestinal organoids218. Concomitant 
with an increased expression of the cell cycle inhibitor p21 (see Figure 3.33, page 60), the 
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shMLL1 Ls174T cells cultured under 2D adherent conditions showed a gradual decrease in 
proliferation (Figure 3.36a) and after 11 days in culture exhibited senescence-associated 
β-galactosidase (SA-β-Gal) activity (Figure 3.36b). Strong SA-β-Gal activity was also observed 
in shMLL1 Ls174T spheres (Figure 3.36c), along with p21 and the senescence-associated 
repressive chromatin mark H3K9me3 (Figure 3.36d) and increased DNA damage foci marked 
by γ-H2A.x (Figure 3.36e)219. The increase in p21 expression coincided with a decreased 
expression of the senescence-inhibiting factor RAC3 220 (Figure 3.36f). Taken together, the 
knockdown of MLL1 in Ls174T cells caused a decrease in GATA6 and c-MYC protein levels 
and a concomitant increase in BMP4 and p21 expression, inducing differentiation and driving 
the cancer cells into senescence (see scheme in Figure 3.36g). The p53-mutant DLD1 cells 
failed to upregulate p21 expression (see Figure 3.35a, page 62) and did not undergo 
senescence, yet differentiated in a BMP4-dependent manner upon knockdown of MLL1 (see 
Figure 3.30, page 57 and Figure 3.32, page 59). 
 
Figure 3.36: shMLL1 Ls174T cells undergo p21-induced cellular senescence. 
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a) Quantification of viable shMLL1 Ls174T cells cultured under 2D adherent conditions, normalized to 
control cells at indicated time points after shRNA induction, n=4, unpaired t test. The data are derived 
from the same experiment as in Figure 3.22 (page 49) and are re-described here to illustrate the gradual 
decrease in shMLL1 Ls174T cell growth. b) Senescence-associated β-galactosidase (SA-β-Gal) 
staining (blue) of control and shMLL1 Ls174T cells at days 3 and 11 after doxycycline induction. dsRed 
as reporter of shRNA production, scale bars 100µm. c) SA-β-Gal staining (blue) of control and 11d 
doxycycline-induced shMLL1 Ls174T spheres, scale bars 10µm. d) Immunostaining for H3K9me3 (red) 
and p21 (green) in control and shMLL1 Ls174T spheres, nuclei in blue (DAPI), scale bars 10µm. 
e) Immunostaining for γ-H2A.x (red) in control and shMLL1 Ls174T spheres. Nuclei in blue (DAPI), scale 
bars 20µm. Quantification on the right, n=12, Mann-Whitney test. f) mRNA expression of p21 (n=4) and 
RAC3 (n=2) in control and shMLL1 Ls174T spheres, unpaired t test. g) Scheme: The knockdown of 
MLL1 induces differentiation. Colon cancer stem cells express stem cell genes, GATA6, c-MYC and 
RAC3. Knockdown of MLL1 reduces their stemness and decreases GATA6 and c-MYC levels, causing 
upregulation of BMP4 and p21, which mediate differentiation and senescence. 
Collectively, the data suggest that Mll1 acts as an upstream regulator of a Gata4/6-Bmp4 axis 
to sustain the stemness and self-renewal of tumor-propagating intestinal cancer cells. Mll1 
promotes Gata4/6 expression to suppress Bmp4 and prevent differentiation. The ablation of 
Mll1 downregulates Gata4/6, upregulates the expression of Bmp4 and enforces differentiation 
of the cancer stem cells, pushing them to less aggressive fates. In p53-competent cells, the 
ablation of Mll1 leads to p21 expression, which may ultimately cause cellular senescence. 
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3.11 Mll1 controls Wnt and Mapk signalling to specify secretory differentiation. 
3.11.1 Mll1 suppresses Mapk signalling and prevents goblet cell differentiation of Wnt-
activated cells. 
A network of Wnt/β-catenin, Mapk and other signalling pathways guides lineage specification 
of secretory progenitor cells in the TA zone (compare 1.1.3, page 10). High Wnt signalling in 
secretory progenitors induces differentiation into Paneth cells and prevents the maturation of 
goblet cells64. The ablation of Mll1 induced differentiation of oncogenic Wnt-activated Lgr5+ 
stem cells and shifted the β-catGOF/Wnt-imposed Paneth-like identity towards a goblet cell fate, 
giving rise to double-positive Paneth-goblet cells (see Figure 3.13, page 39). Goblet cell 
differentiation has been shown to depend on Mapk signalling64. Correspondingly, 
immunohistochemistry staining on sections of β-catGOF; Mll1+/- and β-catGOF; Mll1-/- organoids 
revealed a strong increase in phospho-Erk1/2 levels upon loss of Mll1 (Figure 3.37a, upper 
panel). Western blotting for phospho-Erk1/2 and phospho-Mek1/2 confirmed an increased 
activity of the Mapk pathway in β-catGOF; Mll1-/- organoids compared to β-catGOF; Mll1+/- 
organoids (Figure 3.37b). The high Mapk signalling in the β-catGOF; Mll1-/- organoids correlated 
with increased numbers of goblet cells and strong mucinous secretion towards the inside of 
the organoids, as assessed by Alcian blue staining (Figure 3.37a, lower panel, quantification 
in c). Increased phospho-Erk1/2 levels were also detected in the mutant crypts of 
β-catGOF; Mll1-/- mice at 10 days after induction, compared to β-catGOF; Mll1+/- mice and adjacent 
non-recombined crypts (Figure 3.37d). 
 
Figure 3.37: The ablation of Mll1 increases Mapk signalling and goblet cell differentiation in 
β-cateninGOF intestinal organoids and crypts. 
a) Immunohistochemistry stainings for phospho-Erk1/2 and Alcian blue stainings on serial sections of 
β-catGOF; Mll1+/- and β-catGOF; Mll1-/- organoids, nuclei counter-stained with hematoxylin and nuclear fast 
red, scale bars 50µm. Black arrows indicate Alcian blue-positive goblet cells. b) Western blot for 
phospho-Erk1/2 and Erk1/2, phospho-Mek1/2 and Mek1/2 in β-catGOF; Mll1+/- (+/-) and β-catGOF; Mll1-/- 
(-/-) intestinal organoids. c) Number of Alcian blue-positive cells in β-catGOF; Mll1+/- and β-catGOF; Mll1-/- 
organoids, quantified from at least 20 organoids, unpaired t test. d) Immunohistochemistry staining for 
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phospho-Erk1/2 and Lgr5-GFP on sections of β-catGOF; Mll1+/- and β-catGOF; Mll1-/- intestines at 10 days 
post-induction compared to adjacent non-recombined crypt, nuclei counter-stained with hematoxylin, 
scale bars 20µm. Yellow arrows highlight phospho-Erk1/2 in nuclei of β-catGOF; Mll1-/- crypt cells. 
3.11.2 Mll1 controls the Wnt/Mapk-driven differentiation of secretory cells. 
We aimed to further examine the role of Mll1 in controlling the Wnt/Mapk-driven differentiation 
of secretory cells in the intestinal epithelium. To study the role of Mapk, we crossed in the 
Mek1DD allele221, 222. Cre-mediated recombination removes a translation stop cassette and 
activates the expression of a constitutively active gain-of-function variant of Mek1 (Mek1DD) 
from the Rosa26 locus (compare Materials and Methods, Figure 5.1d, page 84). We 
established organoids from the small intestine of Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mek1DD; 
Mll1flox/+ and Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mek1DD; Mll1flox/flox mice (hereafter called 
β-catGOF; Mek1GOF; Mll1+/- and β-catGOF; Mek1GOF; Mll1-/- mice, respectively) and induced the 
mutagenesis in culture by in vitro administration of tamoxifen. 
 
Figure 3.38: Mll1 controls Wnt/Mapk-driven secretory differentiation. 
a) Left: immunofluorescence for Mmp7 (green) and Mll1 (red) on sections of non-induced (control) and 
tamoxifen-induced β-catGOF; Mek1GOF; Mll1+/- and β-catGOF; Mek1GOF; Mll1-/- mouse intestinal organoids. 
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Middle: immunofluorescence staining for Lyz (green) and ITF (red) on sections of organoids of the three 
genotypes, white arrows indicate cells with weak ITF expression. E-cadherin (yellow) stains cell borders, 
nuclei in blue (DAPI). Right: Alcian blue staining for goblet cells, nuclear fast red counter-staining, black 
arrows indicate Alcian blue-positive goblet cells. Scale bars 50µm. b) H&E staining on sections of small 
intestines of β-catGOF; Mek1GOF; Mll1+/- and β-catGOF; Mek1GOF; Mll1-/- mice at 20 days after induction with 
tamoxifen, scale bars 100µm. c) Quantification of villus length in β-catGOF; Mek1GOF; Mll1+/- (n=8) and 
β-catGOF; Mek1GOF; Mll1-/- (n=6) mice at 20 days after induction relative to control (wild-type) mice (n=3), 
at least 10 villi per mouse measured, Mann-Whitney test. d) mRNA expression of secretory lineage 
markers Spdef, Lyz, Mmp7, Itf, Muc2 and Gob5 in intestines of control (grey, n=3), β-catGOF (green, 
n=3), β-catGOF; Mek1GOF; Mll1+/- (blue, n=5) and β-catGOF; Mek1GOF; Mll1-/- mice (light blue, n=5) at 
20 days after the induction of mutagenesis, unpaired t test. 
The simultaneous activation of Wnt and Mapk signalling impaired the maturation of Paneth 
(Lyz, Mmp7) and goblet cells (Alcian blue) (Figure 3.38a, second panel). Remarkably, Paneth 
and goblet cells re-appeared in organoids with homozygous ablation of Mll1 (Figure 3.38a, 
bottom panel). The stabilization of β-catenin and Mek1GOF and the loss of Mll1 were then 
induced by intraperitoneal injections of tamoxifen in β-catGOF; Mek1GOF; Mll1+/- and β-catGOF; 
Mek1GOF; Mll1-/- mice. The intestines of β-catGOF; Mek1GOF; Mll1+/- mice became dysplastic and 
exhibited elongated villi (Figure 3.38b left, quantification in c). The mice did not survive beyond 
20 days after the induction of mutagenesis. Homozygous ablation of Mll1 attenuated the 
β-catGOF; Mek1GOF-induced hyperplastic phenotype. The villi were of normal (wild-type) length 
(Figure 3.38b right, quantification in c). 
Wnt signalling maintains intestinal stem and progenitor cells and induces differentiation of 
secretory Paneth cells, while it prevents the maturation of goblet cells64. In the intestines of 
β-catGOF mice, we observed an increased expression of the Paneth cell marker Mmp7 and the 
secretory lineage marker Spdef, whereas the goblet cell marker Gob5 strongly decreased 
(Figure 3.38d). The expression of Lyz, which is specific for mature Paneth cells, was not 
increased, indicating an immature nature of the Paneth cells. High Mapk signalling impedes 
differentiation of Paneth cells and shifts secretory cell specification towards a goblet fate64. 
Interestingly, simultaneous activation of Wnt and Mapk signalling in β-catGOF; Mek1GOF; Mll1+/- 
mice on the one hand decreased Mmp7 expression and reverted the β-catGOF-induced 
expression of Spdef to control levels, and on the other hand reduced the expression of the 
goblet cell markers Itf, Muc2 and Gob5 (Figure 3.38d). This indicates that the opposing Wnt 
and Mapk signalling activities work against each other, disturbing the maturation of both 
Paneth and goblet cells, as was also observed in the organoids (Figure 3.38a, second panel) 
and proposed by Heuberger et al. (2014)64 (compare 1.1.3, page 10). The ablation of Mll1 in 
β-catGOF; Mek1GOF; Mll1-/- mice re-established secretory cell differentiation, as demonstrated 
by upregulation of Spdef and the Paneth cell-specific Mmp7, and by expression of the goblet 
cell markers Itf, Muc2 and Gob5 (Figure 3.38d). This fits our observations in organoids, where 
both Paneth and goblet cells re-appeared upon ablation of Mll1; the re-appearing cells were 
largely double-positive for Paneth and goblet cell markers (Figure 3.38a, lower panel). In 
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summary, these data demonstrate that Mll1 keeps intestinal epithelial cells in an immature 
state and a decrease in Mll1 expression is necessary to allow for secretory differentiation. Our 
data further indicate that Mll1 also plays a role in controlling the Wnt/Mapk-driven specification 
of Paneth and goblet cells. In β-catGOF crypts, Mll1 suppressed a Mapk-induced goblet cell 
differentiation. The ablation of Mll1 unleashed Mapk signalling, giving rise to mixed Paneth-
goblet cells. 
3.11.3 Mll1 promotes the crypt proliferation and restricts the goblet cell differentiation 
driven by Mapk signalling. 
To gain deeper insights into the role of Mll1 in the Mapk-driven goblet cell differentiation, we 
analysed Mek1DD mice with heterozygous and homozygous ablation of Mll1 (compare 
Materials and Methods, Figure 5.1c, page 84), Lgr5-EGFP-IRES-CreERT2; Mek1DD; Mll1flox/+ 
and Lgr5-EGFP-IRES-CreERT2; Mek1DD; Mll1flox/flox mice, (hereafter called Mek1GOF; Mll1+/- and 
Mek1GOF; Mll1-/-, respectively) at 10 days after the induction of mutagenesis. Activation of Mapk 
signalling by Mek1GOF in Mek1GOF; Mll1+/- mice increased the proliferation of crypt cells, as seen 
through an increase in the incorporation of BrdU in mutant eGFP-positive crypts compared to 
adjacent non-recombined crypts (Figure 3.39a, upper panel, quantification in b). The eGFP is 
co-expressed with Mek1GOF from an IRES-EGFP linked to the Mek1DD allele221, 222 and allows 
to distinguish recombined from non-recombined crypts. Of note, in Lgr5-EGFP-IRES-CreERT2; 
Mek1DD mice the eGFP also identifies Lgr5-GFP+ stem cells15. High Mapk signalling in the 
crypts decreased the number of Paneth cells, as shown by immunostaining for the Paneth cell 
marker Lyz on serial sections of adjacent recombined and non-recombined crypts 
(Figure 3.39c, upper left). Mmp7 staining revealed the presence of secretory Paneth-like cells 
further up in the crypts (Figure 3.39c, upper middle). Mek1GOF; Mll1+/- crypts did not show a 
strong increase in goblet cells, as revealed by ITF and Alcian Blue staining compared to 
adjacent non-recombined crypts (Figure 3.39c, upper panel, quantification in d). 
The homozygous ablation of Mll1 in Mek1GOF; Mll1-/- mice prevented the Mek1GOF-induced 
hyper-proliferation of crypt cells (Figure 3.39a, lower panel, quantification in b). Proliferation 
was restricted to the crypt bottom. Mek1GOF; Mll1-/- crypts were filled with secretory cells, which 
were positive for the Paneth cell marker Mmp7 and exhibited a strong expression of goblet cell 
markers (ITF, Alcian Blue) (Figure 3.39c, lower panel, quantification in d). The loss of Mll1 did 
not interfere with the activity of Mapk signalling, as shown by immunohistochemistry for 
phospho-Erk1/2 in the mutant crypts of Mek1GOF; Mll1-/- mice compared to Mek1GOF; Mll1+/- 
mice (Figure 3.39c, right panel). Like in Mek1GOF; Mll1+/- crypts, the strong Mapk activity in 
Mek1GOF; Mll1-/- crypts reduced the number of Paneth cells at the crypt bottom to one 
(Figure 3.39c, left panel). 
These results confirm that high Mapk signalling counteracts the Wnt-induced differentiation of 
Paneth cells and favours goblet cell differentiation, as had been reported by Heuberger et 
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al. (2014)64. They further reveal that the effect of Mapk signalling depends on the level of Mll1 
expression. In the presence of Mll1, Mapk signalling promotes crypt cell proliferation. Loss of 
Mll1 is required for the Mapk-induced specification of goblet cells. Accordingly, Mll1 restricts 
the Wnt/Mapk-driven secretory differentiation to sustain stem and progenitor cells in the 
intestinal epithelium. Mll1-deficient secretory cells in Mek1GOF; Mll1-/- crypts were double-
positive for Paneth and goblet cell markers and did not fully mature into goblet cells, despite a 
strong activity of Mapk signalling. This indicates that Mll1 also plays a role in safe-guarding the 
Wnt/Mapk-driven differentiation of secretory cells by preserving lineage-specific maturation. 
 
Figure 3.39: Mll1 restricts the Mapk-induced specification of goblet cells. 
a) Immunofluorescence for BrdU (red) and GFP (green) in crypts of Mek1GOF; Mll1+/- mice and Mek1GOF; 
Mll1-/- mice at day 10 after induction, nuclei in blue (DAPI), scale bars 20µm. Recombined crypts are 
surrounded by dashed lines. BrdU was incorporated for 2h before sacrifice. b) Quantification of BrdU+ 
cells per total cells in mutant crypts of Mek1GOF; Mll1+/- mice and Mek1GOF; Mll1-/- mice compared to 
adjacent non-recombined crypts, n=2 mice each, Mann-Whitney test. c) Left: immunofluorescence for 
Lyz (green) and ITF (red) on sections of Mek1GOF; Mll1+/- and Mek1GOF; Mll1-/- mouse small intestine at 
10 days after induction. Middle: immunofluorescence staining for Mmp7 (green) on serial sections. 
E-cadherin (yellow) stains cell borders, nuclei in blue (DAPI), scale bars 20µm. Recombined crypts 
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surrounded by dashed lines. Right: immunohistochemistry for phospho-Erk1/2 and Alcian blue staining 
for goblet cells, nuclei counter-stained with hematoxylin, scale bars 20µm. d) Number of Alcian blue-
positive cells in Mek1GOF; Mll1+/- and Mek1GOF; Mll1-/- crypts compared to adjacent non-recombined 
crypts, quantified from at least 20 crypts per mouse, n=3 mice each, Mann-Whitney test. 
3.12 Translational approaches: Targeting MLL1 in colon cancer. 
We investigated the effect of MLL1 inhibition in Wnt-dependent colon cancer cells and 
intestinal organoids in vitro. Previous research in our lab had demonstrated a direct interaction 
of MLL1 and β-catenin/TCF4 in Wnt-driven cancer cells162. That is why we treated human 
Ls174T colon cancer cells with inhibitors of the MLL1/β-catenin/TCF4 complex, ICG-001101, 
LF3100 and MI-2147 (Figure 3.40a). Control cells expanded into cell colonies within 14 days, 
while inhibition of Wnt signalling with the β-catenin-CBP inhibitor ICG-001 and the β-catenin-
TCF4 inhibitor LF3 completely blocked colony formation (Figure 3.40b). Treatment with the 
Menin-MLL1/2 inhibitor MI-2 was as efficient in preventing colony formation as the treatment 
with the Wnt inhibitors (Figure 3.40c). MI-2 and ICG-001 treatment impaired Ls174T colon 
cancer sphere formation in a concentration-dependent manner (Figure 3.40d). MI-2 treatment 
significantly impaired sphere formation of Ls174T colon cancer cells within 48h (Figure 3.40e). 
 
Figure 3.40: Pharmacological interference with the MLL1/β-catenin/TCF4 complex. 
  Results 
71 
a) Scheme: Small molecules interfering with the MLL1-β-catenin/TCF4 complex, the Wnt inhibitors 
ICG-001 and LF3 and the Menin inhibitor-2 (MI-2). b) Colony formation from Ls174T human colon 
cancer cells treated with 2.5µM ICG-001 or 30µM LF3 for 13 days compared to control cells. 
Quantification on the right, n=4 from two independent assays, unpaired t test. c) Colony formation from 
Ls174T cells treated with 1.25µM MI-2 for 13 days. Quantification relative to control on the right, n=4 
from two independent assays, unpaired t test. d) Numbers of Ls174T colon cancer spheres >50µm 
relative to control after 48h of MI-2 and ICG-001 treatment at indicated concentrations, n=3 from two 
independent assays, unpaired t test. e) Brightfield images of control and 48h MI-2-treated Ls174T 
spheres, scale bars 75µm. Quantification of spheres >50µm on the right, n=7 from two independent 
assays, unpaired t test. 
Treatment of tamoxifen-induced Lgr5-EGFP-IRES-CreERT2; β-catGOF intestinal organoids with 
increasing concentrations of MI-2 reduced cell viability and resulted in death of the β-catGOF 
organoids within 3-4 days in a concentration-dependent manner (Figure 3.41a). MI-2 treatment 
did not prevent the β-catGOF-induced expansion of the Lgr5-GFP+ stem cell niches until the 
death of the organoids at 72h (Figure 3.41b). 
 
Figure 3.41: MI-2 treatment of β-cateninGOF intestinal organoids. 
a) Viability of tamoxifen-induced Lgr5-GFP-IRES-CreERT2; β-catGOF mouse intestinal organoids treated 
with MI-2 at indicated concentrations, relative to control. b) Live imaging of tamoxifen-induced 
Lgr5-GFP-IRES-CreERT2; β-catGOF control and 1.5µM MI-2-treated organoids at 0h, 48h and 72h. Lgr5-
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4 Discussion 
The work presented in this doctoral thesis identifies the epigenetic modifier Mll1 as an essential 
regulator in Wnt/β-catenin-driven intestinal tumors. A detailed knowledge of the oncogenic 
signalling and gene regulatory processes in colon cancer cells is crucial for the future 
development of rational therapies. Our study demonstrates the critical role of epigenetic 
regulation in colon cancer growth by dissecting the role of Mll1 in Wnt/β-catenin-induced 
cancer stemness, which is expected to shape future therapeutic approaches. 
About 90% of human colon cancers exhibit mutations in APC or β-catenin which deregulate 
Wnt signalling and initiate intestinal transformation77. The impact of aberrant Wnt signalling on 
colon cancer growth and progression is well studied. Little is known, however, on the 
epigenetic regulation of Wnt-induced intestinal tumorigenesis. Recent work has implicated the 
histone methyltransferase Mll1 in the Wnt/β-catenin-dependent growth of solid tumors of the 
salivary gland162, 178, but a proposed role for Mll1 in Wnt-induced cancer stemness remained 
mechanistically undefined. By conditional genetic ablation in a stem cell-based intestinal 
mouse tumor model and by RNA interference in self-renewing sphere cultures and xenografts 
of human colon cancer cells, we now demonstrated a crucial role of Mll1 in Wnt/β-catenin-
driven intestinal tumor formation and cancer stemness. We showed that Mll1 promotes the 
β-cateninGOF-induced expansion of Lgr5+ intestinal tumor-initiating cells. Mechanistically, Mll1 
does not interfere with the global activity of Wnt signalling, but controls its outcome at the level 
of gene regulation. Mll1 sustains the expression of stem cell genes in Wnt-activated tumor cells 
by antagonizing PcG-mediated silencing. We further identified Mll1 as an upstream regulator 
of Gata4/6 transcription factors that promote stemness of Wnt-mutated cancer cells and 
counter differentiation. Cancer stem cells were depleted upon loss of Mll1. 
4.1 Mll1 is essential for the β-cateninGOF-induced intestinal stem cell expansion 
and tumorigenesis. 
We showed that Mll1 promotes the β-cateninGOF-induced expansion of Lgr5+ intestinal stem 
cells, which initiates tumor formation. Intestinal stem cells at homeostasis divide symmetrically 
and produce an excess of daughter stem cells that maintain the stem cell pool in the crypts 
and ensure the continuous production of progenitor cells223. The niche space at the crypt base 
is limited. To compensate for overcrowding, surplus stem cells are randomly expelled from the 
crypt base and differentiate. The intestinal stem cell pool is thus not long-lived but highly 
dynamic and subject to constant stochastic replacement, the ‘neutral drift’. These neutral drift 
kinetics drive polyclonal crypts towards monoclonality within 1-6 months in adult mice223, 224. 
Genetic alterations causing activation of Wnt signalling are gatekeeper mutations in intestinal 
transformation and major drivers of intestinal tumorigenesis2. Aberrant activation of Wnt 
signalling in a crypt stem cell, e.g. by β-catGOF, biases the neutral drift kinetics operating in the 
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stem cell niche225, 226. The β-catGOF mutation confers a selective advantage to the particular 
stem cell. As a consequence, the mutated stem cell displaces non-mutated stem cells and 
takes over the crypt. The aberrant Wnt signalling then expands the mutant stem cell niches227. 
Such enlarged mutant crypts are highly prone to multiply by crypt fission, spreading Wnt-
mutated stem cells across the epithelium227. The tumorigenic stem cells are capable of 
expanding independently of the crypt-based stem cell niche to initiate tumor formation79, 86. The 
cell-intrinsic molecular features required for the niche-independent growth of β-catGOF-mutant 
stem cells remained unclear. Recent years have revealed epigenetic regulation as a critical 
determinant of adult stem cell function228. The polycomb repressive complex PRC1 has been 
shown to be crucial for adult intestinal stem cell maintenance, intestinal homeostasis and tissue 
identity140. Genetic inactivation of PRC1 in oncogenic Wnt-activated intestinal stem cells has a 
tumor-preventive effect140, implying a role of PRC1 in promoting Wnt-driven intestinal 
tumorigenesis. 
We now identified the epigenetic modifier Mll1 as an essential cell-intrinsic determinant of the 
oncogenic Wnt/β-catenin-driven stem cell expansion. The conditional ablation of Mll1 
prevented the β-cateninGOF-induced expansion of Lgr5+ stem cells and tumorigenesis in an 
intestinal mouse tumor model. The knockdown of Mll1 in human colon cancer xenografts 
impaired tumor formation and growth, and slowed down tumor progression. Thus, the 
epigenetic regulation by Mll1 is crucial for the initiation and growth of Wnt-driven colon cancer. 
Mll1-deficient cells did not undergo apoptosis, but exhibited a reduced proliferation, as 
β-catGOF; Mll1-/- stem cells in mice and organoids showed a diminished incorporation of the 
thymidine analogues BrdU and EdU. According to the neutral drift kinetics, a reduced 
proliferation would exclude Mll1-deficient stem cells from the crypt stem cell pool, thus 
eliminating the β-catGOF-mutant tumor-initiating stem cells and preventing tumorigenesis. 
However, entire crypts rather than individual stem cells were deficient for Mll1 after 5-10 days 
of induction and the proliferative and self-renewal capacities of β-catGOF; Mll1-/- cells were only 
gradually lost. Hence, the β-catGOF; Mll1-/- stem cells retained their potential to divide, although 
in a slowed-down manner, persisted in the crypts and generated Mll1-deficient progeny up to 
100 days after the induction of mutagenesis. Consequently, the minor reduction in stem cell 
proliferation upon ablation of Mll1 is unlikely to solely account for the prevention of the 
β-cateninGOF-driven stem cell expansion. Our studies in organoids confirmed that the loss of 
Mll1 did not immediately eliminate β-catGOF stem cells but progressively exhausted their 
stemness. The ablation of Mll1 did not globally alter oncogenic Wnt signalling, as assessed by 
a TCF/LEF luciferase reporter assay in shMLL1 human colon cancer cells. Mll1-deficient stem 
cells in β-catGOF; Mll1-/- mice exhibited nuclear β-catenin and highly expressed classical Wnt 
target genes such as Axin2. Despite functional β-catGOF activity, though, the β-catGOF; Mll1-/- 
stem cells were unable to expand niche-independently to form tumors, indicating that the 
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oncogenic Wnt activity per se is incapable of promoting cancer stemness but relies on a 
permissive epigenetic setting. The presence of Mll1 is a prerequisite for the oncogenic Wnt-
induced intestinal cancer stemness. Our data propose that Mll1 promotes the β-cateninGOF-
induced stem cell expansion and tumorigenesis by directly controlling the expression of key 
stem cell genes and preventing differentiation of tumor-initiating stem cells. 
4.2 Mll1 sustains oncogenic Wnt-induced stem cell gene expression and colon 
cancer stemness. 
Colon cancer cells with a stem-like gene expression profile possess high tumor-initiating 
potential and self-renewal capacity89, implying that intestinal stem cell gene products play an 
instrumental role in tumorigenesis. We discovered that Mll1 sustains the expression of the 
intestinal stem cell genes Lgr5, Smoc2, Igfbp4 and Olfm4 in oncogenic Wnt-activated cells. 
Expression of Lgr5 correlates with the malignant potential of colon cancer cells. Colon tumors 
with increased Lgr5 levels are more invasive and aggressive229. Wnt/β-catenin signalling is 
known to directly activate the expression of the stem cell genes Lgr5, Ascl2 and Cd44 107. In 
addition, the Wnt pathway cross-talks with other signalling pathways such as NF-κB to induce 
the expression of stem cell genes like Smoc2 94. Thus, Wnt signalling imposes a stem-like 
identity on colon cancer cells82. In accordance, we found that the β-cateninGOF-driven 
adenomas in β-catGOF mice exhibited an increased expression of the β-catenin/Tcf4-regulated 
stem cell gene Lgr5 as well as the NF-κB-induced Smoc2. Our study identified the histone 
methyltransferase Mll1 as an essential epigenetic regulator of the Wnt-induced colon cancer 
stemness. Mll1 did not merely regulate Wnt target genes, but controlled the expression of both 
the β-catenin/Tcf4-dependent Lgr5 and β-catenin/Tcf4-independent stem cell genes such as 
Smoc2, Igfbp4 and Olfm4. We detected a strong correlation of MLL1 expression with high 
levels of nuclear β-catenin in human colon carcinomas. Likewise, β-catGOF tumor cells showed 
elevated levels of Mll1. Wnt3a treatment increased Mll1 expression in intestinal organoids, 
suggesting a Wnt-controlled regulation of Mll1. This is consistent with a previous study in 
Wnt/β-catGOF; Bmpr1aLOF salivary gland and head and neck cancer that proposed a Wnt-driven 
upregulation of Mll1 and identified functional Tcf4 binding sites in regulatory regions upstream 
of the Mll1 promoter162. The ablation of Mll1 hampered the ability of β-catGOF to confer a stem-
like identity and to promote self-renewal of colon cancer cells. Our data demonstrate that the 
high expression of Mll1 in Wnt-activated tumor cells is essential to promote a stem-like identity 
and sustain Wnt-induced colon cancer stemness. 
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4.3 Mll1 antagonizes Polycomb-dependent silencing to sustain the expression 
of stem cell genes. 
We identified Mll1 as an epigenetic regulator of a panel of intestinal stem cell genes. Mll1 
knockdown resulted in a switch of the histone methylation marks at the TSS of the stem cell 
genes Lgr5, Smoc2, Igfbp4 and Olfm4 from activating H3K4me3 to repressive H3K27me3. To 
exert its regulatory functions on chromatin, Mll1 can act through its intrinsic methyltransferase 
activity, recruitment of acetyltransferases or antagonism of polycomb repressive factors. Mll1 
is known to prevent PRC2-mediated H3K27me3 and gene silencing230. Our data suggest that 
the ablation of Mll1 vacated a PRC2 binding site or unleashed PRC2 activity at the Lgr5, 
Smoc2, Igfbp4 and Olfm4 promoters, allowing for PRC2-mediated H3K27 tri-methylation and 
gene silencing. CpG-dense regions have been identified as the main target sites for Mll1-
deposited H3K4 methylation, antagonizing PRC2-dependent H3K27me3 at these sites230. In 
agreement, the intestinal stem cell genes Lgr5, Smoc2 and Igfbp4 identified here as Mll1 
targets possess CpG islands around their TSS. Strikingly, the inhibition of the polycomb H3K27 
tri-methyltransferase Ezh2 with Gsk126209 partially restored the expression of Lgr5 and the 
other stem cell genes in Mll1-deficient cells despite the absence of Mll1 and H3K4me3 marks. 
This implies that Mll1 and its H3K4me3 activity are dispensable for initiating the expression of 
the stem cell genes but crucial for preventing PRC2-mediated silencing of the Lgr5 and other 
stem cell promoters231. These observations concord with the opposition between trithorax and 
Polycomb group proteins in Drosophila232. Acetylation of H3K27 (H3K27ac) by the histone 
acetyltransferase CBP has been shown to initiate the expression of PcG-repressed genes 
upon depletion of H3K27 methylation marks233. This might account for the re-activation of Lgr5, 
Smoc2, Igfbp4 and Olfm4 in Mll1 knockdown cells upon Gsk126 treatment. 
The ablation of Mll1 eliminated cancer stemness and prevented Wnt-driven tumor growth. 
Remarkably, the genetic inactivation of the polycomb complex PRC1 in oncogenic Wnt-
activated intestinal stem cells also has a tumor-preventive effect140. Further, PRC2 ablation in 
the mouse intestine causes loss of stem cells and aberrant secretory differentiation by 
deregulating Wnt signalling and cell proliferation234. In the light of our data, this indicates that 
a fine-tuned balance of active and repressive histone modifications controlled by the Mll1-PcG 
antagonism is essential for the maintenance of intestinal stem and tumor-initiating cells, a 
regulatory mechanism of stemness in which Mll1 is crucially involved. 
The finding that Mll1 is required as an anti-silencing factor for maintaining and stabilizing stem 
cell gene expression is consistent with the emerging concept that H3K4 tri-methylation is 
essential for stabilizing gene expression rather than initiating transcription124, 125. A recent study 
has highlighted the importance of the non-catalytic co-activator functions of TrxG complexes: 
in pancreas development, the promoter binding of TrxG proteins such as Mll1 is critical for 
lineage specification, but their H3K4 methyltransferase activity is dispensable for the activation 
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of lineage-specific genes235. The tri-methylation of H3K4 by TrxG complexes proved essential, 
however, for stabilizing transcriptional activity and maintaining lineage-specific expression 
patterns235. In the postnatal brain, Mll1 maintains the expression of the ventral transcription 
factor Nkx2-1 to sustain the regional identity of ventral neural stem cells and distinguish them 
from dorsal cells236. Even transient interference with Mll1 function durably abolishes Nkx2-1 
expression and ventral identity, as Mll1 fails to re-initiate Nkx2-1 expression236. The role of Mll1 
in transcriptional maintenance rather than initiation of intestinal stem cell gene expression 
complies with our observations in organoids and the in vivo Lgr5-GFP+ stem cell tracing: 
β-catGOF; Mll1-/- intestinal stem cells retained their Lgr5-GFP expression and stemness as long 
as they persisted in the crypt stem cell niche, but were unable to sustain the expression of Lgr5 
and other stem cell genes independent of the niche. Mll1-deficient β-catGOF stem cells 
differentiated once they left the stemness-promoting niche environment. 
4.4 Mll1-deficient cancer cells lose their stemness and differentiate. 
Transcriptome profiling of β-catGOF; Mll1-/- stem cells identified the transcription factors Foxa1 
and Gata4/6 as Mll1-regulated genes in β-catGOF intestinal stem cells and Wnt-mutated colon 
cancer cells. Both transcription factors have been implicated in the regulation of stemness: 
Foxa1 maintains the identity of intestinal stem and progenitor cells in Drosophila237. High 
expression of Foxa1 is observed in poorly differentiated colon cancer238. The Gata transcription 
factors Gata4 and Gata6 maintain jejunal-ileal identities in the adult intestine and promote 
proliferation in intestinal crypts211, 239. A recent study has linked Gata6 to the regulation of 
stemness in Wnt-driven colon cancer203. Our data suggest that Mll1 sustains the stemness of 
Wnt-mutated intestinal stem cells by controlling the expression of stem cell genes and the 
stemness-promoting transcription factors Gata4/6. High levels of Mll1 are essential for Wnt-
activated colon cancer cells to sustain a non-differentiated stem-like state. 
The transcriptome profiling of β-catGOF; Mll1-/- stem cells further revealed an increase in the 
expression of differentiation markers upon ablation of Mll1. The loss of Mll1 also enforced 
differentiation of human colon cancer cells in sphere cultures and xenograft tumors. Mll1 
knockdown colon cancer cells showed a decreased expression of Gata6 that was associated 
with an upregulation of Bmp4. Gata6 has been reported to compete with β-catenin/Tcf4 for 
binding to a distal regulatory region of the Bmp4 locus, sustaining stemness and preventing a 
Bmp4-induced differentiation of colon cancer cells203. Besides Bmp signalling, secretory 
differentiation in the intestinal epithelium depends on the expression of Atoh1, a transcription 
factor that instructs secretory lineage specification and promotes a goblet cell differentiation 
programme54, 56. The β-catGOF; Mll1-/- stem cells exhibited a strongly increased expression of 
Atoh1. Atoh1 has been shown to act as a tumor suppressor in colorectal neoplasia and is 
frequently silenced in colon cancer cells240. Increased Atoh1 levels and goblet cell numbers 
have been observed in Gata4-deficient intestines211, 241. Similar to our observations in β-catGOF; 
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Mll1-/- stem cells, the ablation of Gata4 increases Atoh1 levels independent of a decreased 
expression of Hes1 and other Notch target genes241, indicating that Gata4 can directly repress 
Atoh1. Our data support a Gata4-mediated restriction of Atoh1 expression and goblet cell 
differentiation. The β-catGOF; Mll1-/- organoids and crypts exhibited an increased activity of 
Mapk signalling. The high Mapk activity in β-catGOF; Mll1-/- cells imposed a goblet cell-like 
identity on the Wnt-activated stem cells, giving rise to mixed Paneth-goblet cells, as previously 
suggested by Heuberger et al. (2014)64. The Mapk-induced goblet cell differentiation was 
supported by the increased levels of Atoh1 and Bmp4 in the Mll1-deficient cancer cells. Bmp4 
treatment of intestinal organoids induced the expression of goblet cell-specific genes, while it 
decreased the expression of Paneth cell markers. Taken together, we here identified Mll1 as 
an upstream epigenetic regulator of the Gata4/6-mediated repression of Bmp4, Atoh1, Mapk 
signalling and goblet cell differentiation. 
Remarkably, the high Wnt activity caused by β-catGOF imposed a Paneth-like identity on the 
β-catGOF; Mll1+/- stem cells. This proposes that the cells-of-origin of intestinal cancer might not 
be “pure” stem cells but rather stem cells that exhibit Paneth-like properties. We may speculate 
that a population of tumor-initiating stem cells with a Paneth-like identity intrinsically has all the 
attributes to expand niche-independently and initiate tumorigenesis. In the crypt stem cell 
niche, Paneth cells support Lgr5+ intestinal stem cells by providing essential niche ligands, 
growth factors such as Wnt3 and EGF, and metabolic supply48, 242. Paneth cells can convert 
into functional stem cells under regenerative conditions73. The priming towards a Paneth fate 
might thus drive tumor formation by creating a self-supporting system that expands 
independently of a crypt-based niche. Consistent with the idea of a requirement of a Paneth-
like identity for the expansion and tumorigenicity of Wnt-mutated intestinal stem cells, colon 
cancer cells have been shown to require ligand-dependent Wnt signalling for the maintenance 
of a stem-like behaviour, even in case of mutations in the downstream Wnt effectors APC or 
β-catenin243. Our data revealed that Mll1 is essential for the Paneth-like behaviour and 
stemness of the β-catGOF stem cells. The ablation of Mll1 shifted the Paneth-like identity of the 
β-catGOF stem cells to a goblet cell fate in an Atoh1- and Mapk-driven manner. This rendered 
the β-catGOF; Mll1-/- stem cells incapable of niche-independent expansion and caused a 
progressive exhaustion of the Mll1-deficient stem cells which were ultimately lost by 
differentiation. Correspondingly, high Mapk signalling has previously been shown to exhaust 
intestinal stem cells by converting them into proliferative TA cells244. It is remarkable that the 
Mll1-deficient Atoh1+ stem cells failed to sustain their stemness, since Atoh1+ secretory 
progenitor cells have been attributed a high plasticity that renders the cells capable of acquiring 
functional stem cell properties and promoting tumorigenesis70, 71. Apparently, the loss of Mll1 
abolished the cellular plasticity of Atoh1+ progenitor cells, as β-catGOF; Mll1-/- crypts did not 
expand into tumors. 
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Taken together, our data show that Wnt-activated intestinal stem cells depend on high levels 
of Mll1 to sustain stemness, a Paneth cell-like fate and cellular plasticity, which are required 
for niche-independent growth and tumorigenicity. A role of Mll1 in fine-tuning the specification 
of Paneth cells while restricting a goblet cell fate contributes to its tumor-promoting function in 
the intestinal epithelium. Our data do not indicate whether the main function of Mll1 in intestinal 
cancer stem cells is to sustain stem cell gene expression or to prevent differentiation. The RNA 
sequencing of isolated Lgr5+ stem cells at 10 days after genetic recombination did not identify 
a decreased expression of the stem cell genes Lgr5 and Smoc2 in β-catGOF; Mll1-/- mutant cells, 
arguing that the primary function of Mll1 in the β-catGOF stem cells is to prevent differentiation. 
This would imply that the Mll1-deficient β-catGOF stem cells initially activated a goblet cell 
differentiation programme. The decreased expression of Mll1-controlled stem cell genes 
occurs timely delayed. In Wnt-activated colon cancer cells, however, we identified Mll1 as a 
direct regulator of stem cell genes. To further clarify this issue, it will be interesting to 
investigate whether depletion of the Mll1-regulated stem cell gene products in cancer stem 
cells would induce Atoh1 expression, Mapk signalling and differentiation similar to Mll1 
ablation. We can conclude that Mll1 sustains the stemness of intestinal cancer cells both by 
sustaining the expression of stem cell genes and by preventing differentiation. The loss of Mll1 
enforces differentiation of tumorigenic β-catGOF-mutant stem cells, pushing them to less 
aggressive fates and disabling tumor formation. 
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4.5 Mll1 is a gene-specific co-regulator of β-catenin/Tcf4. 
Our study identified the histone methyltransferase Mll1 as an epigenetic regulator of the Wnt-
dependent stem cell gene Lgr5. Mll1 had previously been shown to associate with the 
β-catenin/Tcf4 complex161, 162. Our data support a role of Mll1 in the differential regulation of 
Wnt/β-catenin target genes. Wnt signalling exerts diverse functions in the intestinal epithelium: 
on the one hand, it maintains intestinal stem cells and drives proliferation of transit-amplifying 
progenitor cells, on the other hand it guides the maturation and terminal differentiation of 
Paneth cells107. The cellular context critically defines the spectrum of Wnt target genes that 
become expressed in response to active Wnt signalling106, 108. It has been unclear, however, 
how such differential and cell type-specific Wnt responses are regulated on the molecular level. 
Our data suggest critical roles for epigenetic modifiers in the selective regulation of Wnt target 
genes and identify Mll1 as a gene-specific co-regulator of the β-catenin/Tcf4 complex. Mll1 
regulated the expression of the stem cell gene Lgr5, whereas it did not regulate the expression 
of the Wnt targets Axin2, Sox9 and Ascl2. Lgr5 expression critically depends on Mll1: in the 
absence of Mll1, β-catenin binding was not sufficient to sustain Lgr5 expression. 
We showed that Mll1 is crucial for tumorigenesis and confers Wnt-induced cancer stemness. 
Sphere cultures of human colon cancer cells, which enrich for self-renewing cancer stem cells, 
showed an increased expression of Mll1 but not its family member Setd1a. In fact, Setd1a had 
been reported to control Wnt target genes that drive the proliferation and growth of colon 
cancer cells141, rather than cancer stemness. Mll1 did not regulate the expression of the Wnt 
targets Tcf1 and Tcf4, which have been shown to be controlled by the Mll family member 
Setd1a141. These observations indicate non-overlapping functions of the Mll family members 
Mll1 and Setd1a in Wnt-driven colon cancer. It argues that distinct epigenetic regulatory 
components of the β-catenin/Tcf4 complex are implicated in the activation of different sets of 
Wnt target genes. Mll1 and Setd1a appear to be part of distinct co-regulatory complexes that 
determine a differential Wnt responsiveness of common β-catenin/Tcf4 target genes. 
Accordingly, the spectrum of activated Wnt target genes in any given cell type might differ 
depending on which co-regulators are expressed, thus allowing for the diverse and cell type-
specific effects of Wnt signalling. 
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4.6 Mll1 controls adult epithelial stem cells and cell fate choice in the intestine. 
Extensive research has established a crucial role of Mll1 in the hematopoietic system167, 170, 171. 
Recent studies have associated Mll1 with adult stem cell function and lineage maturation also 
in solid tissues such as muscle and neural tissue174, 176. Here we detected a so far unknown 
role of Mll1 in the stem and progenitor cells of the adult intestinal epithelium. Mll1 is highly 
expressed in the Lgr5+ intestinal stem cells and in progenitor cells of the TA zone, and its 
expression decreases as the cells differentiate. The ablation of Mll1 in the Lgr5+ intestinal stem 
cells resulted in loss of a substantial number of mutated crypts over time. The progressive but 
not immediate loss of Mll1-deficient intestinal stem cells relates to its role in sustaining rather 
than conferring intestinal stemness. The gradual loss of Mll1 knockout crypts might be due to 
progressive exhaustion of the stem cells deficient for Mll1. Exhaustion of Mll1-deficient stem 
cells has also been reported in the hematopoietic system and for muscle satellite cells171, 176. 
Since similar effects have been observed in different tissues, this suggests a more general 
function of Mll1 in adult stem cell maintenance. This function might relate to the role of Mll1 in 
sustaining the expression of transcription factors that maintain stem cell identity, e.g. Pax7 in 
muscle satellite cells176, and Gata4/6 in intestinal epithelial stem cells. 
We demonstrated that Mll1 is repressed upon differentiation in a Bmp-dependent manner. The 
stimulation of Bmp signalling by administration of Bmp4 repressed Axin2 and Mll1 expression 
in intestinal organoids, suggesting that the inverse crypt-villus gradients of Wnt and Bmp 
signalling restrict Mll1 expression to the intestinal crypts. Our data indicate that a decrease in 
Mll1 protein levels is essential for the differentiation of intestinal epithelial cells. We showed 
that Mll1 sustains the expression of stem cell genes by antagonizing PRC2-mediated silencing. 
PRC2 is known to support crypt-villus differentiation by mediating the H3K27me3-dependent 
silencing of intestinal stem cell genes such as Lgr5 231. In conjunction, these data propose that 
Mll1 is involved in the maintenance of intestinal stem cell gene expression at homeostasis and 
needs to be downregulated to enable PRC2/H3K27me3-mediated silencing of intestinal stem 
cell genes and permit terminal differentiation. 
Mll1 controls the Wnt/Mapk-driven specification of secretory progenitor cells. 
Our data suggest that Mll1 exerts a dual role in intestinal homeostasis: it sustains intestinal 
stem cells and needs to be downregulated to enable terminal differentiation, but also plays a 
role in safeguarding cell fate determination of secretory Paneth and goblet cells driven by the 
counteracting activities of Wnt and Mapk signalling, respectively. We observed that 
simultaneous activation of Wnt/β-catenin and Mek1/Mapk signalling abrogated secretory cell 
maturation in intestinal organoids and imposed an immature precursor state, as had previously 
been suggested by Heuberger et al. (2014)64. While β-catGOF-induced Wnt activation promoted 
a Paneth cell fate and prevented Mapk-induced goblet cell differentiation, the ablation of Mll1 
in β-catGOF and in β-catGOF; Mek1GOF cells led to the re-appearance of goblet cells, largely as 
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mixed Paneth-goblet entities. This suggests that Mll1 restricts Mapk signalling and goblet cell 
differentiation in Wnt-high secretory progenitor cells. In Mll1-competent Mek1GOF crypts, Mapk 
signalling promoted cell proliferation. The ablation of Mll1 shifted the effect of Mapk signalling 
from pro-proliferative to differentiation-inducing. Mek1GOF; Mll1-/- crypts exhibited increased 
numbers of goblet cells. The presence of Mll1 thus maintains a proliferative progenitor state 
and restricts goblet cell differentiation. This closely fits our observation of high levels of Mll1 in 
TA cells, in which active Mapk signalling promotes cell proliferation64. Whether the loss of Mll1 
increases Mapk activity or changes the target gene spectrum to allow for goblet cell 
differentiation remains to be determined. Our data suggest that in the process of differentiation, 
Wnt-high secretory progenitor cells retain Mll1 expression to restrict a Mapk-induced goblet 
cell fate and ensure Paneth cell differentiation. Vice versa, Wnt-low secretory progenitors lose 
Mll1, which causes a Mapk-induced goblet cell differentiation, presumably by decreasing the 
expression of the Mll1-dependent Gata4/6. The transcription factors Gata4 and Gata6 are 
required for secretory cell differentiation and lineage maturation in the epithelium of the small 
intestine and colon239. Gata4 is expressed throughout the small intestinal epithelium of the 
jejunum, but is absent in goblet and enteroendocrine cells211. The ablation of Gata4 promotes 
maturation of goblet cells239. Our data suggest a regulatory sequence in the process of cell 
specification that is controlled by Mll1: reduction of Wnt signalling is followed by decreased 
expression of Mll1, which results in downregulation of Gata4/6 expression and unleashes an 
Atoh1- and Mapk-driven goblet cell differentiation. By sustaining the expression of Gata4/6 
transcription factors and balancing opposing Wnt and Mapk activities, Mll1 suppresses goblet 
cell specification of mixed-lineage secretory progenitor cells and promotes the alternate 
Paneth cell fate. A similar mechanism has been described in the immune system, where Mll1 
regulates Gata3 to specify and maintain memory Th2 cells245. 
The accumulating secretory cells in Mek1GOF; Mll1-/- crypts were double-positive for Paneth 
and goblet cell markers despite high Mapk activity and absence of Mll1, indicating that Mll1 is 
essential for preserving the lineage-specific differentiation and cell identity of Paneth and 
goblet cells. Like Mll1, polycomb PRC2 complexes have been implicated in the maintenance 
of intestinal stem and progenitor cells: their genetic ablation causes loss of stem cells and 
aberrant secretory differentiation into mixed Paneth-goblet cells234, 246. In the light of our study, 
this highlights the importance of a proper balance of antagonistic Mll1 and PcG activities for 
establishing cell specification and maintaining cell identity during secretory differentiation138. 
Our observations illustrate an interplay of epigenetic and signalling cues in the control of cell 
fate determination in adult tissues. The aberrancies in secretory differentiation could result 
from changes to the epigenome of the Mll1-deficient progenitor cells, though, rather than be a 
direct effect on the counteracting activities of Wnt and Mapk signalling. Further dissecting the 
role of Mll1 in balancing the effects of Wnt and Mapk signalling as well as its interplay with PcG 
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proteins to control cell fate specification of intestinal secretory progenitors will be a relevant 
subject for future investigation. 
4.7 Mll1 as a rational target for colon cancer therapy. 
Recent years have seen limited success in the development of rational treatments for colon 
cancer. Therapeutic targeting of aberrant Wnt signalling has not yet reached the clinics, but 
recent preclinical studies in adult mice have indicated that a systemic inhibition of Wnt 
signalling severely impairs intestinal homeostasis and causes high mortality51. An in-depth 
understanding of the mechanistic differences between physiological and pathological Wnt 
signalling is therefore crucial and will be key to tumor-specific targeting of the Wnt pathway. 
Current therapies are often ineffective due to cancer stem cells which escape treatment and 
the plasticity of non-stem cancer cells that can readily revert into stem-like cells91, 99. Combining 
experimental depletion of Lgr5+ cancer stem cells with conventional chemotherapy prevented 
the reprogramming of differentiated cancer cells into cancer stem cells and led to tumor 
regression in preclinical studies99. As cancer stem cells are highly reminiscent of their normal 
tissue counterparts, a detailed understanding of the regulatory mechanisms which control 
stemness, de-differentiation and cellular plasticity of intestinal cancer cells will be required to 
safely eliminate colon cancer stem cells without affecting intestinal stem cells and tissue 
homeostasis. To succeed in colon cancer therapy, we therefore need to identify targets that 
allow for defined interference with the stemness-promoting effects of oncogenic Wnt signalling. 
Our work is a major step forward in the understanding of the epigenetic regulation of oncogenic 
Wnt-induced cancer stemness. We show that the epigenetic regulator Mll1 promotes intestinal 
tumorigenesis and plays a crucial role in sustaining Wnt-activated colon cancer stem cells. 
Somatic mutations of Mll1 in colon cancer are rare, but human colon carcinomas exhibited 
high expression of Mll1 that coincided with nuclear β-catenin. This suggests that the oncogenic 
Wnt/β-catenin signalling exploits the histone methyltransferase Mll1 to promote intestinal 
tumorigenesis and colon cancer stemness. Our data demonstrate that oncogenic Wnt-
activated colon cancer cells strongly depend on Mll1. Accordingly, Mll1 represents an 
‘epigenetic vulnerability’ 103 in Wnt-driven colon cancer. Interfering with Mll1 function can 
eliminate colon cancer stem cells, might further prevent differentiated tumor cells from 
acquiring stemness, and has potential as a rational treatment for Wnt-driven colon cancer. 
Human colon cancer cells with β-catenin gain-of-function (Ls174T) and APC loss-of-function 
mutations (DLD1) were equally sensitive to the knockdown of Mll1, indicating that patients with 
either mutation of the Wnt pathway would benefit from Mll1 inhibition. 
Targeting Mll1 in colon cancer therapy will require a fine balancing, and a beneficial effect will 
depend on the precise dosing of Mll1 inhibition, maintaining a ‘just-right’ level of Mll1 function 
for the intestinal stem cells to thrive but eliminating the Mll1-addicted colon cancer stem cells. 
Our analyses indicated that the loss of Mll1 impacts the β-catGOF-mutant Lgr5+ stem cells more 
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severely than the Lgr5+ stem cells at homeostasis. However, further preclinical studies in vivo 
are required to dissect the role of Mll1 in adult intestinal stem cells to anticipate potential drug 
toxicities and to determine whether we will be able to play on the Mll1 dependency of colon 
cancer stem cells without perturbing intestinal homeostasis. It further remains to be determined 
in detail whether the inhibition of Mll1 will have a beneficial effect in advanced colon cancer. 
We approached the role of Mll1 in tumor maintenance using a xenograft assay. However, the 
Mll1 knockdown efficiency varied, which rendered the assay impractical to conclusively 
demonstrate a beneficial effect of Mll1 inhibition in established intestinal tumors. An important 
follow-up study to help clarify these issues will be to treat intestinal tumors of β-catGOF mice 
with Mll1 inhibitors such as MI-2147. In our in vitro studies, MI-2 treatment resulted in death of 
human colon cancer cells and β-catGOF intestinal organoids, which might be partially attributed 
to an inhibition of Mll1 function. We did not observe apoptosis upon specific knockdown or 
genetic ablation of Mll1, though, indicating that the effect of MI-2 treatment on cell viability may 
rather be caused by interference with Mll2 and Menin functions147, 247. The MM-401 inhibitor 
holds promise to have a greater specificity for Mll1148. However, MM-401 and its derivatives 
particularly interfere with the methyltransferase activity of Mll1, which we found to be subsidiary 
for the role of Mll1 in sustaining colon cancer stemness. MM-401 targets the Mll1-Wdr5 
interaction to prevent the assembly of the WRAD complex which is essential for 
methyltransferase activity148. It needs to be tested whether inhibition of the WRAD complex 
assembly by MM-401 also impairs Mll1 chromatin binding and has an effect in the Wnt-mutated 
colon cancer cells. A systemic application of Mll1 inhibitors is anticipated to cause severe side 
effects, in particular due to the crucial role of Mll1 in the hematopoietic system. A tumor-
directed application of Mll1 inhibitors will thus be critical and ongoing technological advances 
in this field will profoundly increase the clinical value of Mll1 as a rational target in colon cancer 
therapy. As indicated by our studies in Ls174T cells that underwent a p53-dependent 
senescence in response to prolonged Mll1 depletion, p53-competent cancer cells might require 
a senolytic follow-up therapy to eradicate cancer cells that have become senescent due to 
Mll1-inhibiting therapy. 
To sum up, our study reveals Mll1 as a critical factor in the epigenetic regulation of stem cell 
gene expression induced by oncogenic Wnt/β-catenin signalling. Mll1 sustains the Wnt-
induced stemness of colon cancer cells and prevents cancer cell differentiation. Our data 
suggest targeting Mll1 as a powerful strategy to eliminate the stemness and plasticity of Wnt-
driven colon cancer cells.  
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5 Materials and Methods 
5.1 Mice. 
All mice were bred in pathogen-free conditions, and care and use of animals were performed 
according to the European and national regulations, published in the Official Journal of the 
European Union L 276/33, September 22, 2010. All animal procedures were approved by the 
Landesamt für Gesundheit und Soziales (LaGeSo), Berlin (G0101/18). The transgenic mouse 
lines used in this study have been described: Lgr5-EGFP-IRES-CreERT2 15, β-catenindeltaEx3/+ 78, 
Gt(ROSA)26Sortm1Sor 189, Mll1flox (Kmt2atm1Afst) 188, Mek1DD221, 222. Compound mutant mice were 
obtained by crossing with Lgr5-EGFP-IRES-CreERT2 mice as depicted in Figure 5.1. 
 
Figure 5.1: Genetically engineered mouse models. 
a) Lgr5-CreERT2; Mll1flox mice express GFP and the tamoxifen-inducible CreERT2 under the control of the 
Lgr5 promoter. Cre activity deletes the floxed exon 2 of the Mll1 locus and removes a STOP cassette in 
the Rosa26 locus, enabling LacZ expression. b) In Lgr5-CreERT2; β-catdeltaEx3; Mll1flox mice, Lgr5-Cre 
activity deletes the floxed exon 3 of the Ctnnb1 locus and the floxed exon 2 of the Mll1 locus, and 
removes a STOP cassette in the Rosa26 locus, enabling LacZ expression. c) In Lgr5-CreERT2; Mek1DD; 
Mll1flox mice, the Lgr5-Cre activity deletes the floxed exon 2 of the Mll1 locus and removes a STOP 
cassette in the Rosa26 locus, driving expression of a constitutively active gain-of-function variant of 
Mek1 (Mek1DD). d) In Lgr5-CreERT2; β-catdeltaEx3; Mek1DD; Mll1flox mice, the Lgr5-Cre activity deletes 
the floxed exon 3 of the Ctnnb1 locus and the floxed exon 2 of the Mll1 locus and removes a STOP 
cassette in the Rosa26 locus, driving expression of a constitutively active gain-of-function variant of 
Mek1 (Mek1DD). 
Mutagenesis was induced in 4-6 weeks-old mice by intraperitoneal (i.p.) injections of tamoxifen 
(Sigma, 50mg/kg, diluted 1:10 in sunflower oil) on three consecutive days. Mice were analysed 
at indicated time points after the last tamoxifen injection. The mice were given i.p. injections of 
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BrdU (Millipore) at 2h before sacrifice, final concentration 50µg/g of body weight in PBS. 
Kaplan Meier plot for tumor incidence was calculated based on macroscopic observation of 
hyperplastic intestinal tissue. Both females and males were analysed. 
For genotyping, ear biopsies were treated with 1µg proteinase K (Sigma) in lysis buffer 
(100mM Tris pH 8.5, 10mM EDTA, 0.2% SDS, 200mM NaCl) at 56°C. Lysates were diluted 
1:10 in nuclease-free H2O and genotyped by PCR, using Taq DNA polymerase (Invitrogen) 
and the following primer sequences: 
Table 1: Primer sequences for genotyping. 














For crypt-villus fractionations, the mouse small intestinal epithelium was fractionated into 
crypts and villi following the procedure for the preparation of intestinal organoids (compare 5.2, 
page 86). Fractions were passed through a 70µm cell strainer, separating the fractions in 
crypts in the flow-through and villi stuck on the filter. Villi were recovered from the filter by 
rinsing in ice-cold 0.1% BSA-PBS upside-down. Fractions were collected by centrifugation at 
1000rpm for 5min and snap-frozen in liquid nitrogen. 
The fluorescence-activated cell sorting (FACS) of Lgr5-GFP+ intestinal stem cells was 
performed by Neha Goveas in the lab of Francis Stewart at the Technical University Dresden. 
In brief, small intestinal crypts from Lgr5-EGFP-IRES-CreERT2 mice of the respective genotypes 
were enriched, and crypts were dissociated into single cells with TrypLE Express (Thermo 
Fisher Scientific) for 30min at 37°C. Dissociated cells were passed through a 70µm cell strainer 
and washed with 5% FBS/PBS. Cells were stained with APC-conjugated anti-326 (EpCAM) 
antibody (1:100 dilution, eBioscience, Cat no. 17-5791-80) and Alexa-Fluor 700 CD45 antibody 
(1:50 dilution, BD, Cat no. 560693) for 45min on ice. EpCAM labels epithelial cells, the cell 
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surface marker CD45 was used to exclude haematopoietic cells. The stained cells were 
collected by centrifugation and resuspended in SYTOX blue dead cell stain (1:20,000 dilution, 
Thermo Fisher Scientific). FACS sorting was performed on a FACS AriaTM III cell sorter (BD). 
RNA sequencing of isolated Lgr5-GFP+ intestinal stem cells from four independent mice per 
genotype was performed in collaboration with the Stewart lab (Technical University Dresden, 
Germany) as described in 5.12 (page 93). 
5.2 Organoid culture. 
Intestinal organoids were obtained as previously described64. Small intestines were dissected 
and villi were removed by gentle scraping with a glass coverslip. Intestines were cut into pieces 
of 5mm and dissociated in 8mM EDTA/PBS for 5min at RT followed by 20min incubation in 
ice-cold 2mM EDTA/PBS at 4°C. The epithelia were fractionated by shaking in ice-cold PBS. 
Crypt-enriched fractions were collected by centrifugation, washed once in ice-cold 0.1% BSA-
PBS/HBSS (Gibco #14175-053) (1:1) and applied on a 70µm cell strainer to isolate the crypts 
and remove remaining villi and large debris. 250 crypts were seeded in 20µl of growth factor-
reduced Matrigel (Corning #356231) and cultured in basic crypt medium (60/40 Advanced 
DMEM/F12 supplemented with N2 (Gibco) and B27 (Gibco), GlutaMax (Gibco), 
N-Acetylcysteine (Gibco) and Penicillin/Streptomycin (Invitrogen)) containing 50ng/ml murine 
EGF (Gibco), 100ng/ml murine Noggin (Peprotech) and 500ng/ml human R-spondin1 
(Peprotech). Organoids were split every 3-4 days by mechanical disruption. Cre-mediated 
recombination was induced by addition of 800nM 4-hydroxy-tamoxifen (Sigma #94873) for 
2 days. β-catGOF organoids were selected by R-spondin1 withdrawal. Analyses were performed 
starting from 7-10 days after mutagenesis. EdU incorporation was assayed with the Click-iT 
EdU Imaging kit (Invitrogen). Recombinant human BMP4 (Peprotech) was added for 24h in 
Noggin-free crypt medium supplemented with EGF and R-spondin1. For serial re-plating, 
β-catGOF; Mll1-/- organoids were dissociated into single cells by 5min incubation in TrypLETM 
(Gibco) at 37°C in a water bath, and 2,000 cells were seeded in 20µl of growth-factor reduced 
Matrigel and cultured in crypt medium supplemented with EGF, Noggin and R-spondin1. 
5.3 Cell culture. 
HEK293TN cells, DLD1 and Ls174T human colon cancer cell lines were cultured in 1xDMEM 
(Gibco) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin 
(PenStrep) at 37°C, 90% H2O, 5% CO2. Cell line identity was confirmed by Multiplex human 
Cell line Authentication (MCA, Multiplexion). For non-adherent sphere culture, dishes were 
coated with 12mg/ml polyhema/95% EtOH (Sigma) over night at 55°C. Single cells were 
cultured in cancer stem cell (CSC) medium (DMEM/F12 (1:1) + GlutaMAX (Gibco), 
1%PenStrep supplemented with N2, 10ng/ml human FGF (Gibco) and 10ng/ml human EGF 
(Peprotech)) for 4-5 days, dissociated with trypsin for 5min at 37°C, and re-plated in CSC 
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medium on polyhema-coated dishes. After 1 day of secondary sphere culture, spheres were 
harvested by centrifugation and processed for RNA/protein analyses. Gsk126209 (ApexBio) 
was administered for 96h at 5µM. Recombinant human BMP4 (Peprotech, final concentration 
500ng/ml) and recombinant human Noggin (Peprotech, final concentration 100ng/ml) were 
added for 48h. ICG-001101, LF3100 and MI-2147 were administered for 48h at indicated 
concentrations. 
5.4 Generation and cloning of shMLL1. 
Doxycycline-inducible shRNA knockdown cell lines were generated by lentiviral transduction, 
using the doxycycline-inducible pInducer11 system established by Meerbrey et al. (2011)201. 
shRNA targeting MLL1 was designed with the optimized miR30a backbone (Fellmann et al. 
2013248) and cloned into the pInducer11 vector (addgene #44363). To introduce restriction 
sites the shMLL1 was amplified in a PCR reaction using the following primers (5’-3’: mirE Amp-
fwd TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG; mirE Amp-rev TCTCGAATTC 
TAGCCCCTTGAAGTCCGAGGCAGTAGGC). The PCR product was purified with the PCR 
purification kit (Roche). Purified shMLL1-mirE Amp and the pInducer11 vector were digested 
with EcoRI and XhoI restriction enzymes (New England Biolabs) for 8h at 37°C to generate 
compatible overhangs. The digested shMLL1 insert was purified with the PCR purification kit 
(Roche). The cut pInducer11 vector was separated on a 1% agarose gel and the vector 
backbone was purified with the QIAgen gel purification kit (Qiagen). The shMLL1 insert was 
ligated into the pInducer11 vector for 3h at RT using the T4 DNA ligase (Promega). The ligation 
reaction was performed in a total volume of 15µl using 8µl shMLL1-mirE Amp PCR product 
and 30ng of the processed pInducer11 vector. Competent XL10 gold bacteria were 
transformed with the ligation product by incubation on ice for 45min followed by a heat shock 
at 42°C for 45sec in a water bath. Bacteria were cultured over night at 30°C on agar plates in 
the presence of 100µg/ml ampicillin. Successfully transformed bacteria possess ampicillin 
resistance and grow into clonal colonies. Colonies were picked and cultured over night at 30°C 
with gentle shaking in LB medium containing 100µg/ml ampicillin. Plasmid DNA was isolated 
using the QIAgen plasmid purification kit (Qiagen) and incorporation of the shMLL1 insert was 
checked in a restriction digest with XhoI and MluI (New England Biolabs). Sequence identity 
was verified using the Sanger sequencing service from Source Bioscience. 
Table 2: Sequence shMLL1. 
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5.5 Generation of lentiviral particles and lentiviral transduction. 
For production of lentiviral particles, HEK293TN cells were co-transfected with 10µg psPAX2 
(addgene #12260), 2.5µg pMD2.G (addgene #12259) and 10µg pInducer11-shMLL1 by 
transfection with polyethylenimine (PEI) (Sigma). Supernatants containing lentiviral particles 
were collected at 24h and 48h after transfection. For lentiviral transduction, the lentiviral 
particle-containing supernatant was mixed 1:1 with fresh growth medium containing 8µg/ml 
polybrene. Ls174T and DLD1 cells were transduced at 1000rpm for 1h at RT followed by over 
night incubation at 37°C. Transduced cells with high expression of shRNA were selected by 
FACS for GFP and tRFP201, and cultured as single cell clones to establish shMLL1 Ls174T cell 
lines. Knockdown was induced by addition of doxycycline to the growth medium (LKT 
Laboratories D5897, final concentration 300ng/ml). 
5.6 Serial re-plating and colony formation assay. 
For serial re-plating assays, cells were seeded at a density of 0.5x106 cells on 10cm-cell culture 
dishes. Upon passaging every 2-3 days, cells were trypsinized and resuspended in 
10ml growth medium. Cell suspensions were diluted 1:2 in 0.4% Trypan Blue/PBS to 
distinguish viable and dead cells. Viable cells were counted manually and re-plated at a density 
of 0.5x106 cells. 
For colony formation assays, cells were counted with a cell counter (CASY). 500 cells were 
seeded per well of a 6-well tissue culture plate, and cultured for a period of 13 days. Inducible 
shMLL1 Ls174T cells were pre-treated with 300ng/ml doxycycline for 3 days and kept on 
doxycycline throughout the assay. Inhibitors at indicated concentrations were added upon 
plating, the medium was changed every other day. Cell colonies were stained with crystal violet 
and counted manually. The colony formation rate was further quantified by de-staining in 
10% acetic acid and measuring the absorbance of the released dye with an iMark microplate 
reader (BioRad). 
5.7 TCF/LEF luciferase reporter assay. 
To assess the transcriptional activity of the β-catenin/TCF complex in control and shMLL1 
Ls174T cells, cells were transiently transfected with 1µg of a reporter construct which encodes 
a firefly luciferase under the control of a TCF/LEF promoter element (TOPflash) and responds 
to canonical Wnt signalling by driving luciferase activity206. In parallel, control and shMLL1 
Ls174T cells were transfected with a negative control plasmid (FOPflash). The FOPflash 
plasmid contains mutated TCF binding sites and is unable to respond to active Wnt signalling; 
it serves to control for non-specific effects of luciferase activity. All cells were co-transfected 
with 0.1µg of a constitutively active construct encoding Renilla luciferase (SV40 Renilla, 
addgene #27163). All transfections were performed in 12-well tissue culture plates, using 
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LipofectamineTM 2000 (Invitrogen) and following the manufacturer’s instructions. The 
composition of the transfection mix was as follows: 
 TOPflash or FOPflash 1 µg 
 SV40 Renilla   0.1 µg 
 LipofectamineTM 2000  2 µl 
 OptiMEM (Gibco)  200 µl 
The culture medium was changed at 24h after transfection and 3µM CHIR99021207 (Axon 
#1386) and 50µM LF3100 were added. The shMLL1 Ls174T cells were pre-treated with 
300ng/ml doxycycline for 6 days prior to transfection and kept on doxycycline throughout the 
assay. At 48h after transfection, cells were washed once with PBS and lysed in Passive Lysis 
Buffer (Promega) for 10min at RT. Lysates were harvested by scraping, centrifuged for 1min 
at 14,000rpm and transferred into MicroWell Assay microplates (Nunc). Luciferase activity was 
measured with a Centro XS3 LB960 microplate luminometer (Berthold technologies) with 
automated addition of firefly and Renilla substrate buffers (firefly luciferase buffer: 150mM 
HEPES, 8mM MgSO4, 40mM DTT, 200µM EDTA, 1.06mM ATP pH 8 diluted 1:1 in H2O and 
supplemented with 270µM CoA and 200µM luciferin; Renilla luciferase buffer: 30mM Na4PPi, 
15mM NaAc, 20mM CDTA, 800mM Na2SO4 pH 5.0 diluted 1:1 in H2O and supplemented with 
2.2µM coelenterazin and 50µM APMBT), each sample was measured in triplicate. Firefly 
activity was normalized to respective Renilla control, TOPflash values were calculated relative 
to FOPflash activity (TOP/FOP activity). 
5.8 Xenografts. 
For xenograft assays, 1x106 cells in 200µl PBS were injected under the skin of nude mice, 
NMRI:nu/nu, female. The inducible shMLL1 Ls174T cell lines were pre-treated with 300ng/ml 
doxycycline for 4 days and mice were administered doxycycline in drinking water (2mg/ml 
doxycycline in 5g/l sucrose) from day -1 throughout the experiment. Mice inoculated with non-
induced control cells were kept without doxycycline. Health condition, tumor size and mouse 
body weight were measured every other day. For the tumor maintenance xenograft, 1x106 
non-induced shMLL1 Ls174T cells were resuspended in 200µl PBS and injected under the 
skin of female NMRI:nu/nu mice. For ablation of MLL1, mice were administered doxycycline in 
drinking water (2mg/ml doxycycline in 5g/l sucrose) starting from day 8 after cell inoculation. 
Control mice were kept without doxycycline throughout the experiment. Health condition, tumor 
size and body weight were monitored throughout the experiment. All xenograft assays were 
performed with the Experimental Pharmacology and Oncology (EPO), Berlin-Buch. 
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5.9 Histology, immunofluorescence staining and analysis. 
Analysis of naïve human colon cancer biopsies was approved by the ethic commission of the 
Friedrich-Alexander Universität Erlangen-Nürnberg (148_19 BC). Murine tissue was fixed in 
4% formaldehyde/PBS over night at 4°C or for 3h at RT and transferred to 70% EtOH at 4°C. 
Tissue was dehydrated by sequential incubation in 70%, 80%, 90% and 100% EtOH for 
1h each at RT, cleared in toluol and paraffin-embedded. Organoids were fixed in 
4% formaldehyde/PBS for 1h at RT and embedded in 1.5% agarose-PBS prior to dehydration 
and paraffin embedding. 5-7µm sections were cut with a microtome (Microm HM355S) and 
placed on microscope slides (Menzel Glass, Superfrost Plus, Thermo Fisher). For 
H&E staining, tissue sections were incubated with hematoxylin solution for 1min, washed 
under running tab water for 5-10min and stained with eosin for 5min prior to dehydration and 
mounting with non-aqueous mounting medium. Hematoxylin stains nuclei blue, eosin stains 
cytoplasm and extracellular matrix in different shades of pink. Alcian blue solution (pH 2.5 in 
3% acetic acid) was incubated for 30min to stain acidic polysaccharides and 
glycosaminoglycans, sections were washed under running tab water for 1min and counter-
stained with nuclear fast red for 5min or hematoxylin for 30sec. 
For immunostaining on paraffin sections, antigen retrieval was carried out by boiling in 10mM 
sodium citrate pH 6.0 or 1mM EDTA 20mM Tris pH 8.5 in a microwave oven at P100 and P40 
as indicated in Table 3 (compare 5.13, page 96). For immunohistochemistry (IHC), sections 
were incubated in 4% H2O2/PBS for 5min prior to 1h incubation with blocking solution 
(0.1% Tween20, 5-10% horse serum, 1% BSA in PBS) followed by incubation of the primary 
antibody diluted in blocking solution over night at 4 °C. Fluorochrome-conjugated or HRP-
coupled secondary antibodies and 4′,6-diamidino-2-phenylindole (DAPI) were incubated in 
blocking solution for 1-2h at RT. Immunohistochemistry was developed with the DAB 
chromogenic substrate (DAKO), dehydrated and mounted with non-aqueous mounting 
medium (Entellan). Cells for Mll1 immunofluorescence staining were cultured on chamber 
slides, fixed in 4% formaldehyde/PBS for 10min at RT, washed twice with PBS, permeabilized 
in 0.1% Triton-X100/PBS for 1min, treated with ice-cold methanol for 10min at -20°C and 
incubated in blocking solution (0.1% Tween20, 5% horse serum, PBS) for 1h at RT prior to 
incubation of primary antibodies over night at 4°C. 
All antibodies used were validated by the manufacturers for immunostaining applications. 
Specificity of the Mll1 antibody (D6G8N, Cell Signaling Technology #14197) was confirmed by 
the absence of staining on Mll1-deficient tissue (see Figure 3.15c, page 42). Secondary 
antibody specificity was validated by lack of staining in the absence of targeted primary 
antibodies (see Supplementary Figure 2, page 115). 
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5.9.1 LacZ whole-mount staining. 
Murine intestine was cut open longitudinally, fixed for 2h in ice-cold fixative (1% formaldehyde, 
0.2% glutaraldehyde, 0.02% NP-40 in PBS), washed twice in PBS, incubated in staining 
solution (2mM MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 0.01% NP-40, 0.01% sodium 
deoxycholate, 1mg/ml X-gal (Roth) in PBS) over night at RT protected from light, dehydrated 
and processed for paraffin embedding. 10µm paraffin sections of LacZ-stained tissue were 
counter-stained with nuclear fast red. 
5.9.2 Senescence-associated β-galactosidase (SA-β-Gal) staining. 
Cells were washed with PBS, fixed in 4% PFA/PBS for 5min at RT, washed twice with 
0.1% BSA-PBS for 20min and stained with SA-β-Gal staining solution (40mM citric 
acid/sodium phosphate pH 6.0, 1mM MgCl2, 1 mg/ml X-gal, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6 
in H2O) for 3-5hrs or over night at 37°C without CO2. 
5.9.3 Light microscopy and data analysis. 
Representative z-stacks were acquired with inverted laser scanning microscopes LSM710 and 
LSM700 using 405nm, 488nm, 561nm, and 633nm lasers and a PlanApochromat 40x NA 
1.3 objective (Zeiss Jena, Germany) or a spinning disc confocal microscope CSU-W1 
(Nikon/Andor) equipped with an iXON888 camera, using PlanApo 20x NA 0.75 and Apo LWD 
40x NA 1.15 objectives of the advanced light microscopy (ALM) core facility at the MDC. 
Maximal intensity projections of z-stacks were performed with ImageJ. Mean fluorescence 
intensity in 3D reconstructed samples was quantified with Imaris 8 (Bitplane/Andor) software, 
using the surface module and selecting for nuclear fluorescence signal with a mask created in 
the DAPI channel. Mll1 staining intensity in the crypt cell populations was quantified with the 
measurement point tool in Imaris 8 and normalized to the mean staining intensity in the TA cell 
population. H&E and IHC stainings were imaged with an Axio Scope.A1 (Zeiss). 
5.10 Chromatin immunoprecipitation. 
Chromatin immunoprecipitation (ChIP) of histone modifications was performed from 
pInducer11-shMLL1 Ls174T lines induced with 300ng/ml doxycycline for 11 days, following 
the instructions of the iDEAL ChIP-seq kit for histones (Diagenode). In brief, cells were grown 
to 80% confluency, trypsinized for 3min at 37°C, collected by centrifugation in growth medium 
and resuspended in PBS for cell counting. Aliquots of 10x106 cells per 500µl were fixed in 
1% formaldehyde/PBS for 8min at RT and quenched by addition of glycine for 5min at RT. For 
ChIP of Mll1, Tcf4 and β-catenin, pInducer11-shMLL1 Ls174T and DLD1 cell lines were 
induced with 300ng/ml doxycycline for 6 days and 8 days, respectively, and chromatin was 
prepared using the ChIP-IT Express kit (Active Motif). Cells were grown to 80% confluency, 
trypsinized for 3min at 37°C, fixed in 1% formaldehyde-DMEM for 10min at RT and quenched 
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with glycine for 5min at RT. Chromatin was sheared with a Branson Sonifier 450 at 4°C: 3min 
shearing time, duty cycle 60, output control 6, sonicate 10x for Diagenode kit, 4x for Active 
Motif kit Ls174T cells, 2x for Active Motif kit DLD1 cells, 1min pause between each sonication 
round. Shearing efficiency was checked on a 1% agarose gel. 10 µg of sheared chromatin 
were used for ChIP anti-Mll1, -Tcf4, and -β-catenin. ChIP-qPCR analysis was performed in a 
total volume of 20µl SYBR green reaction mix (Roche Diagnostics) containing 0.25µM of 
forward and reverse primers each in a CFX96-C1000T thermal cycler (BioRad): 2min 50°C, 
2min 95°C followed by 42 cycles of 15sec 95°C and 1min 60°C. Ct values of precipitated DNA 
were calculated relative to input DNA (% input). ChIP-qPCR primers were designed using 
H3K4 methylation profiles available in the UCSC genome browser (human reference genome 
GRCh37/hg19) and the Mll1 ChIP-seq UCSC genome browser data set from Active Motif 
(https://www.activemotif.com/catalog/details/61295/mll-hrx-antibody-pab). Primer sequences 
used for ChIP-qPCR are given in Supplementary Table 2 (page 117). 
5.11 SDS-PAGE and Western blotting. 
Organoids were harvested and washed once in ice-cold 0.1% BSA-PBS and rinsed once in 
ice-cold PBS, cells were washed twice in ice-cold PBS prior to lysis in ice-cold RIPA buffer 
(50mM Tris pH8.0, 150mM NaCl, 0.1% SDS, 1% NP40, 0.5% sodium deoxycholate) containing 
1x protease inhibitors (cOmplete Mini EDTA-free, Roche). For analysis of protein 
phosphorylation, phosphatase inhibitor cocktails 2 and 3 (Sigma) were added. Snap-frozen 
tissue samples were grinded with mortar and pestle on dry ice and lysed in RIPA buffer. 
Lysates were sonicated to disrupt cell membranes and fragment genomic DNA. Protein 
concentration was determined using the Bio-Rad Protein Assay (Bio-Rad, #500-0006) and 
measuring absorbance at 595nm with an iMark microplate reader (BioRad) according to the 
Bradford method. Equal concentrations of total protein were diluted with ice-cold PBS and 
denatured by boiling at 95°C for 5min in 1x SDS loading buffer (3x buffer: 180mM Tris/HCl 
pH6.8, 6% SDS, 30% glycerol, 15% β-mercaptoethanol and 0.01% bromphenol blue). The 
whole cell protein extracts were separated by molecular weight on polyacrylamide gels 
(stacking gel: 125mM Tris/HCl pH6.8, 0.1% SDS, 3% acrylamide, 0.1% ammonium persulfate, 
0.1% TEMED; separating gel: 375mM Tris/HCl pH8.8, 6-12% acrylamide, 10% glycerol, 0.1% 
SDS, 0.025% ammonium persulfate, 0.1% TEMED) via SDS-PAGE running at 20mA per gel 
for about 1h in electrophoresis buffer (25mM Tris, 20mM glycine, 2% SDS). Proteins were 
transferred to a methanol-activated nitrocellulose membrane via semidry transfer for 1h 15min 
at 90mA or wet transfer for 3h at 85V and 4°C. Transfer buffer for semi-dry transfer was 
composed of 25mM Tris, 192mM glycine and 20% methanol; for wet transfer of 25mM Tris, 
191mM glycine, 0.01% SDS and 20% methanol. To detect specific proteins, membranes were 
blocked with 5% BSA or 5% skim milk in 0.1% Tween20/TBS and probed with primary 
antibodies diluted in blocking solution over night at 4°C. Blots were washed three times in 
  Materials and Methods 
93 
0.1% Tween20/TBS and HRP-conjugated secondary antibodies were incubated in blocking 
solution for 1h at RT. Western blots were developed with Western Lightning Plus ECL (Perkin 
Elmer) for 3min and imaged with a Vilber Lourmat imaging system FUSION SL-3. 
5.12 RNA preparation for RT-PCR analysis and RNA sequencing. 
Total RNA from cells, organoids and snap-frozen tissue was isolated by Trizol extraction 
(Invitrogen) or with the NucleoSpin RNA isolation kit (Macherey-Nagel). DNA contaminations 
were removed by DNase1 digestion (Invitrogen) in the presence of RNase inhibitor (RNase 
Out, Invitrogen) and RNA was purified by phenol/chloroform extraction. For quantitative 
reverse transcription (RT)-PCR, 5µg of total RNA were reverse transcribed with random 
hexamer primers (Invitrogen) and MMLV reverse transcriptase (Promega, 200U/µl). RT-PCR 
was performed in a total volume of 20µl SYBR green reaction mix (Roche Diagnostics) 
containing 0.25µM of forward and reverse primers each in a CFX96-C1000T thermal cycler 
(BioRad): 2min 50°C, 2min 95°C followed by 42 cycles of 15sec 95°C and 1min 60°C. All 
reactions were performed in duplicates. Expression of target genes in treated versus control 
samples was calculated relative to the endogenous reference Gapdh, using the ΔΔCt method. 
Primer sequences used for RT-PCR are listed in Supplementary Table 3 (page 118). 
For RNA sequencing of human colon cancer cells, total RNA from shMLL1 Ls174T cells 
induced with 300ng/ml doxycycline for 3 days and non-induced parental cells was isolated with 
the NucleoSpin RNA isolation kit (Macherey-Nagel). RNA from three independent pairs of 
induced and non-induced shMLL1 Ls174T cell clones was sequenced on a NextSeq500 
(Illumina). RNA-seq reads were quality-checked by FASTQC (v0.11.5) software. Sequencing 
reads were mapped to the human whole genome (hg38) using STAR aligner (v. 2.5.3a) and 
default parameters. Read counts for each gene (gencode v12) were extracted from the BAM 
file using featureCounts software (v. 1.5.1). Read counts from different biological groups were 
subjected to differential expression analysis using the DESeq2 R statistical package. 
Comparisons between shMLL1 and parental control cells were corrected by individual 
technical replicates (paired comparison). In order to avoid background signal/noise, genes with 
less than 10 reads over all samples were excluded before adjusting the p-value for multiple 
testing. Genes with adjusted p-value lower than 0.05 and absolute fold-change (log10) higher 
than 0.5 were considered differentially expressed. Gene expression profile comparison was 
done by GeneOverlap R package by overlapping lists of differentially expressed genes (MGI 
symbol) from different sources (‘Clevers’195, ‘Soshnikova’204, ‘Batlle’89) with our own data. All 
conversions from Ensembl ID to MGI symbol and from human gene names to mouse gene 
names were done by biomaRt. Heatmap was generated using the heatmap.2 function from R. 
Gene set enrichment analysis (GSEA) was performed using the R/Bioconductor package 
DOSE249. Volcano plots were generated by a generic R X-Y plotting using the log2FoldChange 
versus the log2 adjusted p-values. RNA-seq data from shMLL1 Ls174T human colon cancer 
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cells are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-8152. 
For RNA sequencing of Lgr5-GFP+ mouse intestinal stem cells, 300 single cells were sorted 
into a PCR tube containing 2µl of nuclease-free H2O with 0.2% Triton-X100 and 4U murine 
RNase Inhibitor (NEB), and stored at -80°C. RNA isolation and library preparation were 
performed based on the Smart-seq2 protocol250. In brief, RNA was denatured for 3min at 72°C 
in the presence of 2.4mM dNTP (Invitrogen), 240nM dT-primer and 4U RNase Inhibitor (NEB), 
and reverse transcribed using the Superscript II Reverse Transcriptase (Invitrogen). Single-
stranded cDNA was amplified with the Kapa HiFi HotStart Readymix (Roche) and purified 
using Sera-Mag SpeedBeads (GE Healthcare). cDNA quality and concentration were 
determined with the Fragment Analyzer (Agilent). Sequencing was performed on a 
NextSeq500 (Illumina) with a sample sequencing depth of 30mio reads on average. RNA-seq 
reads were aligned to the mm10 transcriptome with GSNAP (version 2018-07-04) and a table 
of read counts per gene was created based on the overlap of the uniquely mapped reads with 
the Ensembl Gene annotation (version 92), using featureCounts (version 1.6.3). Read counts 
were further processed with the DESeq2 R package (version 1.22.2). Sample-to-sample 
correlation was computed by Euclidean distance between samples based on the normalized 
counts. Differential gene expression analysis was performed with DESeq2, for which a 
maximum of 10% false discoveries (10% FDR) was accepted. Volcano plots were generated 
by a generic R X-Y plotting using the log2FoldChange versus the log2 adjusted p-values. 
RNA-seq data from Lgr5-GFP+ intestinal stem cells are available under the GEO accession 
GSE148394. 
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5.13 Antibodies. 
The following antibodies were used in this study (dilutions given for immunostaining/Western 
Blot and ChIP if applicable): 
anti-Mll1 (D6G8N, Cell Signaling Technology #14197, RRID:AB_2688010, 1:100/1:2000, 1:50 
for ChIP), anti-hSet1 (Bethyl A300-289A, RRID:AB_263413, 1:2000), anti-H3K4me3 (Cell 
Signaling Technology #9727, RRID:AB_561095, 1:2000/1:10,000, 1:50 for ChIP), anti-
H3K27me3 (Millipore #07-449, RRID:AB_310624, 1:1000, 5µg for ChIP), anti-H3K4me2 
(Millipore #07-030, RRID:AB_11213050, 1:5000), anti-H3K4me1 (Millipore #07-436, 
RRID:AB_310614, 1:5000), anti-H3K9me3 (Abcam Cat# ab8898, RRID:AB_306848, 
1:2000/1:10,000), anti-H3 (Abcam ab1791, RRID:AB_302613, 1:10,000), anti-p21 (Santa Cruz 
Biotechnology sc-6246, RRID:AB_628073, 1:100/1:1000), anti-p53 (Millipore MABE327, 
RRID:AB_11213651, 1:500, 3µg for ChIP), anti-cleaved Caspase-3 (Cell Signaling 
Technology #9661, RRID:AB_2341188, 1:400/1:2000), anti-E-cadherin (BD Biosciences 
#610181, RRID:AB_397580, 1:200), anti-Mmp7 (Santa Cruz Biotechnology sc-26680, 
RRID:AB_2144469, 1:100), anti-GFP (Abcam #ab6673, RRID:AB_305643, 1:500), anti-Ki67 
(Thermo Fisher Scientific MA5-14520, RRID:AB_10979488, 1:300), anti-BrdU (Abcam 
ab6326, RRID:AB_305426, 1:100), anti-β-catenin (BD Biosciences #610153, 
RRID:AB_397554, 1:300/1:1000, 3µg for ChIP), anti-β-catenin (PAIII, self-made by Huelsken 
et al. (1994)251, 1:1000), anti-TCF4 (Cell Signaling Technology #2569, RRID:AB_2199816, 
1:50 for ChIP), anti-Lyz (Agilent A0099, RRID:AB_2341230, 1:500), anti-ITF (Santa Cruz 
Biotechnology sc-18272, RRID:AB_2287326, 1:300), anti-GATA6 (R and D Systems Cat# 
AF1700, RRID:AB_2108901, 1:100-1:500), anti-GATA4 (Santa Cruz Biotechnology sc-25310, 
RRID:AB_627667, 1:200), anti-phospho-Erk1/2 (Sigma-Aldrich M8159, RRID:AB_477245, 
1:3000 for Western Blot), anti-phospho-Erk1/2 (Cell Signaling Technology #4370, 
RRID:AB_2315112, 1:200 for IHC) anti-Erk1/2 (Cell Signaling 9102, RRID:AB_330744, 
1:1000), anti-phospho-Mek1/2 (Cell Signaling Technology 9154, RRID:AB_2138017, 1:1000), 
anti-Mek1/2 (Cell Signaling Technology 4694, RRID:AB_10695868, 1:1000), anti-alpha tubulin 
(Sigma-Aldrich #00020911, RRID:AB_10013740, 1:10,000) and anti-vinculin antibody (Sigma-
Aldrich V9131, RRID:AB_477629, 1:5000). 
For immunofluorescence and immunohistochemistry, cyanine-labelled secondary antibodies 
(Jackson ImmunoResearch) and HRP-conjugated polymer and DAB reagent (DAKO) were 
used. IgG control antibodies were rabbit monoclonal IgG isotype control (Cell Signaling 
Technology #3900, RRID:AB_1550038) and mouse monoclonal IgG isotype control (Santa 
Cruz Biotechnology sc-2025, RRID:AB_737182). The specificity of histone modification 
antibodies was confirmed by dot blotting against synthetic peptides carrying the modifications 
of interest (Diagenode). 
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5.14 Quantification and Statistical analysis. 
All data are presented as mean ± SD unless otherwise indicated. For normalization data were 
calculated relative to the average value of controls. Statistical details of the experiments can 
be found in the figure legends. Graphs and statistics were generated with GraphPad Prism 
software. Tests for normal distribution were performed with D'Agostino-Pearson and Shapiro-
Wilk tests. Significance (p-value) was determined with Mann-Whitney test (two-tailed) or two-
tailed Student’s t test. No statistical method was used to estimate sample size. No specific 
randomization or blinding protocol was used. N indicates the numbers of independent 
biological replicates per experiment unless otherwise indicated. p-value ≤ 0.05 was considered 
statistically significant (p ≤ 0.05 *, p ≤ 0.01 **, p ≤ 0.001 ***, p ≤ 0.0001 ****). 
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Supplementary Figure 1: MLL1 expression in human colon carcinomas. 
a) Representative immunohistochemistry stainings for MLL1 (upper panels) and β-catenin (lower 
panels) on colon cancer patient biopsies: tumor stages T1-T4, with high expression (left) and low 
expression (right) of MLL1 and β-catenin, insets show magnifications of indicated regions. 
b) Quantification of MLL1 expression in tumor sections with low and high β-catenin across tumor stages 
T0-T4, determined by immunohistochemistry analysis, n=39. 
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Supplementary Figure 2: Secondary antibody staining controls. 
Immunostainings on sections of mouse small intestine to validate specificity of secondary antibodies 
used in this study: donkey anti-rabbit (a), donkey anti-mouse (b), donkey anti-goat (c), donkey anti-
rat (d). Nuclei in blue (DAPI). Specific staining is detected in the presence of the primary antibodies 
rabbit anti-H3K4me3 (a), mouse anti-β-catenin (b), goat anti-GFP (c), rat anti-BrdU (d) (first panels), but 
is absent in serial control specimens incubated with blocking solution only (second panels) or control 
IgG (third panels in a, b). White arrowheads mark non-specific signal due to recognition of mouse 
immune cells by anti-mouse secondary antibody; the non-specific signal is well distinguishable from the 
specific staining in the epithelium (b, first panel) and does not interfere with our analyses. 
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Supplementary Table 1: MLL1-regulated colon cancer stem cell signature. 
ARHGEF4 PLCG2 ISG20 TINAG 
PRKD3 NFIA SMPDL3A A1CF 
DYNC2H1 SULT1B1 FBP1 PPM1K 
ISYNA1 RUNDC3B IQGAP2 SLC28A2 
SMOC2 BCL2L15 RBM43 FAM20B 
CLIC4 CCL28 MERTK CIB2 
CLU DDX60 PLA2G2A RASSF10 
IL17RD AGMO UBA7 VWA2 
RASSF5 NPC1L1 SLC4A4 KLHL13 
OLFM4 VAV3 PLAC8 IGFBP4 
WWTR1 ELL2 SERPINB9 NRP1 
SMAD5 RABGAP1L FHDC1 TACC1 
WDR35 AREG UBE2L6 MDFIC 
PRKACB FHL2 KLF9 ABTB2 
ENPP1 KCNJ2 SLC7A7 LGR5 
FAM13A TLR3 NEURL3  
IFITM2 B4GALT6 ALDH1L1  
TLR2 FILIP1L MAML2  
SOAT1 AKR1B10 MYO1A  
SLCO3A1 CKB CD14  
CACHD1 CCL20 TRIM31  
ADRA2A XIAP SULT1C2  
AK7 GPRIN3 RELB  
KRT23 ALDOB SPCS3  
APCDD1 PLA2G16 ZC3H12A  
SNX10 TNFRSF11A ST5  
POLI CASP1 OSBPL6  
NME4 XK ENC1  
TNFSF10 SNPH SLC39A8  
ESRRG CTSS RNF128  
BLVRA TFPI CLDN12  
ACP5 MBNL2 ZC3H12D  
KLHL24 RNASE1 BIRC3  
AKAP7 SLC6A4 ACVR1C  
SLC5A9 SLC3A1 AMPD3  
BTG2 ZG16 SP1  
CTH ADCY9 THRB  
THBS1 DUOXA2 TGFBI  
STARD13 MOCS1 DOCK11  
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Supplementary Table 2: Primer sequences for ChIP-qPCR. 
ChIP-qPCR primer sequence (5’-3’) 
ASCL2 fwd GATCCGCCAGCACTAGAGAC 
ASCL2 rev TGGCTTCGATTTCGCTCACT 
AXIN2 fwd ACTAAGAAGGGTAGGGGCTGAA 
AXIN2 rev CTCGAGGCTCTGGTCGGG 
AXIN2_TCF4 fwd GGCTTTCTTTGAAGCGGCTC 
AXIN2_TCF4 rev TAACCCCTCAGAGCGATGGA 
GATA6 fwd GGGTCGCTAGCCAGGTCA 
GATA6 rev AGGCAGACAATGAGAGCCGC 
GATA6_Mll1 fwd CACAAGCTCTCCGCATTGCC 
GATA6_Mll1 rev GCCCCAGAGAGAAATGCAACT 
IGFBP4 fwd GAAGGCAGGTACGTGGCAG 
IGFBP4 rev CACTGGGATTTCACCCTCGG 
IGFBP4_Mll1 fwd TGCACACACTGATGCACGG 
IGFBP4_Mll1 rev CACTCAGGAGGGAATTGGGA 
LGR5 fwd GAGGGGAAGGAAGGTTCGTC 
LGR5 rev CATTTCTCTGCGGGTCCAGA 
LGR5_Mll1 fwd CTACTTCGGGCACCATGGAC 
LGR5_Mll1 rev CTCAGCAACACACCAGACCT 
LGR5_TCF4 fwd GCAACCACAAACCCCGATTA 
LGR5_TCF4 rev CCCGGGGGAAGAGATGGTTA 
MECOM fwd GAAACCGACGGACAGAGACA 
MECOM rev TCCTTGTTCCTCCTGCGAAA 
OLFM4 fwd ACTCAGATTCCTGGGTGTCCT 
OLFM4 rev TGTCCTCTTAGCTGGAGCCG 
OLFM4_Mll1 fwd GGGAAGAAGGCAGAGGTCAC 
OLFM4_Mll1 rev CCTGAGCTTCTTGTGAGCCA 
p21 -2282 fwd216 AGCAGGCTGTGGCTCTGATT 
p21 -2282 rev216 CAAAATAGCCACCAGCCTCTTCT 
SMOC2 fwd CCTGTGGGGAACCAGGTCT 
SMOC2 rev CGGCTCACTTACGAGGGTC 
SMOC2_Mll1 fwd GACCTGGAGCTCAAGTGGTG 
SMOC2_Mll1 rev TCCTACCTGCTCCAGCCTC 
TAL1 +70 fwd141 GTGGCCACAAAGCAAGGAAT 
TAL1 +70 rev141 TCTCTGGAATCTCCAAGGCAA 
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Supplementary Table 3: Primer sequences for RT-PCR. 
RT-PCR primer species sequence (5’-3’) 
ASCL2_fwd human GCGTGAAGCTGGTGAACTTG 
ASCL2_rev human GGATGTACTCCACGGCTGAG 
AXIN2_fwd human AACTGAAACTGGAGCTGGAAAGCC 
AXIN2_rev human TTTGTGGGTCCTCTTCATAGCTGC 
BMP4_fwd human TCTATGTGGACTTCAGCGATGTGG 
BMP4_rev human AATTGACCAGGGTCTGCACAATGG 
CD166_fwd human ACACGATGAGGCAGACGAGA 
CD166_rev human AGTAGACGACACCAGCAACA 
CD44_fwd human GGCTTTCAATAGCACCTTGC 
CD44_rev human ACACCCCTGTGTTGTTTGCT 
DEFA5_fwd human TCCCTCCTGCAGGTGACCCCA 
DEFA5_rev human GTGGCTCTTGCCTGAGAACCTGA 
GAPDH_fwd human AAGGTGAAGGTCGGAGTCAA 
GAPDH_rev human AATGAAGGGGTCATTGATGG 
GATA6_fwd human TGCCAACTGTCACACCACAA 
GATA6_rev human CATAGCAAGTGGTCTGGGCA 
IGFBP4_fwd human TTCCACCCCAAGCAGTGTCA 
IGFBP4_rev human TCCAGAGCACAGGAGTAGCA 
ITF_fwd64 human ATCCAGAGCAGCTGTGCAAACAAC 
ITF_rev64 human TTTGCAGACAGGCCCACGTACTC 
KRT20_fwd human CAGTGGTACGAAACCAACGC 
KRT20_rev human CACACCGAGCATTTTGCAGT 
LGR5_fwd human TGCTTACCAGTGCTGTGCATTTGG 
LGR5_rev human TGCACTGAATGAAGGGCTTTCAGG 
LRIG1_fwd human GGTGAGCCTGGCCTTATGTGAATA 
LRIG1_rev human CACCACCATCCTGCACCTCC 
LYZ_fwd64 human GCCTAGCAAACTGGATGTGTTTGG 
LYZ_rev64 human TTTGCACAAGCTACAGCATCAGCG 
MLL1 (KMT2A)_fwd human, mouse TGAGCTGCAGATGACTGGTTA 
MLL1 (KMT2A)_rev human, mouse CCAGAGCATCAGAGGAGAGC 
MLL2 (KMT2B)_fwd human ATCCCAGCGAGGTCGAG 
MLL2 (KMT2B)_rev human GCCGGAGAAGTTCAGTCAGT 
MLL3 (KMT2C)_fwd human CAAAGAACAATCTGCAGAAGAGGA 
MLL3 (KMT2C)_rev human GGTTGGTTTCTCCATGGCAAG 
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MLL4 (KMT2D)_fwd human CCCTGAGTATCTGAAGGGCG 
MLL4 (KMT2D)_rev human AGGGTATGGGGCCGTTTGTA 
MUC2_fwd64 human TTTGATGCCAGCATTTGCATCCCG 
MUC2_rev64 human TTGGCCGAGTACATGACAAATGTCCC 
OLFM4_fwd human ATCATCTGCCTCTTCAGGCG 
OLFM4_rev human CCCAGGTTTCTTCCAGGCAT 
p21_fwd human AGTCAGTTCCTTGTGGAGCC 
p21_rev human CATTAGCGCATCACAGTCGC 
RAC3_fwd human CGAGAATGTTCGTGCCAAGTG 
RAC3_rev human ACAGAGCCCACCAATCTCCC 
SETD1A_fwd human GTCGAAGACCTCCAAGACCC 
SETD1A_rev human ACCTCTTCCACCTCACCGTA 
SETD1B_fwd human ACTCGTTGGGCATGGAAGAG 
SETD1B_rev human GGCTCTGGAGACAGCAACAT 
SMOC2_fwd human AAGCCCGGAAGGAGTTTCAG 
SMOC2_rev human TGCGGCATCATCTGTTTTTCC 
SOX9_fwd human AGTACCCGCACTTGCACAAC 
SOX9_rev human CGTTCTTCACCGACTTCCTC 
TCF1_fwd141 human TCAGGGAAGCAGGAGCTG 
TCF1_rev141 human TTCTTGATGGTTGGCTTCTTG 
TCF4_fwd141 human ATGGAGGGCTCTTTAAGG 
TCF4_rev141 human AGGCGATAGTGGGTAATAC 
Ascl2_fwd64 mouse AAAGCTTGGTCCGGTTCTTCATCC 
Ascl2_rev64 mouse GCAGATGCTTAGCTTATTGCGTCC 
Axin2_fwd mouse AGTCAGCAGAGGGACAGGAA 
Axin2_rev mouse CTTCGTACATGGGGAGCACT 
Bmp4_fwd mouse AGAAGAATAAGAACTGCCGTCGCC 
Bmp4_rev mouse ATGGCATGGTTGGTTGAGTTGAGG 
Cd44_fwd64 mouse CACCTTGGCCACCACTCCTA 
Cd44_rev64 mouse TTGGATGTGAGATTGGGTCGAA 
Gapdh_fwd64 mouse AAATGGTGAAGGTCGGTGTGAACG 
Gapdh_rev64 mouse TGATGACAAGCTTCCCATTCTCGG 
Gata4_fwd mouse AAACGGAAGCCCAAGAACCT 
Gata4_rev mouse ACACAGTACTGAATGTCTGGGA 
Gob5_fwd64 mouse TGAAATTGTGCTGCTGACCGATGG 
Gob5_rev64 mouse TGCTGCGAAAGCATCAACAAGACC 
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Itf_fwd mouse TGGGATAGCTGCAGATTACGTTGG 
Itf_rev mouse TTTGAAGCACCAGGGCACATTTGG 
Lgr5_fwd252 mouse CCTACTCGAAGACTTACCCAGT 
Lgr5_rev252 mouse GCATTGGGGTGAATGATAGCA 
Lyz_fwd64 mouse GCAGCCATACAATGTGCAAAGAGG 
Lyz_rev64 mouse TTTGCCCTGTTTCTGCTGAAGTCC 
Mll2_fwd mouse GATGGTTCCTCAGACCTACTG 
Mll2_rev mouse CTCCACACTGAAGCCATCATC 
Mll3_fwd mouse CAGAGGAGCACATTGAAGTGG 
Mll3_rev mouse GGCTTTTCTCCACAACTTGGC 
Mll4_fwd mouse CTGTGCCAGATCAGAACCGAA 
Mll4_rev mouse CTGAGATGACTTGGAGTGCAC 
Mmp7_fwd mouse AGGAGTGAACTTCCTGTTTGCTGC 
Mmp7_rev mouse TTCTGAATGCCTGCAATGTCGTCC 
Muc2_fwd64 mouse TGTGATGCCAATGACAAGGTGTCC 
Muc2_rev64 mouse ACCACAATGTTGATGCCAGACTCG 
Olfm4_fwd64 mouse TTGGGTTACCAAGCAGTACAAGCC 
Olfm4_rev64 mouse TCTCATTGTGATGCCTAGGTTGCC 
Setd1a_fwd mouse GTTTGCCATGGAACCCATTGC 
Setd1a_rev mouse GTGCAGCAGTGGTTGATGAAC 
Setd1b_fwd mouse CTGTTGGTGAGCTGGATGCTA 
Setd1b_rev mouse CTGGAGTAAGCTGTGTCTTGG 
Smoc2_fwd64 mouse CATAGGACCGCGGAGCAGTT 
Smoc2_rev64 mouse AGGCTGCAGTCTCTGTCTTTG 
Spdef_fwd64 mouse AACATGTATCCCGACGATAGCAGC 
Spdef_rev64 mouse TCAATATCTTTCAGGACCTCGCCC 
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